Quantitative lung CT analysis for the study and diagnosis of Chronic Obstructive Pulmonary Disease by Bragman, Felix J.S
Quantitative lung CT analysis for the study
and diagnosis of Chronic Obstructive
Pulmonary Disease
Felix J.S. Bragman
A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
of
University College London.
Centre for Medical Image Computing
Department of Medical Physics & Biomedical Engineering
University College London
March 16, 2018
2I, Felix J.S. Bragman, confirm that the work presented in this thesis is my own. Where
information has been derived from other sources, I confirm that this has been indicated in
the work.
Abstract
The importance of medical imaging in the research of Chronic Obstructive Pulmonary Dis-
ease (COPD) has risen over the last decades. COPD affects the pulmonary system through
two competing mechanisms; emphysema and small airways disease. The relative contribu-
tion of each component varies widely across patients whilst they can also evolve regionally
in the lung. Patients can also be susceptible to exacerbations, which can dramatically ac-
celerate lung function decline. Diagnosis of COPD is based on lung function tests, which
measure airflow limitation. There is a growing consensus that this is inadequate in view of
the complexities of COPD. Computed Tomography (CT) facilitates direct quantification of
the pathological changes that lead to airflow limitation and can add to our understanding of
the disease progression of COPD.
There is a need to better capture lung pathophysiology whilst understanding regional
aspects of disease progression. This has motivated the work presented in this thesis. Two
novel methods are proposed to quantify the severity of COPD from CT by analysing the
global distribution of features sampled locally in the lung. They can be exploited in the
classification of lung CT images or to uncover potential trajectories of disease progression.
A novel lobe segmentation algorithm is presented that is based on a probabilistic segmen-
tation of the fissures whilst also constructing a groupwise fissure prior. In combination
with the local sampling methods, a pipeline of analysis was developed that permits a re-
gional analysis of lung disease. This was applied to study exacerbation susceptible COPD.
Lastly, the applicability of performing disease progression modelling to study COPD has
been shown. Two main subgroups of COPD were found, which are consistent with current
clinical knowledge of COPD subtypes.
This research may facilitate precise phenotypic characterisation of COPD from CT,
which will increase our understanding of its natural history and associated heterogeneities.
This will be instrumental in the precision medicine of COPD.
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Chapter 1
Introduction
1.1 Problem statement
Chronic Obstructive Pulmonary Disease (COPD) is defined as the progressive development
of airflow limitation that is not fully reversible. Airflow is inhibited by two major compo-
nents; emphysema and small airways disease. The relative contribution of each component
varies widely across subjects, demonstrating an important subject-specific variability in dis-
ease progression [165]. COPD affects the respiratory system in a heterogeneous fashion,
leading to variety of clinical symptoms. An example of this heterogeneity is exacerbation
susceptibility in COPD. Exacerbations are acute events where lung function can signifi-
cantly worsen and may lead to hospitalisation of the patient. Importantly, there is a subgroup
of patients who are susceptible to these episodes.
The severity of COPD is defined by the degree of lung function impairment, which
is best known as the Forced Expiratory Volume in 1 second (FEV1). This is currently the
most important diagnostic marker for determining the presence of COPD and evaluating
response to treatment both in routine clinical care and drug development. However, it is
now clearer than ever that the reliance on FEV1 is inadequate in view of the complexities
of COPD. There are multiple phenotypes of COPD with differing clinical characteristics
and varying contributions of emphysema and airway disease [85, 231]. There are various
subtypes of emphysema that contribute differently to airflow limitation [34]. Pathological
alterations in tissue structure can vary regionally with differing affects on lung physiology
[104]. These complexities also translate to the molecular level with numerous inflamma-
tory markers that may be responsible for the systemic inflammation of COPD [85]. These
difficulties are motivating the development of novel computational tools that enable more
precise stratification of patients to facilitate prognosis and cater therapy to the individual.
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The importance of medical imaging for researching COPD has steadily risen over the
last decades. Computed Tomography (CT) is presently the gold standard for analysing
COPD. Through various technological developments, three-dimensional scans that have a
high resolution and excellent contrast can now be acquired. This has promoted the de-
velopment of a variety of algorithms and computational tools that can support the clinical
research of COPD to improve diagnosis and management.
A significant amount of high-dimensional data can now be extracted, which is moti-
vating the development of various analytical tools that are both automated and objective
in their quantification of disease. A variety of anatomical structures are affected in COPD
such as the parenchyma, the airway tree, the lobar fissures and the vasculature. It is im-
portant to accurately segment these structures whilst also effectively capturing the disease
processes that affect them. The lung anatomy is incredibly complex with large variability
across the population. Combined with the pathological alterations that occur, algorithms
that aim to segment the pulmonary structures must be flexible. They need to be able to
adapt to cases where pathology alters and occludes the structure of interest but also where
the lung anatomy differs significantly from the norm.
Methods that can effectively capture regional aspects of disease and other complex rep-
resentations are necessary. The lung parenchyma can be pathologically altered in a variety
of ways. The traditional method for the analysis of lung tissue and the most extensively used
in large clinical studies is the global average. Whilst it is clinical intuitive, it may not be
specific in view of the complexities of COPD. Novel algorithms and imaging features that
are designed specifically to track various aspect of COPD pathology at a local and global
scale are needed. Importantly, there must be a delicate balance between interpretability of
the results and complexity of the modelling. It may be desirable for a classifier to learn
an abstract feature set that leads to accurate results in a classification setting. However,
the strength and clinical utility of a diagnostic algorithm is also dependent on the ease of
interpretation of the results, that will invariably further our knowledge of COPD.
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1.2 Main contributions
The purpose of the research described within this thesis was to develop novel tools for the
advanced analysis of lung CT scans to probe various clinical hypotheses related to COPD
progression. The main contributions of this thesis are:
• A novel framework for analysing the distribution of density-based and biomechan-
ical features. Local feature distributions are analysed throughout the lung. Their
global distribution can be exploited to study differences between patients and to train
a classifier. This algorithm is applied to classify exacerbation susceptible and non-
susceptible patients at equal levels of COPD severity. It is tested on three cohorts and
is the first example in the literature attempting this problem (Chapter 3).
• A novel unsupervised lobe segmentation algorithm. This includes a probabilistic
segmentation of the fissures based on Gaussian Mixture Modelling of a multi-scale
fissure enhancement filter. A groupwise fissure prior is also constructed to assist the
lobe segmentation in regions of grossly incomplete fissures. Results demonstrate the
performance of the fissure segmentation and the state-of-the art accuracy of the lobe
segmentation (Chapter 4).
• Local disease and deformation distributions are presented to better quantify the spread
of the disease and its effect on lung biomechanics. Through the use of manifold learn-
ing and manifold fusion, I show that the distributions outperform conventional met-
rics to predict lung function impairment. I also present the possibility of constructing
potential trajectories of disease progression of COPD in the manifold space of the
distributions (Chapter 5).
• A pipeline for the regional analysis of lung structure and deformation that is applied
to the study of exacerbation susceptible COPD. The study analyses lung features
from a global to a lobar level to investigate whether regional analysis of the lung
adds important information to characterise an exacerbation susceptible lung from CT.
Various new features that correlate with spirometry are also presented. (Chapter 6).
• The application of disease progression modelling to COPD. A novel clustering algo-
rithm called SuStaIn (Subtype and Stage Inference) was applied to the COPDGene
cohort. This has demonstrated the utility of applying disease progression modelling
1.3. Thesis outline 17
to progressive lung diseases. The model detected two main subgroups of COPD with
various clusters associated to them, which differ by the disease progression trajec-
tory. These subgroups correspond to previous clinical knowledge on the subject of
COPD subtypes. I also demonstrate the utility of early diagnosis in COPD manage-
ment and provide preliminary results in its application to studying exacerbations of
COPD (Chapter 7).
1.3 Thesis outline
This thesis presents research on novel methods for automated analysis of lung CT scans
with a focus on COPD. This research has exploited various analytical tools; leveraging
methods from image processing to machine learning to quantify and investigate new clinical
hypotheses related to COPD.
In Chapter 3, I present a novel algorithm that aims to classify patients by considering
the distribution of various local features across the lung. This was applied to exacerbation
susceptible COPD and tested on three cohorts of patients from COPDGene. In Chapter
4, I present a lobe segmentation algorithm that is based on the probabilistic segmentation
of the fissures and the creation of a groupwise fissure prior. State of the art validation
results are presented for both the fissure and lobe segmentation. Chapter 5 extends the
work in Chapter 3 and presents the concept of local disease and deformation distributions
to better model the spread of disease and its effect on lung biomechanics. In Chapter 6,
the methods from Chapter 4 and 5 are exploited to study differences between exacerbation
susceptible and non-susceptible patients and assess if regional measurements associate with
exacerbation susceptibility. In Chapter 7, an event-based model called SuStaIn (Subtype and
Stage Inference) is applied to investigate different trajectories of COPD disease progression.
In Chapter 8, I summarise and discuss the main results and contributions and present future
directions for this project.
Chapter 2
Background
Within this chapter, I first introduce Chronic Obstructive Pulmonary Disease (COPD). The
aim is to outline how it affects the lung, how it is currently diagnosed and the main treatment
options. I also discuss the complexities faced in its diagnosis, which is motivating the de-
velopment of various new tools such as those from medical image analysis. I then introduce
how images of the lung can be acquired from Computed Tomography and Magnetic Reso-
nance Imaging, which are the two main modalities used for COPD diagnosis and research.
I then summarise the main efforts in COPD image analysis and present the main technolog-
ical developments that are enabling researchers and clinicians to better study COPD. More
focused discussions on the state of the art can be found in Chapters 3, 4, 5, 6 and 7.
2.1 Chronic Obstructive Pulmonary Disease
2.1.1 Pathophysiology of COPD
Chronic Obstructive Pulmonary Disease (COPD) is defined as the progressive development
of airflow limitation that is not fully reversible. The main components of COPD are small
airways disease and emphysema. COPD affects the respiratory system in a heterogeneous
fashion, leading to variety of clinical symptoms with numerous extra-pulmonary comor-
bidities [158]. The relative contribution of each component varies widely across subjects,
demonstrating an important subject-specific variability in the progression of disease [165].
Studies have shown that the small airways are the major sites of airflow limitation in
COPD [97, 96], which correlate well with the pathological alterations in tissue composi-
tion. These can be attributed towards a long-term exposure of toxic gases and particles
[165], with a strong historic association to tobacco smoking [12]. This leads to airway in-
flammation and mucus hyper-secretion, which is caused by a cascade of immune-mediated
2.1. Chronic Obstructive Pulmonary Disease 19
events [96]. Tissue remodelling is a by-product of the immune system response. Within this
process, damaged tissue is repaired by restoring the epithelium and the micro-vasculature
whilst adding a connective-tissue matrix. This tends to thicken the airway wall by a progres-
sive narrowing of the luminal area, which may conclude in a total occlusion of the airway
[12]. This can lead to gas trapping, which is a pathological retention of air that cannot be
expired [121]. The mechanical repercussion of inflammation and remodelling are key deter-
minants in the pathophysiology of COPD. Laminar flow within the respiratory bronchioles
is governed by Hagen-Poiseuille flow. As a result, airflow resistance varies according to the
fourth power of the luminal radius. In a healthy state, the small airways are seen to exhibit
low airflow resistance, with a total contribution of 10% with respect to total airway tree
resistance [123]. However, narrowing of the small airway luminal area yields an increase in
resistance, which is reflected by airflow limitation.
The second major component of COPD is emphysema. This is defined as the progres-
sive destruction of the alveolar architecture. It is categorised pathologically as an abnormal
or progressive enlargement of the distal airspaces (generation > 21) [6]. These lesions can
be easily visualised in CT images as contiguous areas of attenuation close to the Hounsfield
Unit (HU) of air (-1000). Emphysema risk factors are similar to those affecting the air-
ways. These include cigarette smoke, environmental irritants, genetic factors and pollutants
[12]. A variety of theories have been proposed to explain the principal mechanisms of em-
physema [202]. These include the hypothesis that tissue destruction occurs as a result of
an imbalance between protease and anti-protease activities or through oxidative stress and
matrix remodelling [202]. These mechanisms lead to severe alterations in the load-bearing
components of the lung parenchyma, which severely impacts the stress-bearing properties
of the lung and leads to a loss of elasticity [201]. Moreover, tethering forces which may
help airway distensibility are lost [50]. This causes airflow limitation [147] and impaired
diffusing capacities [134], which are important determinants in COPD mortality.
2.1.2 Exacerbations of COPD
Exacerbations of COPD significantly add to the clinical and economic burden of COPD.
They are a prime example of the heterogeneity of COPD. They are acute events that can
dramatically alter the normal time-course of COPD [186]. They are a major determinant
in the mortality, morbidity and quality of life of COPD patients [234]. Reducing the fre-
quency of exacerbations and improving the efficacy of therapeutic interventions are key
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future targets in the management of COPD.
A potential dichotomy in COPD exists based on susceptibility to exacerbations. Al-
though exacerbation frequency is seen to increase with COPD severity, there is an indepen-
dent susceptibility phenotype [101] associated with higher severity of disease and a prior
history of exacerbations. Patients with a history of 2 or more exacerbations per year have
a high likelihood of future exacerbations whilst those with less are more likely to experi-
ence no future episodes. Identification of the exacerbation susceptible subtype facilitates
isolating a specific high-risk group to identify novel preventative strategies for personalised
medicine.
2.1.3 Diagnosis of COPD
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) have defined four
GOLD stages [227], which represent a simple set of spirometric tests that define the severity
of airflow limitation attributed to COPD (Table 2.1).
GOLD Stage Severity FEV1/FVC% FEV1%predicted
GOLD 1 Mild < 70 ≥ 80
GOLD 2 Moderate < 70 < 80
GOLD 3 Severe < 70 < 50
GOLD 4 Very severe < 70 < 30
Table 2.1: Spirometric classification of COPD severity recommended by the Global initiative for
Obstructive Lung Diseases (GOLD 2013) [227].
The spirometric indices important for the diagnosis of COPD are the Forced Vital
Capacity (FVC) and the Forced Expiratory Volume in 1 second (FEV1) (Figure 2.1). The
FVC represents the maximum volume of air, which can be exhaled from a position of full
inspiration. The FEV1 measures the maximum amount of air exhaled in the first second of
the FVC manoeuvre. Airflow limitation is defined in an individual when the ratio between
FEV1 and FVC (FEV1/FVC) drops below 70%. Severity is assessed by considering the FEV1,
corrected according to reference values based on age, height, sex and race. This index
is defined within this report as FEV1%predicted. Recently, GOLD have introduced new
guidelines [227] for the classification of COPD by adding a symptom-based feature to the
spirometric indices. However, the old classification (Table 2.1) is used throughout this
thesis.
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Figure 2.1: Flow volume versus time curve of breathing during a normal state and pulmonary
function test state. Prior to the pulmonary function test, a patient is breathing
freely, which corresponds to the resting tidal volume. The patient is then required
to inhale maximally from tidal respiration to Total Lung Capacity (TLC) and then
rapidly exhale in a forceful manner until no further volume is exhaled at resid-
ual volume (RV). The volume change from TLC to RV is the Forced Vital Ca-
pacity (FVC). The volume of air exhaled in one second is the FEV1. Figure
reproduced from Wikipedia Commons https://en.wikipedia.org/wiki/
Spirometry#/media/File:Lungvolumes_Updated.png
2.1.4 Therapeutic practice of COPD
The management of COPD is largely reactive to pulmonary function tests. Assessment
of disease severity and determining the need for treatment is based around the level of
FEV1%predicted. Whilst COPD is not curative, there are a various strategies that may be
employed to slow down disease progression and relieve symptoms of COPD.
Smoking cessation is the most important intervention for modifying the course of dis-
ease [7] and efforts should be focused on helping patients to quit. In terms of a therapeutic
intervention, bronchodilators are central to the management of COPD. Prevention and relief
of symptoms can be achieved by inhalation of long-acting β agonists and can significantly
improve symptoms, exercise capacity and health status in COPD patients [124] in addition
to reducing exacerbation frequency [29]. Inhaled corticosteroids on the other hand have
had a variable anti-inflammatory effect on patients with COPD with a lack of evidence to
support that they modify the natural history of COPD. Surgical intervention is also possi-
ble through lung volume reduction surgery (LVRS). This practice aims to remove the least
functional parts of the lung to improve lung function. It is most effective in patients with
upper-lobe emphysema and has been shown to increase exercise capacity, reduced dynamic
hyperinflation and improve pulmonary elastic recoil [124]. Effective patient stratification is
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necessary for surgical planning since patients with a more homogeneous CT distribution of
emphysema have a higher mortality with LRVS than conservative medical treatment [124].
2.1.5 The need for better diagnostic tools
Spirometry is the current gold standard for the staging of COPD severity and is also the
most commonly used endpoint for drug development studies. There is a growing consensus
that FEV1 does not adequately describe the complexities of COPD [86]. FEV1 is a global
measurement and does not capture regional manifestations that may be implicated with
disease progression [162]. It may also fail to characterise COPD heterogeneity, defined
as the presence of both small airway disease and emphysema. Both phenotypes can occur
synchronously and associate with airflow limitations [188].
It is also now apparent that various clusters of COPD exist, as demonstrated by un-
supervised clustering [32, 27, 232]. Clusters of patients with similar levels of airflow ob-
struction can belong to different phenotypes with differing clinical characteristics as defined
by symptoms, comorbidities and predicted mortality [27]. Genetic associations in COPD
may be subtype dependent as seen in a cluster analysis using CT-features with a post-hoc
analysis using genetic data [32]. These methods all used different patient cohorts, fea-
ture sets and clustering methods. However, the underlying theme of these studies is that
a multi-dimensional assessment of COPD is needed upon which medical imaging may be
a fundamental pillar. The current international guideline for therapy recommends adapta-
tion of therapy based on severity of COPD, as assessed by post-bronchodilator FEV1 and
other symptoms [165]. This strategy may be correct for certain identified clusters but not
in clusters with various extra-pulmonary comorbidities [27]. New end-points to evaluate
therapy may be necessary and also better ways to stratify patients in clinical trials to assess
the development of novel inhaled therapies.
2.2 Beyond spirometry: imaging lung structure and function
The major limitations of spirometry are significant arguments that the assessment of COPD
should be multi-dimensional. The management of COPD, initiated with diagnosis and con-
cluding with an accurate therapeutic strategy should rather follow the philosophy of P4
medicine (Personalised, Predictive, Preventive, Participatory) [2]. The use of imaging;
through Computed Tomography and Magnetic Resonance Imaging is now emerging as a
key determinant in precisely quantifying COPD. This is through the technological develop-
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ments it is supporting such as segmentation, registration and pattern recognition that enable
automated, robust and objective quantification of lung disease.
2.2.1 Computed Tomography
Computed Tomography (CT) is a diagnostic imaging procedure, which relies on X-ray
emissions to acquire cross-sectional slices of the body (Figure 2.2). CT is based on the
principle that tissue density can be measured by calculating the attenuation of a transmitted
X-ray beam. The slices and attenuation values that are visualised in CT are reconstructed
by measuring the transmission of X-rays through a series of detectors. The output is a
three-dimensional representation of the underlying anatomy with respective macrostruc-
tural information relating to tissue density. Through various technological developments, it
is now possible to acquire three-dimensional, high-resolution images with excellent contrast
resolution that can be applied to various organs [114]. Despite the radiation-related cancer
risks of computed tomography [16], it plays a major role as a tool for both diagnosis and
research.
Figure 2.2: Three-dimensional CT image of the thorax created by stacking individual two-
dimensional axial slices. Figure created using a control patient from the COPDGene
study [166].
2.2.1.1 Fundamentals of Computed Tomography
The fundamental principle of CT is the differential absorption of X-rays by tissue [190].
To acquire images with sufficient signal-to-noise ratio (SNR) and contrast-to-noise ratio
(CNR), there are three main requirements: 1) a sufficient number of X-rays need to be
transmitted through the body for a high SNR, 2) X-ray absorption through different types
of tissue needs to differ significantly to produce high CNR and 3) X-rays that are scattered
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at random angles must be removed.
There are two main mechanisms that govern the behaviour of X-rays in tissue that
affect the SNR and CNR of the image. They are the photoelectric attenuation and Comp-
ton scattering of X-rays. There are other mechanisms that occur such as pair production,
Rayleigh scattering and photodisintegration. However, these can be ignored at the energy
levels of conventional CT (0.1 to 1.5MeV).
Photoelectric attenuation describes absorption of the X-rays by the tissue. This pro-
vides contrast in the image since the probability of photoelectric interaction is strongly
dependent on the effective atomic number of the tissue, the tissue density and the energy of
the incident X-ray. Compton scattering refers to the interaction between the incident X-ray
and a loosely bound electron in the outer shell of an atom. This collision causes the X-ray
to scatter at a specific angle θ . The energy of each scattered X-ray photon is determined by
a complex function linking incident photon energy and the angle of scatter θ . The reduc-
tion in beam intensity is proportional to the tissue electron density, which is approximately
proportional to the physical density of the tissue.
Several factors in the imaging hardware affect the SNR, CNR and the spatial resolution
of acquired images. However, photoelectric attenuation and Compton scattering are the
principal determinants of X-ray attenuation and the grey-level of acquired images. The
image stemming from CT is a parametric map of the linear tissue attenuation coefficient
µ . Attenuation of N0 incident X-rays through tissue can be determined by an exponential
process that is a function of the distance travelled x such that
N = N0 exp
(−µ(E)x) (2.1)
where E is the X-ray energy (keV) and N is the number of transmitted X-rays. The
linear tissue attenuation coefficient is a function of the photoelectric absorption, Compton
scattering and the energy of the X-ray:
µ(E) = µ(E)photoelectric+µ(E)Compton . (2.2)
The intensity of a voxel is directly related to the X-ray attenuation. The acquired image
from CT is a parametric map of tissue attenuation. This map is obtained on a voxel-wise
basis by image reconstruction. The reconstruction algorithm aims to determine the level
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of attenuation in each voxel by analysing the fraction of X-ray beams (ln(N/N0)) that are
measured in all detectors.
The intensity of a voxel in CT is a quantitative measure of the density of small discrete
parts of the body. It is commonly expressed in Hounsfield units (HU). It is a dimensionless
quantity, which is scaled based on the attenuation of air and water [57]. The radiodensity of
air is usually given a value of −1000 HU whilst water is set to 0 HU. The attenuation value
of a measured voxel is defined as
CTvoxel(HU) = 1000 · (µvoxel−µw)/(µw−µa) (2.3)
where µw, µa and µvoxel are respectively the attenuation values for water, air and the
probed tissue. The attenuation values of water and air are generally calibrated by the manu-
facturer of the scanner. A general assumption is that the lung is composed of two materials:
air and tissue/blood. A mixture model can be assumed, which states that the HU in lung
CT images is a function of tissue and air content [95]. A linear relationship between HU
and tissue density can thus be assumed although this breaks down in the presence of other
materials such as fat and contrast agents. Radiographic values from CT consequently pro-
vide a non-invasive index of tissue density. This is particularly useful as it enables the
segmentation and analysis of various pulmonary structures to quantify and study COPD.
2.2.1.2 Application to COPD image analysis
CT has great potential to influence the routine diagnosis and study of COPD. It has seen
a rapid evolution in the quantitative evaluation of thoracic images [189, 222, 217]. It is
the modality of choice for lung imaging as it permits direct evaluation of the pathological
changes that contribute to airflow limitation. Novel developments in the segmentation of
pulmonary structures [222], non-rigid registration [144], and pattern recognition with image
classification [189, 217] are providing a rich array of tools for pulmonary image analysis.
2.2.1.2.1 Quantification of emphysema
The sensitivity of CT in probing tissue density has placed it as the optimal tool for quan-
tifying emphysema. Various subtypes of emphysema exist (centrilobular, panlobular and
paraseptal), which can be quantified by recognition of radiologic patterns in supervised
[131] and unsupervised frameworks [131, 245]. However, emphysema is most frequently
quantified by analysis of voxels with low attenuations. Emphysema is defined as the de-
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struction of the lung tissue in the distal ends of the airway tree. This causes the voxel atten-
uation to decrease close to the value of air and appear as black regions in CT. Quantification
of emphysema has typically been based on densitometric measures where statistical met-
rics stemming from the attenuation frequency distribution (Figure 2.3) are obtained. They
have been used extensively in imaging studies of COPD, demonstrating strong associations
with FEV1 and GOLD severity [185], diffusing capacity of the lung for carbon monoxide
(DLCO) [79] and the 6-minute walk distance [49].
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Figure 2.3: Frequency distribution of CT attenuation values with %LAA< −950 (red) and Perc15
(blue) thresholds. The distributions were obtained by fitting a cubic spline to a histogram
obtained by quantising the CT attenuations in bins with a 25HU width. A threshold of
−950HU is used to calculate the percentage of low attenuation areas (LAA), where
percentage emphysema is defined as %LAA< −950HU. The Perc15 metric is the 15th
percentile of the frequency distribution.
The most common approach relies on the application of a density mask [142]. This
uses a threshold on the voxel intensity to calculate the percentage of low attenuation ar-
eas (%LAA). The most common threshold is −950HU as it has been shown to have the
strongest correlations with microscopic evaluation and pulmonary function tests [74]. In
addition to the %LAA, percentile densitometry is used, which seeks a HU threshold based
on the percentile in the frequency distribution (Figure 2.3). The most common threshold is
the 15th percentile based on studies of α1-antitrypsin deficiency [156].
2.2.1.2.2 Quantification of small airway disease
The main contributor to airflow limitation in COPD are the small airways [96]. Their quan-
tification is a major challenge in pulmonary image analysis and there is currently no gold
standard for measuring small-airway disease. Accurate quantification of the smaller airways
is inhibited by the resolution of modern CT scanners. Main developments in the assessment
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of small-airway disease have thus focused on indirect measures. Remodelling of the airway
wall leads to narrowing and eventually obliteration of the lumen of smaller airways. This
will lead to an abnormal retention of air in the distal ends of the airway tree, which is known
as gas trapping and is a surrogate marker of small airways disease.
Various techniques have been used to quantify the extent of gas trapping from CT.
Gas trapping causes a decrease in the mean attenuation value of an expiration scan due
to the retention of air after expiration [119]. A threshold of -900HU was initially used to
quantify gas trapping in asthmatic patients [149]. A threshold of −860HU was then seen
to have the strongest correlation with pulmonary function tests [126]. The threshold of
−856HU (Figure 2.4) which is the current gold standard, was later adopted after a large-
cohort study as part of COPDGene study [185]. The authors state that the mean attenuation
of a normally inflated lung (6 mL air per gram of lung) is −856HU. Therefore, regions
which are inflated above 6mL/g in a normal lung are morphologically abnormal. However,
the origin of −856HU as a threshold remains unclear since there are no studies to my
knowledge, which propose it as a threshold for gas trapping.
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Figure 2.4: Frequency distribution of expiration CT attenuation values with %LAA<−856 thresh-
old. The distributions were obtained by fitting a cubic spline to a histogram obtained by
quantising the CT attenuations in bins with a 25HU width. A threshold of −856HU is
used to calculate the percentage of low attenuation areas (LAA), where percentage gas
trapping is defined as %LAA<−856HU.
Classic densitometric method do not compensate for the level of emphysema. They
lack accuracy since voxels classified as gas trapping in expiration scans can be classified as
emphysematous in corresponding inspiration scans. Various methods have been developed
that exploit paired breath-hold scans such as the inspiratory-to-expiratory volume change of
voxels with attenuations between −860 and −950HU (RVC−860to−950) [126] and the ratio
of mean lung attenuation from expiration to inspiration (E/I ratio) [59]. However, it is the
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Parametric Response Mapping (PRM) technique [71] that has shown the greatest promise
in quantifying small airways disease. It is based on the registration of paired breath-hold
scans. The joint histogram of inspiration and expiration voxels yield a signature unique to
the patient, which can be exploited to classify gas trapping that is not emphysema at inspira-
tion (PRMfSAD) and emphysema (PRMemphysema). Whilst it has not yet been histologically
validated, PRM measurements are reproducible over short periods of time [25], generally
robust to scanner characteristics and misregistration [24] and have been shown to predict
pulmonary function [163] and correlate longitudinal changes in FEV1 [17].
2.2.1.2.3 Common limitations of tissue analysis
The attenuation value of a voxel is dependent on several factors such as radiation dose, scan-
ner modality, the reconstruction algorithm and kernel, and the inspiration level [132]. This
is an important issue specifically in longitudinal and multi-centre studies where controlling
for all variables is difficult. Furthermore, the use of thresholds for quantifying emphysema
(−950HU) and gas trapping (−856HU) in the lung may not be applicable. Various tools
have emerged to mitigate these issues when faced with densitometry or the analysis of the
voxel attenuations. These range from intensity modulation of the voxels [72] and volume
correction of emphysema metrics [199] to data-driven modelling techniques for voxel-wise
classification [84]. For instance, the lung attenuation signal (Figure 2.3) can be modelled
as a mixture of skew-normal distributions, where the components correspond to emphyse-
matous and healthy voxels [84]. This technique naturally builds on neuroimaging methods,
which classify white matter, grey matter and cerebrospinal fluid (CSF) voxels by assuming
a mixture of Gaussians [219]. This method [84] provides a more robust method for emphy-
sema quantification since it removes the need for thresholding, which may not be suitable
when faced with longitudinal scans or data stemming from different imaging protocols.
Data-driven techniques can also overcome further major limitations of classic densit-
ometric techniques. The visual analysis of the lung parenchyma may suffer from intra and
inter-observer variability [94]. This has motivated the development of techniques that may
objectively quantify emphysema and its associated subtypes. This is primarily performed
through the measurement of patterns of local features at the scale of secondary pulmonary
lobule, which is called texture analysis. Within the context of pulmonary image analy-
sis, texture analysis involves analysing lung intensity patterns in distinct regions of interest
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(ROIs). Given appropriate labels that are obtained manually by a trained expert, a clas-
sifier can learn the appearance of various subtypes for future classification in new scans
[131, 245, 194]. This may provide a more robust measure of lung disease that can differ-
entiate structural differences between patients with equivalent lung function [243] or which
may be complimentary to mean levels of emphysema [88].
A limitation of emphysema and small airways disease quantification is that they do not
accurately quantify both the size distribution of disease clusters and their regional distri-
bution in the lung. These can be important dimensions of COPD and may have important
clinical implications. There have been attempts to quantify the size of emphysema clusters
by analysing the size distribution of emphysema clusters [134] and it has been shown that a
homogeneous presentation of emphysema can contribute to an accelerated decline in lung
function independent of baseline FEV1 [204]. In the context of small airway disease, there
have been no reports on quantifying its appearance and distribution in the lung. Advanced
analysis of small airways disease may help in our understanding of COPD progression such
as at milder stages of COPD [17].
Lobar analysis of disease may also build on the limitation of global averages and
can add important information on the disease state of the patient. It has been seen that
lung volume reduction surgery may be particularly beneficial for patients with predomi-
nantly upper-lobe emphysema [66]. Regional analysis of emphysema has further shown
that clinical manifestations of COPD may depend on the regional progression of emphy-
sema [104, 75, 81, 180] however there are conflicting reports in the literature on the effects
of upper-lobe and lower-lobe emphysema. However, it has been seen that a more homoge-
neous distribution of emphysema accelerates the decline of FEV1 [204]. Despite necessitat-
ing the addition and quality control of lobe segmentation to the processing pipeline, regional
analysis of COPD may prove to be crucial in advancing our understanding of COPD, as a
staging tool for surgery and for the precise phenotypic characterisation of COPD from CT.
2.2.1.2.4 Quantification of pulmonary structures
To detect and quantify lung abnormalities from CT, it is necessary to first localise and seg-
ment structures of interest. Segmenting the lung is generally a prerequisite although there
are structures outside of the lung cavity that can be analysed such as the pectoral muscles
[89]. The high spatial resolution and CNR of modern multi-detector CT scanners permits
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the visualisation of various pulmonary structures such as the airway tree, the vasculature
and the lobar fissures (Figure 2.5). The segmentation of the airways, vasculature and fis-
sures all have unique challenges and are active areas of development as illustrated by the
EXACT09 [117], LOLA11 [99] and VESSEL12 [176] challenges.
Within this section, I focus on airway segmentation and its use in COPD analysis. An
in-depth discussion on fissure and lobe segmentation can be found in Chapter 4 and lobar
analysis of disease is discussed in Chapter 5. Whilst the segmentation of the vasculature can
yield new insights on pulmonary vascular morphology [61], and is particularly useful in lobe
segmentation, I focus on the challenges of airway segmentation and its clinical applicability
since airway disease is one of the main components of COPD. An in-depth discussion of
vessel segmentation techniques and applications can be found in a recent review by van
Rikxoort and van Ginneken [222] and by Washko et al. [230].
Figure 2.5: Illustration of the main constituents of respiratory system that can be segmented in
CT. The right lung is divided into the lower, middle and upper lobes whilst the
left lung is composed of the lower and upper lobes. During inspiration, air en-
ters the trachea, which bifurcates into the main bronchi and further divides until
the distal ends of the airway tree, where diffusion of O2 and CO2 occurs. Fig-
ure adapted from Wikipedia Commons https://en.wikipedia.org/wiki/
Lung#/media/File:Lungs_diagram_detailed.svg.
Segmentation of the airways generally follows a two-step process. The airway lumen
and the inner surface of the airway tree must first be identified. The airway tree in CT ap-
pears as a dark tubular, connected structure surrounded by bright walls. Methods generally
exploit this property using grey-level region growing to iteratively grow the lumen from a
seed point [218]. The airways become progressively smaller as they bifurcate, which can
lead to partial volume effects. This can cause leaking of the airway tree and the segmen-
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tation of spurious branches. Pathology such as collapsed airways and mucous deposition
will terminate the region growing prematurely. A collapsed airway leads to a disconnected
tree whilst mucous deposition and noise can lead to locally higher density, which inhibits
the detection of distal branches. This had led to techniques that aim to prevent leaking
through explosion-control [140], to detect and correct leaks through convolutional neural
networks [38] or that are not based on intensity-based region growing such as supervised
classification with a bronchi-enhancement filter [151].
The second step in airway segmentation exploits the segmented lumen to identify the
outer airway wall surface. The most commonly used method is the full width at half maxi-
mum (FWHM). It is based on an analysis of the intensity profiles along a two-dimensional
cross-section of the airway. It defines the wall boundary at the location where the intensity
is half the peak value of the intensity profile. A limitation of this method is that it requires
reconstruction of a two-dimensional cross-section of the lumen perpendicular to the airway
centreline. Moreover, it can be biased by partial-volume effects and the reconstruction ker-
nel [169]. Three-dimensional airway wall segmentation methods have therefore emerged,
which rely on graph-cuts [161] and three-dimensional active surfaces [80].
Multiple airway measurements can be obtained from the segmentations that can be
used to assess airway disease such as airway wall thickness, bronchial wall mean attenu-
ation, wall area percentage (%WA) and internal perimeter (Pi). A standardised parameter
called the Pi10 SRWA and Pi15 SRWA has been developed, which measures the square
root of wall area (SRWA) for a hypothetical airway with an internal perimeter of 10 and
15mm [148]. Studies have shown increases in bronchial thickening in patients with COPD
[178, 78]. Statistical modelling of airway tree structure and geometry has shown that air-
ways from COPD and control patients stem from different distributions [65]. Increased
wall thickness associated with FEV1 [208] and other markers of airway abnormality corre-
lates with functional markers such as the SGRQ and BODE index [125] and exacerbation
frequency [87].
It is quite clear that airway segmentation has tremendous potential to monitor mor-
phological changes attributed to COPD. Airway segmentations can be exploited for com-
putational fluid dynamics (CFD) to better understand the effects of airway morphology on
airflow [115] and assist in the development of aerosols used for drug deposition [211]. How-
ever, standardisation of measurement protocols is necessitated since studies often perform
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measurements in different anatomical regions e.g. averaging across a generation versus
measuring a single airway location.
2.2.1.2.5 Nonrigid registration and biomechanics from pulmonary CT
Nonrigid registration is an optimisation problem that aims to find the spatial transformation,
which puts a floating image, into correspondence with a reference image. It is particularly
suited to the diagnosis and characterisation of COPD. Longitudinal scans can be registered
to a common space to locally monitor abnormal textural changes related to emphysema
[77]. Biomechanical parameters that quantify lung deformation can be extracted from the
registration of paired breath-hold scans [5] and may be predictive of patient outcomes in
COPD [22].
Various registration algorithms focused on thoracic registration from CT have been
developed. The EMPIRE10 challenge [144] and the DIR-Lab reference set [35] represent
a good overview of the state of the art. Algorithms are now able to reach mean target
registration errors1 less than 1.0mm on paired breath-hold scans of both control and COPD
patients. Novel developments in the literature are generally related to solving two major
challenges: variations in intensity contrast caused by breathing [191, 247, 177, 92], and the
sliding motion of the lung [93, 184, 155, 171]. Research into developing better optimisation
strategies to find the minima of the optimisation are also ongoing [177, 93].
The deformation obtained from the registration can be exploited to investigate biome-
chanical properties of the lung, which may improve COPD characterisation from CT. Pa-
rameters that capture local volume change and heterogeneities can be derived such as the Ja-
cobian determinant, the Anisotropy Deformation Index (ADI), [5], Jacobian heterogeneity
[18] and measures from the Lagrangian strain tensor eigenvalues [107]. These biomechan-
ical parameters have been shown to improve associations between emphysema and spirom-
etry [18] but also associate with patients outcomes such as the SGRQ, 6-minute walking
distance the BODE index [22].
The clinical utility of registration has also been shown when attempting to stage pa-
tients using CT-features in supervised classification [143, 23]. Addition of features only
available through registration such as density change [143] or the ADI [23] significantly
1The target registration error (TRE) is the Euclidean distance between the coordinates of corresponding
landmarks. A TRE equal to zero after registration means the transformation successfully put the landmarks in
correspondence.
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improve the performance of classifiers. This is not surprising as various studies have inves-
tigated significant associations between local volume change measurements and ventilation
[168] or spirometry [43].
The application of registration to the study of COPD is not limited to the analysis of the
deformation field. It is an instrumental process of the Parametric Response Mapping (PRM)
technique, discussed in Section 2.2.1.2.2 that enables voxel-wise classification of emphy-
sema and fSAD. Longitudinal scans may be registered to a common space to investigate the
progression of emphysema [77, 198]. For instance, a local disease progression measure can
be constructed to evaluate textural changes attributed to emphysema progression, which can
track subtle local changes in tissue destruction. Moreover, registration is a cornerstone in
the creation of statistical atlases. It may be desirable to construct an average model of lung
function and structure such that normative ranges of structural and functional measures can
be created [113]. This may provide an important basis for creating age-matched or disease-
specific atlases to investigate how various covariates affect lung pathophysiology.
2.2.1.2.6 On the lack of longitudinal data to validate imaging research
A tremendous amount of effort has been made in the development of automated tools that
aim to extract clinically useful data from Computed Tomography. This is evident in view
of the methods presented within this chapter. Many techniques are aimed at extracting
potential biomarkers that better predict lung function decline. For instance, Harmouche
et al. [88] have presented a new emphysema metric based on the classification of various
emphysema subtypes whilst the use of Parametric Response Mapping by Galba´n et al. [71]
has suggested that small-airway disease precedes emphysema in the progression of COPD.
A significant limitation of these papers and by extension the work presented in this thesis
is the lack of longitudinal data for validation. Most imaging studies are focused on cross-
sectional data. Whilst this may provide a snap-shot of the disease process in a collection
of individuals, it is not possible to extrapolate whether the findings better predict disease
progression and whether they are suitable candidates as imaging biomarkers.
COPD is a progressive disorder that spans several decades. This has led to a lack
of longitudinal data that permits effective validation of developed imaging biomarkers. A
small minority of papers have performed analysis on longitudinal data at short time-scales
(less than 3 years). These datasets are generally small such that there are questions on their
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ability to capture heterogeneities present in the COPD population.
At the time of writing, there are several large studies that contain or aim to gather lon-
gitudinal data. These are: 1) ECLIPSE [224], 2) COPDGene [167] and 3) the Danish lung
cancer CT screening trial [159]. Only ECLIPSE and COPDGene were focused on study-
ing phenotypes and the progression of COPD. The ECLIPSE study is a 3-year longitudinal
study that recruited 2,180 COPD subjects. It is not yet publically available but is intended to
be submitted to the Genotypes and Phenotypes dbGaP repository of the National Institutes
of Health. The COPDGene study is the largest multi-center study with over 10,000 patients
recruited. However, the acquisition of data at 5-year follow-up has not been completed.
In future work, the ECLIPSE and COPDGene studies present the exciting opportunity to
be used for longitudinally studies of developed imaging biomarkers, the validation of dis-
ease progression models and the independent validation of research either performed on
ECLIPSE or COPDGene.
2.2.2 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) exploits the abundance of hydrogen protons (1H) in
water and fat to acquire images. Tissue contrast in a magnetic resonance (MR) scan is
generally related to the proton density of various tissues. This differs from computed to-
mography, which relies on the ionising radiation of x-rays and the attenuating properties of
various tissues to acquire images. It is therefore an exciting potential alternative and can-
didate for future routine diagnostic use in lung imaging. Due to the excellent soft tissue
contrast of MRI, the lack of ionising radiation and its high spatial and temporal resolution,
it is often the modality of choice when frequent scanning is necessary for diagnosis and
therapy.
2.2.2.1 Image acquisition
Image acquisition in MRI is largely due to the interaction between the nuclear spin of a
proton and the application of an external magnetic field [41]. A bulk magnetisation of the
protons occurs when a strong, static magnetic field is applied to the body. It is the manip-
ulation and detection of the proton magnetisation with a combination of radio-frequency
pulses (RF) that permits non-invasive probing of the underlying macro and microstructure
of tissue.
The intensity of a voxel is directly related to the proton density and magnetisation of
the tissue. The cyclic application of RF pulses leads to a periodic proton magnetisation
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and decay. The decay process is governed by several time constants (T1, T2 and T∗2). These
constants differ with tissue type and pathology, helping to produce contrast in an MR image.
Acquisition parameters such as the echo time (TE) and the relaxation time (TR), which
govern the application of the RF pulse and the measurement of signal decay are instrumental
in setting tissue contrast.
There is a growing interest in the application of MRI for pulmonary research and
COPD [20, 45, 62]. Due to the combination of morphological and functional informa-
tion that MRI provides, it is a particularly attractive tool in the study of COPD. Probing
the pulmonary architecture is however a challenging task. The proton density of hydrogen
(1H) is low in lung tissue because of the absence of both fat and water, which translates to
a very poor 1H signal using conventional MRI techniques. The alveolar network creates a
multitude of air-tissue interfaces and causes significant magnetic field distortions (suscepti-
bility artefacts), which weakens the strength of the acquired signal. Respiratory and cardiac
motion complicate the acquisition process and further degrade the quality of pulmonary MR
imaging. Whilst novel reconstruction methods [129] or protocols such as respiratory gating
and rapid breath-hold imaging [239] attenuate these issues, the fundamental issue of proton
density and susceptibility artefacts has inhibited the use of pulmonary MR imaging both as a
diagnostic tool and a research-based method. Despite these issues, recent advances such as
new acquisition protocols, hyperpolarised MRI and diffusion MRI are proving instrumental
in pushing MRI as a key technique for the study of COPD.
2.2.2.2 Pulmonary proton MRI
The fundamental drawback of lung MR imaging relates to the apparent transverse relaxation
time T∗2. Local inhomogeneities in the magnetic field, caused by air-tissue interfaces at the
alveoli cause a rapid dephasing of the signal. It can be as fast as 2ms in the lung at 1.5T [239]
compared to averages of 35ms and 40ms for skeletal muscle and cartilage [197]. It may be
appealing to increase the magnetisation from 1.5T to 3.0T to increase the signal-to-noise-
ratio (SNR). Magnetic susceptibility is however sensitive to the magnetisation strength,
leading to an even shorter T∗2 of 0.5ms [239]. Detection of the 1H pulmonary signal has
therefore only been historically achievable by including venous contrast agents to evaluate
pulmonary blood flow and vessel hemodynamics [111].
Various methods have been designed that combine the relaxation signals inherent to
various tissues and contrast agents to differentiate inflammation [228] from smooth mus-
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cle remodelling and mucus deposition [111, 228]. Further paired studies between CT and
contrast-enhanced MRI have shown the possibility of visualising gas trapping effects [13].
These methods are proving instrumental in quantifying the underlying pathologies associ-
ated with COPD although many more studies are needed for further validation.
The feasibility of automatically quantifying disease from pulmonary MR has been
improved with the development of protocols such as ultra-short echo times (TE) [127, 122].
This is facilitating the detection of traditional CT densitometric features such as emphysema
[122] and diffuse lung disease [120]. Automated analysis is either performed by direct
quantification of parametric T∗2 maps [152] or through direct assessment of the 1H signal
intensity [122]. It has also been shown that that COPD patients have significantly shorter
longitudinal relaxation times [3] (T1) and that parametric mapping of T1 detects differences
between emphysema and fibrosis [196].
To further tackle the challenge of low 1H signal, methods applying optimisation tech-
niques [103] and new protocols such as zero echo time (ZTE) [235] are producing images
with similar qualities to those acquired with CT. More ingenious techniques have been pro-
posed, which aim to reconstruct the image data and respiratory motion in a unified frame-
work [129]. It has been hypothesised that relative changes in lung volume during tidal
breathing causes relative changes in MR signal intensity [11]. This has been exploited in
Fourier decomposition MRI (FDMRI) [47, 15], which disentangles the intensity changes
due to the respiratory and cardiac cycles to obtain ventilation and perfusion-weighted im-
ages. Since the technique does not rely on the administration of contrast agents, FDMRI
has strong potential for clinical translation.
2.2.2.3 Pulmonary hyperpolarised MRI
A major limitation in 1H lung MRI is the challenge related to proton density and magnetic
susceptibility. Whilst the development of ultra-short TE , zero TE and Fourier decomposition
MRI are generating promising results, conventional 1H lung MRI is at a disadvantage since
it cannot directly image the terminal airspaces of the lung. This limitation can be overcome
by the administration of hyperpolarised gases Helium-3 (3He) and Xenon-129 (129Xe) as
contrast agents, which upon inhalation permits direct visualisation of lung airspaces [63].
Depending on the acquisition protocol and the nature of the quantitative evaluation, hyper-
polarised MRI (HPMRI) facilitates direct quantification of not only pulmonary ventilation
[106] but diffusion and other microstructural properties of the alveolar network [244].
2.2. Beyond spirometry: imaging lung structure and function 37
Gas polarisation, typically through spin exchange optical pumping methods [179]
causes a notable increase in nuclear polarisation and compensates for the low density of
inhaled noble gas nuclei within the lung. This results in an increase in the MR signal, which
can be detected with a scanner tuned to the appropriate resonant frequency. Ventilation
images acquired via HPMRI are generally 1mm in-plane and 5−10mm out of plane [46].
Helium-3 is currently the gold standard in hyperpolarised imaging since its polarisation is
less technically challenging than in 129Xe but also because it has a higher gyromagnetic
ratio, which results in better signal quality. Global quantities of 3He are limited and expen-
sive, which is pushing the development of 129Xe. In addition to the economic benefit of
129Xe, it is also soluble in the pulmonary tissue barrier and red blood cell compartments,
which makes it attractive as a tool for monitoring gas exchange and uptake in the presence
of lung disease [56].
The most common application of HPMRI lies in quantitatively assessing ventilation
maps of either 3He or 129Xe. In healthy adults, inspiration of 3He or 129Xe results in a
homogeneous signal across the lung, which is evidence that all units of the lung are partici-
pating in the respiratory process. In contrast, areas of absent or low signal in the ventilation
image correspond to ventilation defects, which define areas of the lung subject to destruc-
tion of the alveolar network and obstruction of the smaller airways [106]. This leads to
a heterogeneous pattern of ventilation, which is a hallmark of COPD and can be used to
monitor response to treatment [213].
The application of diffusion weighted MR pulses to hyperpolarised gases facilitates
the quantitative evaluation of lung microstructure. Akin to the diffusion of water molecules
in tissue, diffusion weighted HPMRI captures the random Brownian motion of gas atoms
within the airspaces of the lung. At inspiration, gas diffuses within the lung microstructure.
This can be captured and quantified with the Apparent Diffusion Coefficient (ADC) or ex-
tended to quantify morphological properties of the alveoli through microstructural-diffusion
models [244].
The ADC is inversely related with the level of restricted diffusion in the lung. For
instance, the ADC in a healthy lung is 0.2cm2/s (3He) and 0.04cm2/s (129Xe) compared to
0.86cm2/s (3He) and 0.14cm2/s (129Xe) in free unrestricted space [141]. In comparison, the
ADC of an emphysematous lung is larger than a healthy lung, which reflects the enlargement
of the distal ends of the airway tree. A large number of studies have shown the impressive
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sensitivity of ADC to detect pathological alterations in lung tissue [241, 210, 40]. ADC
in both 3He [241] and 129Xe [210] has strongly correlated with measurements from his-
tology whilst differentiating between patients with emphysema and idiopathic pulmonary
fibrosis. Importantly, it has been shown that diffusion-based markers can be useful in the
pre-symptomatic detection of degraded pulmonary function [64]. This is of particular im-
portance as it implies diffusion-weighted HPMRI could be potentially used as an early
diagnostic test.
2.3 Summary
The use of medical imaging is now emerging as a critical tool to aid the routine diagnosis
and management of COPD. The methodological tools that have arisen from both CT and
MRI now facilitate going beyond FEV1. Pulmonary imaging techniques such as HPMRI
now provide a way to visualise and quantify regional improvements in ventilation over
time and in response to therapy. However, a better understanding is necessitated between
ventilation imaging and pulmonary structure-function abnormalities associated with disease
progression.
Computed tomography and magnetic resonance imaging are the current best imaging
modalities in view of studying pathological alterations of COPD and their effect of lung
function. Both modalities have strengths and weaknesses in view of these aims. High
resolution computed tomography has the ability to acquire high resolution scans at sub-
millimeter voxel levels. Moreover, a plethora of methodological work has been performed
on CT that enables a significant amount of information to be automatically extracted. How-
ever, the administration of ionising radiation limits its use especially in view of repeated
follow-up scans and importantly in the peadiatric population. In contrast, the use of MRI in
COPD imaging research is in its infancy. The main technological developments that arise
in COPD-MRI research relates to image acquisition rather than image analysis. The spa-
tial resolution of MRI is not yet at the level of CT. However, since it combines functional
and morphological information and importantly does not adminster ionnising radiation, it
is expected that MRI significantly challenges the use of CT as the dominant tool in COPD
imaging research.
Exploiting the information that is inherent to expiratory and inspiratory CT scans now
enables researchers to quantify more than just emphysema and gas trapping extent such as
emphysema subtypes, an indirected measure of small airways disease, lung deformation
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and measurements of the airway tree. A significant amount of information can thus be
obtained through quantitative CT analysis. The main current challenge is to determine the
features most sensitive to disease progression and which promote our understanding of the
pathological changes that lead to impaired lung function. These features must be validated
in independent studies, which is a difficult process as demonstrated by conflicting results
based on upper and lower-lobe studies. This illustrates that better patient stratification for
imaging-studies is imperative.
Future quantitative image analysis of the lung may be instrumental in the treatment
of COPD. Despite the potential to improve our understanding of COPD, further method-
ological advancements are critically needed. There is a need to better capture the regional
progression of disease, determine its effect of lung physiology and assess whether regional
assessment of lung disease may help phenotype various subtypes of COPD. Moreover,
pathological alterations in lung structure can differ locally. However, most clinical stud-
ies still only consider the mean extent of disease and ignore how local aspects of disease
vary across the lung. By modelling these properties and extending the analysis towards lung
biomechanics, there is a great potential to better phenotype COPD from CT, increase our
understanding of the heterogeneities present in COPD and eventually improve therapy.
Chapter 3
Multiscale analysis of imaging features and
exacerbation susceptible COPD
The work presented in this chapter is based on and reprinted, with permission from F. Brag-
man, J. McClelland, M. Modat, S. Ourselin, J. Hurst and D. Hawkes (2014)∗. “Multi-scale
Analysis of Imaging Features and its Use in the Study of COPD Exacerbation Susceptible
Phenotype”. In: Medical Image Computing and Computer Assisted Interventions - MICCAI
2014. Edited by P. Golland, N. Hata, C. Barrillot, J. Hornegger and R. Howe. Lecture Notes
in Computer Science, vol 8675, pp. 417-424. © 2014 Springer Nature.
∗ Contributions
I conceived the method and developed the framework presented in the paper. I undertook
and designed the experiments, analysed the data and wrote the first draft of the paper. Jamie
McClelland and David Hawkes provided supervisory input and helped prepare the paper.
John Hurst provided clinical input during the development of the methodology. Marc Modat
and Se´bastien Ourselin provided input on the use of NiftyReg for the lung registrations.
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Abstract
In this chapter, I propose a novel framework for exploring patterns of respiratory
pathophysiology from paired breath-hold CT scans. The aim is to quantify
how imaging features are distributed throughout the lung in order to understand
potential differences between COPD subtypes and perform image classification
of these subtypes. Current classification algorithms seek various features that
associate with pulmonary function tests and many exploit global values that ignore
potentially important regional and local information. These techniques may be
limited when attempting to classify patients that belong to different subtypes of
COPD yet have similar levels of lung function impairment. The framework is
therefore designed to address this limitation whilst enabling analysis of large
datasets with the view of of determining relationships between CT features and
disease state.
The algorithm is based on the local distribution of image features at various
anatomical scales. These are sampled throughout the lung to build a distribution of
local features. Principal Component Analysis is then used to visualise and quantify
the multi-scale anatomical variation of features, whilst the distribution subspace
can be exploited within a classification setting. This framework enables hypoth-
esis testing related to the different phenotypes implicated in Chronic Obstructive
Pulmonary Disease (COPD). I applied the framework to the study of exacerbation
susceptible COPD. I tested whether patients who are exacerbation susceptible and
non-susceptible can be classified at equal levels of disease severity.
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3.1 Introduction
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are defined as a sud-
den worsening of symptoms, which accelerate the decline in lung function leading to an
increased risk of mortality. Understanding their pathophysiology is critical for predicting
the patients at greatest risk of hospitalisation. Recent work suggests that the frequency of
exacerbations is a distinct phenotype [101]. This is described as an exacerbation suscep-
tible phenotype, where a patient may exhibit distinct physiological patterns resulting in an
intrinsic susceptibility.
Recent studies have suggested a potential link between changes in lung structure, func-
tion and exacerbations. An association between emphysema progression and exacerbation
susceptibility has been observed over a 2-year study [203] although none was observed in a
larger 3-year study [44]. Changes in airway wall thickness, a primary determinant of airflow
resistance has also been associated with exacerbation frequency [87] whilst pulmonary arte-
rial enlargement relates to severe exacerbations [236]. Further, regional ventilation defects
have been observed prior to acute exacerbations [105].
These studies have suggested a potential dependence between abnormalities in lung
structure, the distribution of disease and exacerbations. This suggests that features from
analysis of Computed Tomography (CT) scans may be extracted that may be sensitive to
exacerbation frequency and may have potential in classifying patients that are exacerbation
susceptible. However, traditional classification algorithms may not be suited to this problem
since they are generally focused on automatically staging COPD severity, as defined by the
GOLD stage. This has motivated the algorithm presented in this chapter. Various classifi-
cation algorithms that have been applied to COPD are now discussed to put into context the
work presented within this chapter.
Classification of COPD from CT scans has either been performed by quantifying
global metrics for the lung or through the analysis of local regions of interest (ROI). Meth-
ods that train classifiers on global averages generally build a feature set by combining var-
ious features that may be informative of COPD severity. Bodduluri et al. [23] combined
global values of density-based, texture-based and biomechanical features and showed that
lung tissue biomechanics can be useful in characterising COPD. This was further echoed
by Murphy et al. [143], who performed a similar experiment at a global and lobar level,
concluding that information stemming from paired breath-hold CT scans is needed to stage
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COPD from CT.
The limitation of classifiers that exploit global averages is that they cannot capture
local textural changes that are products of COPD disease progression [134] and that may
differ between patients at equal levels of severity. They ignore the anatomical presentation
of disease, which may be an important dimension of COPD. Studies in the past have focused
on classifying local textural patterns in ROIs using various features such as wavelet trans-
forms [48], local intensity distributions [131] and local binary patterns [194]. The locally
classified results can be fused together to obtain a singular measure of severity [194, 88].
However, these classifiers heavily depend on the creation of a training set that requires
manual annotation by trained expert.
Different approaches consider lung CT classification as a weak labelling problem. In
the classical setting; each ROI has an associated label for classification. If one considers a
lung CT scan as an ensemble of analysed ROIs, a global label based on pulmonary function
tests can be propagated to each ROI. The strategy then depends on the methodology for
ROI analysis and how a global label can be learnt from the selection of ROIs. Sørensen et
al. [193] proposed a framework that estimates a global posterior probability of COPD. This
was performed by fusing individual ROI posterior probabilities obtained through a k-nearest
neighbours (kNN) classification and a distance metric based on a summed histogram dis-
similarity. This however disregards the fact only a subset of ROIs may be affected whilst
ROIs with early signs of disease may be treated as normal for subjects not yet diagnosed.
Moreover, it is likely not to work on the exacerbation classification problem since the level
of emphysema in susceptible patients may be variable. The ROI limitation has motivated
further classification tools [192, 42]. Sørensen et al. [192] classified CT scans by assum-
ing that all ROIs contribute when an image is compared to others by using bipartite graph
matching between sets of ROIs. Cheplygina et al. [42] exploited the Multiple Instance
Learning (MIL) framework to classify patients where classification is based on distances
between sets of ROIs.
I propose a new framework for the analysis of lung pathophysiology and the classifi-
cation of lung CT scans (Figure 3.1). The main motivation of my work stems from the main
limitations of classifier trained on global features. I hypothesised that the spatial distribution
of disease is a discriminating factor in the presence of pathology. There should be a complex
interplay between various features throughout the lung. This distribution is likely to vary
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based on the subtype and severity of disease and can be captured using a set of ROIs mea-
suring various discriminating features. My method is based on the measurement of image
features representing the biomechanics and density of tissue, using a sliding box window
at various anatomical scales. This is to deal with the bifurcating nature of the respiratory
system. I apply it to the study of exacerbation susceptible and non-susceptible patients. The
distributions measured at multiple scales are exploited to investigate differences between
subtypes whilst attempting to classify susceptible and non-susceptible COPD patients.
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Figure 3.1: CT classification pipeline. 1) Features describing lung structure and lung biomechanics
are sampled at various scales by computing the statistical moments of local distributions.
2) A matrix Hp for a patient p is created by analysing local distributions at J locations
within the lung. 3) A population-wide matrix X is created by analysing P subjects. 4)
Principal Component Analysis of X is performed to create Y. The distribution of the
principal component scores is used as a feature for classifying COPD patients.
3.2 Methods
3.2.1 Non-rigid registration
The NiftyReg registration platform [139] was employed to find the spatial mapping be-
tween the lung at full inhalation (Ω∗) and end exhalation (Ω). This was performed using
a stationary velocity field, parameterised through a cubic B-spline interpolation. The Lo-
cal Normalised Cross Correlation (LNCC) was the similarity measure whilst the bending
energy of the velocity field was used as the regularisation. The registration was performed
by considering only the lungs, delineated by segmented masks. The background volume
was set to 0 Hounsfield Units upon which the masks were dilated to include a 0 HU border
within the lung volume.
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3.2.2 Feature extraction
The transformation ϕ : Ω∗→ Ω, resulting from the registration serves to map each coordi-
nate x∗ ∈ Ω∗ to x ∈ Ω, such that the position of voxels at inspiration (x∗ ∈ Ω∗) is known
at expiration (x ∈ Ω). Biomechanical and density-based feature sets are derived using the
information embedded within the transformation ϕ , which maps all the voxels at expiration
into their new position after deformation. The imaging features analysed within this chapter
are summarised below in Table 3.1 and examples can be visualised in Figure 3.2.
Table 3.1: Feature set and measurements for lung CT analysis
Feature Measurement
Biomechanical
Jacobian determinant (Equation 3.3, Figure 3.2c)
Trace of Lagrangian strain eigenvalues (Equation 3.4)
Variance of Lagrangian strain eigenvalues (Equation 3.4)
Density
Voxel intensity (HU) at inspiration (Iins) (Figure 3.2b)
Voxel intensity (HU) at expiration (Iexp) (Figure 3.2a)
(a) Iexp (b) Iins (c) Jacobian determinant
Figure 3.2: Example feature maps. a) The lung at end expiration, b) at full inspiration and c) the
Jacobian determinant that is obtained by registering Iexp to Iins and analysing the trans-
formation ϕ .
3.2.2.1 Biomechanical features
To analyse the transformation ϕ , I consider the deformation gradient tensor F, which de-
scribes the deformation. It is defined as the gradient of the deformation in the reference
frame Ω∗
F =
∂x
∂x∗
= ∇x∗ϕ (3.1)
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where at each voxel in Ω∗, it is defined in matrix format as
F(x∗) =

F11 F12 F13
F21 F22 F23
F31 F32 F33
=

∂ϕ1
∂x∗1
∂ϕ1
∂x∗2
∂ϕ1
∂x∗3
∂ϕ2
∂x∗1
∂ϕ2
∂x∗2
∂ϕ2
∂x∗3
∂ϕ3
∂x∗1
∂ϕ3
∂x∗2
∂ϕ3
∂x∗3
 . (3.2)
I derive 3 features from F to capture the respiratory process; the Jacobian determinant(
det(F)
)
and the first 2 moments of the distribution of the eigenvalues of the Lagrangian
strain tensor (E). The Jacobian determinant is defined as
det(F) = det(
∂x
∂x∗
)≡ ∆V
V
. (3.3)
It measures the fractional volume change on a voxel-wise basis. The Lagrangian Strain
Tensor E is derived from F, by considering the Right Cauchy-Green Strain (C)
C = F>F, F = R U, F>F = U> R> R U = U>U .
I am interested in analysing the stretches captured by F. The tensor C results from
a polar decomposition of F, where the rotation component R is discarded by considering
its orthogonal properties. The tensor C is thus rotation free, solely containing information
about the stretches U. The computation of the Lagrangian Strain Tensor (E) follows
E =
1
2
(C− I) (3.4)
where I is an identity matrix. I derive the principal strains (λ = {λi | i = 1,2,3}) via an
eigen-decomposition of E. The trace (∑λ ), provides an overall measure of the magnitude
of tissue strain whilst the variance (Var(λ )) characterises anisotropy in the strain profile.
3.2.2.2 Density-based features
The transformation ϕ facilitates the analysis of the voxel densities (HU) at inspiration (Iins)
and expiration (Iexp) scans at corresponding locations. I consider the raw values of the in-
tensities in Iins and Iexp in addition to the percentage of emphysema (%LAAins− 950HU)
and gas trapping (%LAAexp−856HU). In order to analyse the expiratory voxel intensities
in the space of the inspiration scan, the transformation ϕ is exploited such that every voxel
3.2. Methods 47
in Iins has corresponding expiration and inspiration intensities. Emphysema and gas trap-
ping values are expressed as the percentage of voxels below −950 HU and −856 HU in a
given volume. Within my framework, all values are analysed and calculated within local
neighbourhoods across the lung, which is discussed in Section 3.2.3.
3.2.3 Multi-scale analysis of imaging features
I have a set measurements f = { fk|k = 1, · · · ,K} that define lung structure and function.
Each measurement fk (Table 3.1) provides information that is sensitive to COPD and lung
structure. I have K = 5 image features: f1 = Jacobian determinant, f2 = eigenvalue trace,
f3 = eigenvalue variance, f4 = inspiration voxel intensity and f5 = expiration voxel inten-
sity.
I am interested in going beyond global averages that are tradtionally used as features in
lung CT image classification. In this section, I propose a new methodology to sample each
feature fk throughout the lung to capture local feature distributions (Figure 3.3). These local
distributions are parameterised to build a rich feature set that models local aspects of lung
pathophysiology. The collection of local measurements stemming from each fk represents
the feature set that can be exploited as training data to build a classifier.
3.2.3.1 Feature distributions
I propose to sample the local variation of features ( fk) to quantify their distribution across
the lung. This is performed by considering histograms (hi( fk;x j,φi)) of the local distribu-
tions of fk. Each local feature distribution is centered at a voxel x j ( j = 1 · · ·J) within a
neighbourhood ω governed by the scale φi, where i = 1 · · ·n indexes the scale of the neigh-
bourhood ω and j is the jth sampled neighbourhood. Thus, distributions at increasing scales
of analysis (φi) can be computed (Figure 3.3). The histograms are modelled by the first 4
statistical moments and the median. The feature fk within ω centered at x j is defined by:
H j
(
fk(x j)
)
= {µ(h1) ν(h1) σ(h1) γ1(h1) γ2(h1) · · ·
µ(hn) ν(hn) σ(hn) γ1(hn) γ2(hn)}
(3.5)
where µ is the mean, ν the median, σ the variance, γ1 the skewness and γ2 is the
kurtosis. The vector H j
(
fk(x j)
)
thus contains the mean, median, variance, skewness and
kurtosis of the local distribution of fk centered at x j and measured at the scales φ = φ1, · · · ,
φn.
This process is repeated for all features f = f1, · · · , fK at locations x= x1, · · · ,xJ within
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the lung. This enables to creation of a patient-specific matrix (Hp) such that
Hp =

H1
(
f1(x j)
) · · · H1 ( fk(x j)) %LAA1ins/exp(x j)∀φ
...
...
...
HJ
(
f1(xJ)
) · · · HJ ( fk(xJ)) %LAAJins/exp(xJ)∀φ
 . (3.6)
Each row of Hp represents the set of measurements for the feature set f at the sampled
region centered at x j. Each column of Hp represents the collection of a particular histogram
measurement across the lung at sampled regions x = x j, · · · ,xJ .
The Jacobian determinant (det(F)), the trace (∑λ ) and variance (Var(λ )) of the strain
eigenvalues and the voxel densities in Iins and Iexp are modelled locally across the lung
(k = 5). I also incorporate the %LAA− 950HU and %LAA− 856HU for all φi, leading
to 27n features per x j. The number of sampled regions is determined by the sampling
frequency of x j at the finest scale (φ1). For example, if there were J = 1000 sampled regions
and n = 3 scales of analysis, Hp would be ∈ R1000x27·3. It is the matrix Hp that is used as a
feature within this chapter.
1
Hj (fk(x0)) = {µ(h1) ⌫(h1)  (h1)  1(h1)  2(h1) · · ·
µ(hn) ⌫(hn)  (hn)  1(hn)  2(hn)}
2
Figure 3.3: Illustration of the multi-scale sampling for a feature fk. 1) A feature fk (e.g. ∑λ ) at
x j is sampled at n = 3 scales, leading to 3 local histograms hi( fk;x j,φi). 2) Statisti-
cal moments and the median of hi( fk;x j,φi) are calculated for all φi, leading to the set
H j
(
fk(x j)
)
. © 2014 Springer Nature. Reprinted, with permission from F. Bragman et
al., Multi-scale Analysis of Imaging Features and its Use in the Study of COPD Ex-
acerbation Susceptible Phenotype, Medical Image Computing and Computer Assisted
Interventions, 2014.
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3.2.3.2 Statistical feature analysis
A. Hypothesis testing using Hp
Analysis of the distribution of values contained within each Hp allows hypotheses of
changes in the global nature of local features to be made. For instance, consider the
distribution of the variance of det(F) at all x j. Each value demonstrates the local vari-
ation in volume change. The distribution of this measure across the lung will illustrate
how the local variation is expressed, which may vary across subtypes. This facilitates
a direct comparison of patient-specific distributions across phenotypes. To evaluate the
distribution of various measures, one must analyse Hp column-wise.
B. Principal Component Analysis of X
I am interested in modelling the distribution of parameters across the studied population.
To perform this, the feature matrix Hp for each patient P is concatenated such that
X =
[
H>1 · · · H>P
]
where X ∈ RNJ x 27n and NJ is total amount of regions sampled
across all subjects P (Figure 3.4). I apply PCA on X. This seeks a low-dimensional
projection (d << 27n) of X into Y (Figure 3.5), where the variance of the projected
features is maximised.
Figure 3.4: Illustration of the population matrix X. Each patient matrix Hp is concatenated to pro-
duce X. The columns of X represent the different features obtained by analysis of the
local distributions. The rows of X represent the local neighbourhood of a patient p. Each
patient matrix Hp can be extracted from X by considering the row index i of Xi, j. For
the first patient in X, Hp=1 can be extracted by considering the sub-matrix Xi=(1,··· ,J),∀ j.
The entries of X are representative of the local histogram features measured at multiple
scales. PCA of X allows me to compute the component scores within each neighbour-
hood defined by x j (Figure 3.5). Thus, the computed scores can be projected to the
image space to assess their distribution across the lung for each patient. Since the com-
ponent scores are linear projections of the features measured at various scales, they will
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Figure 3.5: Dimensionality reduction of the population matrix X into Y. The column-wise dimen-
sionality of X is reduced from 27n to d by seeking a linear projection of the histogram
features. The projection of each patient-specific matrix Hp within X into the new space
of Y is known since the row indices of Y are equivalent to those in X. Thus, the projec-
tion of Hp=1 within X to Y can be found by Yi=(1,··· ,J),∀ j. This allows one to project the
principal component scores back into the image space since each y ji belongs to a region
of the lung from a patient p. One can also calculate new features by considering the
column-wise mean and variance of the linear projections.
capture potential fractal properties in line with the nature of the lung anatomy. The dis-
tribution of the principal component scores can be analysed to model patient-specific
distributions by computing their respective mean and variance. This is done by calcu-
lating the column-wise mean and variance in Y for each patient (Figure 3.5). Thus,
phenotype-specific distributions can be parameterised to produce a clinically meaning-
ful classifier. Importantly, classification in the PCA subspace prevents overfitting as
PCA removes colinearity in the features.
3.3 Experiments and results
The framework was tested on two sets of data to gauge its applicability in classifying exac-
erbation susceptible and non-susceptible patients. The first dataset was a pilot experiment
(P1 = 20), consisting of 10 patients in both groups with f = 0 and f = 6 exacerbations per
year. The main motivation was to determine if differences in the local features could be
detected between both cohorts and whether the distributions in the PCA subspace could be
used as features to train a classifier. In the subsequent experiment, I increased the size of
cohort to P2 = 49 by including patients with a full spectrum of exacerbation frequencies
( f = 0,1,2,3,4,6). The aim was to determine if similar levels in classification performance
could be achieved whilst better testing the performance of the classifier with repeated k-fold
cross-validation.
3.3. Experiments and results 51
3.3.1 Experiment 1: pilot study
3.3.1.1 Data
Inhale and exhale breath-hold CT images from the COPDGene study [167] were used. CT
scans were acquired from multi-detector CT scanners, at full inspiration (200mAs) and at
the end of normal expiration (50 mAs) with resolutions approximately equal to 0.66mm x
0.66mm x 0.73mm [167].
I tested the framework on P = 20 subjects with a GOLD 3 severity stage exhibiting
f = 0 (n = 10) or f = 6 (n = 10) exacerbations per year. GOLD 3 patients were chosen
due to their low variation in FEV1. I chose two extreme sets ( f = 0 and f = 6) to gauge the
applicability of our framework in discriminating these phenotypes. The patient sets had a
mean age of 60.2 and 67.5, a mean FEV1%predicted of 42.1 and 40.5 and a mean FEV1/FVC
ratio of 42.4 and 47.2.
3.3.1.2 Processing
Prior to the registration, the masks were dilated with a 3 voxel radius sphere. An analysis of
the registration parameters was performed; demonstrating robustness in the registration to
small parameter changes. This was performed by visual assessment of the results. A scoring
system was not developed. A binary decision of pass or fail was used to determine whether
varying the parameters such as control point spacing significantly affected the registration
result. The assessment was performed by analysing the registration of key features such
as the lung boundary, the vasculature, the airways and the lobar fissures. A registration
failure generally occured when major errors at the fissure and lung boundary were detected.
In some cases, a failure occured when there was a significant mismatch in the registered
vasculature. A registration was deemed as a pass when only minor errors were present;
notably at the level of the fissures and the vasculature. Minor differences in the registration
quality were detected across registration parameters.
The standard deviation of the LNCC Gaussian kernel was set to 33 voxels, whilst the
weighting of the regularisation was 0.05% of the overall optimised cost function. The finest
control point spacing of the B-spline grid was set to 5 voxels along each axis. After regis-
tration, the inhale lung mask was eroded by a spherical element with a 7 voxel radius. This
was performed to ignore regions prone to discontinuities and experience an extreme degree
of motion, which may cause undesirable errors. The value of 7 was chosen by analysis of
the Jacobian determinant maps. The majority of outliers could be removed by considering
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an erosion with a spherical element of 7.
Sampling of the biomechanical and density features was performed using a cubic box
window at scales φ1 = 10, φ2 = 20 and φ3 = 30 mm3 (n = 3), which is consistent with the
size of the secondary pulmonary lobule. A sampling frequency of 10mm in the x, y and z
direction was used yielding approximately 7,500 regions per lung. I ignored regions at all
scales where 50% of the voxels fell outside the lung mask.
3.3.1.3 Hypothesis testing of the distribution of local features
Feature distributions at the 3 scales (φ1 = 10mm, φ2 = 20mm and φ3 = 30mm) using Hp
were investigated. I calculated the mean and standard deviation of each feature within Hp
for all 3 scales. For example, the local mean inspiration intensity was sampled throughout
the lung. Therefore, I calculated the mean and standard deviation of all sampled regions for
each patient. This models the global distribution of local features across the lung.
As an exploratory analysis, I investigated if there were differences between these global
measures of the locally sampled features across the susceptible and non-susceptible group.
I performed a two-sample t-test for each subtype mean and standard deviation set to de-
termine discriminating factors between both subtypes. I report the significant differences
when p < 0.05.
A significant difference in the mean of σ (det(F)) (.12± .01 and .21± .02) at all scales
of analysis was found (p < .05). The feature σ (det(F)) illustrates the variation in local
volume change. The lower variation seen by the exacerbation susceptible group suggested
that they exhibit a more homogeneous pattern in their volume change. No significance
was seen in the standard deviation of σ (det(F)) (p < .20). I observed a marked difference
(p < .05) in the mean (.15± .02 and .27± .04) of σ (∑(λ )) at all scales. This insinuated
that for the susceptible group, the anisotropy in the magnitude of local tissue strain was
more homogeneous compared to the non-susceptible patients. These suggested a possible
distinction in deformation patterns, which were exploited in the classification. There were
no significant differences in the density-based features.
Results from the PCA of matrix X corroborated the above, displaying evidence of
distinct feature distributions across subtypes. (Figs. 3.6 and 3.7). Figure 3.6 illustrates 2
patient-specific principal component distributions for each subtype. These are character-
istic of the phenotype distributions and are mostly consistent across each group. As the
component scores are a linear projection of the features, Figure 3.6 suggests that there is
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a consistent physiological pattern per subtype. This is illustrated by a variation in the het-
erogeneity of the scores as observed in the analysis of Hp. This reinforces the notion of
phenotype-specific distributions and the discriminating power of the distribution of disease.
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Figure 3.6: An example of the multi-scale principal component distributions for each sampled
neighbourhood x j for 4 patients (2 susceptible and 2 non-susceptible patients). The first
3 principal components explain ≈ 55% of the variance of X. © 2014 Springer Nature.
Reprinted, with permission from F. Bragman et al., Multi-scale Analysis of Imaging
Features and its Use in the Study of COPD Exacerbation Susceptible Phenotype, Medi-
cal Image Computing and Computer Assisted Interventions, 2014.
As the principal component scores were computed per sampled region (x j) (Figure
3.4 and Figure 3.5), I was able to couple them with their respective anatomical location
(Figure 3.7). This displays varying patterns in the physiology of the lung. As the principal
components aimed to fully explain the lung macrostructure and the deformation captured
within Hp, these maps display a novel way of viewing how lung physiology differs between
patients and across subtypes of COPD.
3.3.1.4 Classification of COPD exacerbation-susceptible patients
I aimed to classify exacerbation susceptible and non-susceptible patients based on the hy-
pothesis that global and local patterns of disease differed across subtypes. This was high-
lighted in Figures 3.6 and 3.7, where a rise in feature homogeneity coincided with exac-
erbation susceptibility. I performed the classification on the feature projections using the
mean and the variance of the principal component scores as features. The set explaining
90% (17/81) of the variance of X was chosen.
A leave-one-patient-out cross validation (LOPOCV) was employed to test the classi-
fier. LOOCV iteratively selects one patient (Hunseen) as the testing data whilst the remaining
are used for training. I assumed independence amongst each training set during the LOOCV
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Figure 3.7: Projection of the first 3 principal components of the multi-scale PCA into the image
space. Coronal slice is at the mid-section. Top row: exacerbation susceptible pheno-
type. Bottom row: exacerbation non-susceptible phenotype. © 2014 Springer Nature.
Reprinted, with permission from F. Bragman et al., Multi-scale Analysis of Imaging
Features and its Use in the Study of COPD Exacerbation Susceptible Phenotype, Medi-
cal Image Computing and Computer Assisted Interventions, 2014.
to calculate accuracy and precision rates. For the classification, I projected Hunseen into the
principal component space of XP−1 and used the mean and variance of the principal com-
ponent scores as features. I used Support Vector Machines (SVM) as a classifier with a
Gaussian radial basis function kernel σ = 2.25 and a soft-margin constant C = 0.5. Clas-
sifier performance from the LOOCV is the ratio of correctly classified labels to the total
number of labels. Results from the LOOCV show that the framework has the ability to clas-
sify an unseen patient as either exacerbation susceptible ( f ≥ 6) or non-susceptible ( f = 0)
with a total accuracy of 75% (Table 3.2). After all iterations of the LOPOCV, 80% of the
susceptible patients and 70% of the non-susceptible when unseen were correctly classified.
This supports the applicability of the framework towards determining relationships between
the distribution of disease with the clinical outcome.
Table 3.2: Classification results using Leave One-Patient-Out Cross Validation. © 2014 Springer
Nature. Reprinted, with permission from F. Bragman et al., Multi-scale Analysis of
Imaging Features and its Use in the Study of COPD Exacerbation Susceptible Phenotype,
Medical Image Computing and Computer Assisted Interventions, 2014.
Susceptible Non-Susceptible Total
Classification accuracy (%) 80 70 75
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3.3.1.5 Summary
I have presented a novel framework for investigating global and local patterns of lung phys-
iology in view of investigating pathological alterations in lung structure and deformation.
The applicability of the framework in determining relationships between feature distribu-
tions and the severity of disease was shown through an analysis of the exacerbation suscep-
tible and non-susceptible phenotypes. Analysis of the local feature distributions displayed
significant differences in the nature of lung deformation across subtypes. This translated to
subtype-specific distributions after dimensionality reduction, suggesting a potential intrin-
sic physiological behaviour attributed to both sets of patients. The main limitation of this
pilot experiment relates to the validation since a relatively low number of patients was anal-
ysed. A larger population of patients is necessitated to correctly evaluate the performance
of the classifier and demonstrate the clinical applicability of the framework.
3.3.2 Experiment 2: larger study
I subsequently tested the proposed framework on a new cohort of patients (Table 3.3) and a
combination of patients used in the previous experiment with the new cohort (Table 3.4). I
included patients with a whole spectrum of exacerbation frequencies ( f ∈ [0,2,3,4,6]).
3.3.2.1 Data
I selected 29 additional patients at GOLD 3 severity from the COPDGene study (Table 3.3).
I did not use all the data available for patients at the GOLD 3 level of severity. This is
because it was desirable to have an unseen set of patients for use as validation in potential
future follow-up experiments. The dataset within this new experiment can be classified as
the training and testing set. At this level of severity, there were no patients exhibiting f = 5
exacerbations per year. There were also no additional patients with f = 6 exacerbations
per year in the COPDGene cohort. Consequently, I randomly included 5 patients from
experiment 1 to force a larger spectrum of susceptible patients. This led to 34 patients
in dataset 1. The clinical characteristics and number of patients stratified by exacerbation
frequency are shown in Table 3.3.
The second dataset consisted of all the patients analysed in experiment 1 (Section
3.3.1) in addition to the new patients in dataset 1 (Table 3.3) leading to a total of 49 patients.
The clinical characteristics and total number of patients stratified by exacerbation frequency
and susceptibility are shown in Table 3.4.
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Table 3.3: Experiment 2: dataset 1
Frequency Frequency Total Total Age FEV1%pred. FEV1/FVC
f = 0 16
}
16 64.51 (8.27) 38.61 (5.84) 45.94 (10.03)
f = 2 8  18 65.97 (8.07) 40.26 (6.15) 44.50 (7.74)f = 3 2f = 4 3
f = 6 5
Total 34 p = 0.62 p = 0.42 p = 0.64
Table 3.4: Experiment 2: dataset 2
Frequency Frequency Total Total Age FEV1%pred. FEV1/FVC
f = 0 26
}
26 65.68 (9.16) 38.66 (5.66) 44.88 (9.61)
f = 2 8  23 63.92 (8.68) 40.93 (5.78) 45.46 (8.71)f = 3 2f = 4 3
f = 6 10
Total 49 p = 0.48 p = 0.15 p = 0.82
3.3.2.2 New registration pipeline
The original registration pipeline (Section 3.3.1.2) was tested on the additional patients
selected (Table 3.3). After visual inspection, I determined that the registration algorithm
was not robust on this larger cohort of patients. I observed various cases with unacceptable
registration errors along the fissures and close to the diaphragm. Therefore, I investigated
the original EMPIRE10 registration pipeline [136]. The EMPIRE10 pipeline consists of
four registration stages (Figure 3.8). It is initiated with an affine registration [154] followed
by three nonrigid registrations [138]. Each step is initialised by the previous registration.
The parameters for the three nonrigid registration steps that were investigated were:
1) the bending energy regularisation weighting, 2) the control point spacing at the finest
resolution scale and 3) the LNCC kernel size. I investigated 150 different parameter com-
binations and visually assessed all results. No visual QA score was developed. The same
process as outlined in Section 3.3.1.2 was performed. A simple binary rule (pass or fail)
was produced for each registration result. Major registration errors at the lobar fissures and
at the lung boundary represented failures. Minor errors in lung features such as at the air-
ways and the vasculatures were ignored and the registration was classified as a pass. The
registration parameters that produced the most consistent results across the cohort in Table
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3.3 are shown in Table 3.5. I repeated the classification experiment in Section 3.3.1.4 to
gauge the effect of the new registration pipeline on the initial cohort. I observed a 13% fall
in the classification performance (Table 3.6).
Affine NRR I NRR II NRR III
Figure 3.8: EMPIRE10 registration pipeline [136]
Table 3.5: Selected registration parameters.
Energy weighting (%) LNCC kernel (voxel) Finest B-spline grid (voxel)
Stage 1 0.08 10 24
Stage 2 0.8 10 24
Stage 3 0.8 10 6
Table 3.6: Classification results using Leave One-Patient-Out Cross Validation on the initial cohort
with the new registration pipeline (Table 3.5)
Susceptible ( f = 6) Non-Susceptible ( f = 0) Average
Accuracy 0.70 0.60 0.65
3.3.2.3 Classification algorithms
I tested different classification models (Table 3.7). I considered linear or non-linear Support
Vector Machines (SVM) whilst also performing no pre-processing and PCA pre-processing.
A linear SVM requires training of a soft-margin parameter C. This parameter is effectively
a regularisation parameter in the SVM and acts as a trade-off between low errors on the
training data and future generalisation of the model. It helps with cases when the data is
not fully linearly separable and contains outliers. In a non-linear SVM, the data is first
projected to a higher-dimensional space using a Kernel function. Linear classification is
then performed in the new mapped space, which may help deal with datasets that are also
not linearly separable. I again used a Gaussian kernel, which is parameterised by σ such
that K(xi,x j) = exp
(
−||xi− x j||2/2σ2
)
where xi and x j are instances of the training data.
3.3.2.4 Model training and validation
The methodology for training and estimating classifier performance is presented in Figure
3.9. The full dataset is denoted as NT . It is divided into training data (N1) and validation
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Table 3.7: Classification models used in experiment 2
PCA pre-processing SVM
Model 1 X Linear
Model 2 X Non-linear
Model 3 × Linear
Model 4 × Non-linear
data (N2). A stratified split is employed such that the number of susceptible and non-
susceptible patients in each set is approximately balanced.
A repeated k-fold cross validation (CV) is performed on N1 to train the model. The
repeated stratified k-fold CV offers a simple platform to evaluate the model parameters,
which generalise best over the data N1. In a stratified k-fold CV, the training data is ran-
domly partitioned into k equal size subsamples ( f1, · · · , fk) with an approximately equal
proportion of group labels across folds. One sub-sample is retained as the validation set
for testing the model whilst the remaining k−1 subsamples are used to train the classifier.
This is performed k-times on all hold out sets. For the model training to be more rigorous,
the k-fold cross validation is repeated n times, which leads to the creation of n× k hold-
out sets. The set of parameters, which minimises the mean squared error across all n× k
hold-out sets is chosen. Error in this experiment is defined as the complementary accuracy
(1− Accuracy). Accuracy is defined as the percentage of correctly classified labels in the
hold-out set or (T P+T N)/(T P+T N+FP+FN), where T P is the true positive rate, FP
is the false positive rate, T N is the true negative rate and FN is the false negative rate.
Once the classifier has been trained and selected, it is applied to the unseen data con-
tained within N2. This provides the quoted level of accuracy for the experiment. To avoid
any potential bias when creating the datasets N1 and N2, the whole process is repeated Q
times. This yields Q levels of accuracy. The final level of model performance is reported as
µ(Q)±σ2(Q) where µ is the mean and σ2 is the standard deviation.
3.3.2.5 Results
All processing as described in Section 3.3.1.2 was applied to dataset 1 and 2. The registra-
tion pipeline presented in Section 3.3.2.2 was used. Datasets 1 and 2 were split into training
and validation datasets with a 65% : 35% ratio. This was performed Q = 5 times. A n = 5
repeated k = 5-fold cross validation was performed to train the classifier in each dataset.
3.3. Experiments and results 59
CV Data
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N2
Q repetitions
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fk
f2
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f1
repeated n⇥ k-fold CV
min(MSE) N2
Figure 3.9: Repeated k-fold cross-validation procedure to train model and evaluate performance on
validation set. The data (NT ) is split into a training (N1) and a separate validation set
(N2). Model parameter optimisation is performed using repeated k-fold cross validation
setting. The classifier and the parameter choice that minimises the mean squared error
on all hold-out sets over all repetitions is chosen. This classifier is then tested on the
validation data (N2) to obtain a measure of accuracy on an independent set of patients.
To avoid any bias in the creation of N1 and N2, the entire process is repeated Q-times.
This resulted in 25 testing sets to pick the model that minimised the mean-squared error.
Within the cross-validation, I enforced an approximate 50% : 50% ratio between class la-
bels in the hold-out sets ( f1, · · · , fk). The amount of patients used for model training and
validation are shown below in Table 3.8. For the cross-validation, I chose the following
range of hyper-parameters to train the SVM: C ∈ [0.05,100] and σ ∈ [0.5,10].
Table 3.8: Number of patients in cross-validation and validation datasets.
Dataset N1 N2
1 22 12
2 34 15
Results for dataset 1 and 2 can be viewed in Tables 3.9 and 3.10 respectively. The
best level of performance in dataset 1 was 0.61± 0.08 (Model 3: No PCA, linear SVM).
The results in dataset 1 displayed inconsistent levels of performance, which was reflected
in fluctuating levels of accuracy across the Q repetitions. For instance, model 2 (PCA, non-
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linear SVM) in dataset 1 exhibited excellent levels of accuracy (0.75) but also very poor
levels of classification (0.17 and 0.33). I measured the value of the minimal mean-squared
error in the cross-validation for each model and repetition. This is also displayed in Table
3.9.
The average level of performance across models in dataset 2 was equivalent (0.53−
0.54). I also observed fluctuations in the level of accuracy across Q repetitions in all models.
For instance, there was a large variation in the level of accuracy in model 4, ranging from
0.73 to 0.20. As seen in dataset 1, model 3 (No PCA, linear SVM) had the most stable
performance with a standard deviation of (0.00 and 0.08). The value of the minimised
mean-squared error for each iteration and model can also be viewed in Table 3.10.
Table 3.9: Classification results for dataset 1.
Model Q1 Q2 Q3 Q4 Q5 Mean CVerror Average
1 0.58 0.58 0.33 0.58 0.58 0.27±0.02 0.53±0.11
2 0.75 0.42 0.75 0.33 0.17 0.31±0.07 0.48±0.26
3 0.58 0.58 0.58 0.58 0.75 0.26±0.02 0.61±0.08
4 0.58 0.58 0.33 0.58 0.43 0.26±0.05 0.50±0.12
Table 3.10: Classification results for dataset 2.
Model Q1 Q2 Q3 Q4 Q5 Mean CVerror Average
1 0.53 0.60 0.40 0.60 0.53 0.19±0.03 0.53±0.08
2 0.80 0.33 0.60 0.33 0.60 0.27±0.05 0.53±0.08
3 0.53 0.53 0.53 0.53 0.53 0.19±0.01 0.53±0.08
4 0.20 0.73 0.73 0.60 0.40 0.29±0.04 0.54±0.23
3.3.2.6 Summary
The aim of this section was to determine the performance of the classification algorithm on
a larger dataset. The experiment showed an expected drop in performance. In dataset 1, the
best performance reached was 0.61±0.08 across all repetitions. This was close to the base-
line level of 0.65 achieved on the original dataset (Table 3.6). However, the performance
of the classifier dropped further to 0.54± 0.23 when tested on the entire cohort (dataset
2). Whilst this level of accuracy is marginally better than random (accuracy = 0.5), the
high variance of the classifier across the Q repetitions, combined with the generally stable
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cross-validation mean squared error has suggested that the population is too heterogeneous,
which may complicate training a classifier that generalises well. For instance, classification
accuracies peaked at 0.75 and 0.73 in Tables 3.9 and 3.10 whilst dropping as low as 0.17.
A limitation of the pipeline, which in part may explain the performance of the algo-
rithm relates to the feature construction. The mean and variance of either the multi-scale
features or the principal components was used. This consequently assumes that the fea-
ture distributions are multivariate normal distributions. A more prudent approach would
have been to either embed the classification in a dissimilarity space or employ the Mul-
tiple Instance Learning approach. For instance, if a dissimilarity-space approach is used,
the classifier is trained in this dissimilarity space, which is built by considering pairwise
distances between images. In the context of the proposed framework, the pairwise distance
between two patients i and j would have been computed by considering distance between
their respective feature matrices Hi and H j.
3.4 Analysis limitation
It has recently come to my attention that two of the biomechanical features used in this
study are equivalent. The Jacobian determinant and the trace of the strain tensor eigenval-
ues both represent fractional volume change. This error was spotted when revisiting the
mathematical formulation of the deformation gradient tensor and the Lagrangian strain ten-
sor eigenvalues. The maximum principle strain should have been used, which is the largest
strain tensor eigenvalue. However, this error does not change the validity of the results nor
does it alter the theoretical foundations of the proposed framework. Excluding either of the
features from the analysis is not expected to alter the chapter conclusions. For future stud-
ies, the biomechanical feature set should only include the Jacobian determinant (relative
volume change) and the variance of the strain eigenvalues (deformation anisotropy).
3.5 Discussion and conclusion
Within this chapter, I have a presented a framework that quantified multi-scale distribu-
tions of features to attempt to classify exacerbation susceptible and non-susceptible patients.
Analysis of features in local ROIs and exploiting their distribution throughout the lung has
allowed me to capture potentially important information not attainable when using scalar
values. Parameterising local density distributions encodes information about potential sub-
types of emphysema [131] whilst the analysis of lung deformation at a local scale may
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capture subtle effects of COPD on lung deformation.
Classification of COPD has traditionally been applied to predicting GOLD stage. To
my knowledge, there were no examples in the literature aiming to classify exacerbation
susceptible from CT scans. Traditional classification methods were not applicable in this
case as they aim to quantify CT features that correlate with spirometry such as emphysema
extent and mean lung deformation. This would not have worked on the chosen datasets since
I analysed patients at equal stages of COPD classification. Whilst the results may seem
poor considering the classification literature, this is the first time exacerbation susceptible
COPD has been attempted to be classified. This work therefore sets the baseline level of
performance for all ensuing work.
There are limitations in the study design that may have affected the obtained results.
The classification problem tackled in this chapter was binary. This was motivated by the
work of Hurst et al. [101] who defined the exacerbation susceptible phenotype. However,
the absence of exacerbations in the past-year does not always equate to an absence of future
episodes. Predicting exacerbation frequency using a Poisson or negative Binomial regres-
sion may have been preferential. An automated threshold then would have been applied to
the prediction.
The classification results in both experiments also highlight the heterogeneity of the
population. It has been observed that various COPD subtypes exist [27, 33]. Various CT-
defined subtypes of COPD had higher likelihoods of exacerbation episodes despite different
levels of emphysema and bronchial wall thickening [31]. Clustering of patients was not
taken into account within this experiment. Therefore, the classifier was trained to recog-
nise CT-features that predict susceptibility on a cohort of patients that may include various
CT-defined subtypes. This would subsequently lead to a low cross-validation error on the
training set yet high variable results on the testing set.
Future work should focus on analysing how the distributions vary with disease severity.
The classification of exacerbation susceptible and non-susceptible patients is challenging
and the difficulty is exacerbated when classifying patients at equal levels of severity. It is
important to determine the clinical utility of the PCA multi-scale distributions. A future
experiment would likely include a range of control patients in addition to those classified at
GOLD stages 1, 2, 3 and 4. This would enable me to quantify a normative range of the multi-
scale distributions in the control population and quantify how they vary with COPD severity.
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This would provide the basis for understanding how sensitive they are to the clinical state
of a patient.
Chapter 4
Pulmonary lobe segmentation with
probabilistic segmentation of the fissures and
a groupwise fissure prior
The work presented in this chapter is based on and reprinted, with permission from F. Brag-
man, J. McClelland, J. Jacob, J. Hurst and D. Hawkes (2017)∗. “Pulmonary lobe segmenta-
tion with probabilistic segmentation of the fissures and a groupwise fissure prior”. In: IEEE
Transactions on Medical Imaging, vol. 36 (8), pp 1650-1663. © 2017 IEEE.
∗ Contributions
I conceived the method and developed the framework presented in the paper. I performed
all the data processing. I designed and undertook all the experiments, analysed the data
and wrote the paper. Jamie McClelland and David Hawkes provided supervisory input and
helped in the preparation of the manuscript. Joseph Jacob performed the manual labelling
to create the COPDGene reference set. John Hurst provided input on the clinical motivation
of the algorithm in Section 4.1. Validation of the LOLA11 dataset was performed by the
LOLA11 organisers.
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Abstract
There is an important regional dimension in the anatomical presentation of
COPD. The spread of tissue damage can evolve regionally and this may vary
widely across the population. There may be discordant effects on lung physiology
depending on whether regional damage in the lung is apical or basal. Moreover,
lung deformation is expected to be heterogeneous across the lung since the level
of deformation is expected to be higher close to the diaphragm. The framework
developed in Chapter 3 was applied across the whole lung. However, it potentially
ignored important region dependent information. To better characterise the
severity of COPD from CT, it is necessary to perform the analysis on a regional
basis. This has motivated me to develop a lobe segmentation algorithm.
In this chapter, I present a fully automated, unsupervised lobe segmentation al-
gorithm is presented based on a probabilistic segmentation of the fissures and the
construction of a groupwise fissure prior. A two-class probabilistic segmentation
segments the lung into candidate fissure voxels and the surrounding parenchyma.
This is then combined with anatomical information and a groupwise fissure prior
to drive non-parametric surface fitting to obtain the final segmentation. Validation
of the fissure segmentation on a cohort of 30 patients from COPDGene is pre-
sented. The lobe segmentation was also validated on 55 cases from the LOLA11
dataset and 80 patients from COPDGene displaying state of the art performance. I
also demonstrate the utility of including a groupwise fissure prior to help segment
the lobes in regions of grossly incomplete fissures.
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4.1 Introduction
Segmentation of the pulmonary lobes can facilitate the localisation and quantification of
respiratory diseases and is of particular interest in Chronic Obstructive Pulmonary Disease
(COPD). COPD can alter the structure of the lung through emphysematous destruction of
lung parenchyma. The speed with which local pulmonary damage evolves can vary between
patients with COPD [233, 206], yet the heterogeneity of local disease progression [233]
may not be captured in lung physiologic indices that quantify function at a global level
[206]. CT-based lobe segmentation provides an anatomically consistent reference frame
for the quantitative analysis of parenchymal damage across large cohorts of patients and
negates the requirement of a groupwise space for analysis. Knowledge of the underlying
lobar distribution of disease may allow the identification of subtle COPD phenotypes or
help identify patients that would benefit from interventions such as lung volume reduction
surgery [36].
To characterise CT disease extent on a lobar basis, it is necessary to identify the pul-
monary fissures. The fissures consist of invaginations of visceral pleura, which extend from
the lung periphery to the lung hilum and separate the right and left lung into five lobes.
The oblique and horizontal fissures divide the right lung into three lobes (upper, middle and
lower) whilst the left oblique fissure divides the left lung into upper and lower lobes. When
visible on CT, the fissures appear as bright, solid lines (Figure 4.1a). They represent two ap-
posed layers of visceral pleura, which are usually devoid of airways and vascular structures
[90]. However, the appearances of the fissures on CT can be variable in the general popula-
tion [10]. A developmental failure of pleural invaginations can result in congenitally absent
or incomplete fissures [90] (Figure 4.1b). Various pathological processes may damage the
pleural surfaces disrupting the integrity of the fissures [90] (Figure 4.1c).
Automated lobar segmentation is most reliable when fissures are complete [53]. In
cases with incomplete fissures, various methods have been developed that draw infor-
mation from pulmonary anatomy and atlases. Lobe segmentation algorithms can be
broadly categorised as either supervised [109, 118, 223, 220, 182, 174] or unsupervised
[253, 54, 214, 255]. In our study, we extend the definition of supervised methods to en-
compass any algorithm that requires prior manual labelling to determine optimal fissure
properties or the construction of anatomical atlases. Segmentation algorithms can be fur-
ther subdivided on the basis of the segmentation of auxiliary structures. Methods can be
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(a) (b) (c)
Figure 4.1: Example in the variation of fissure integrity. Scans with complete (a) and incom-
plete (b and c) fissures can be visualised. The incomplete fissures are due to fu-
sion of lung tissue (b) or pathology (c). Slices are displayed in the intensity range
I ∈ [−1024HU,−600HU]. © 2017 IEEE. Reprinted, with permission from F. Brag-
man et al., Pulmonary lobe segmentation with probabilistic segmentation of the fissures
and a groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
dependent [109, 54, 220, 253, 214, 255, 164] or independent [174, 150] of the informa-
tion provided by the airway and vascular trees. Algorithms can also be classified based on
their dependence on anatomical atlases[150, 220, 253, 174, 182] or whether the method is
uniquely performed in the patient-space [109, 54].
Fissure segmentation can be classified as supervised when posed as a classification task
or unsupervised when applied with a filter. A major shortcoming of filters is their reliance on
arbitrary thresholds for segmentation. The inclusion of fixed segmentation thresholds may
ignore potential fissure voxels or include excessive false positive voxels. Such thresholds
are often compromised when lung attenuation values themselves are variably influenced
by a range of factors including the CT reconstruction algorithm, CT slice thickness and
patient inspiratory effort. The issue of the removal of false-positive voxels and its depen-
dence on prior knowledge is a further limitation of several algorithms [109, 174, 238, 108].
The likelihood function of Lassen et al. [109] requires prior knowledge of fissure Hessian
eigenvalues and may lead to an over-segmentation of fissure voxels that cannot be corrected
through post-processing techniques. The work of Wiemker et al. [238] requires knowl-
edge of the underlying Hounsfield intensity distribution of the fissures with no data-driven
method presented to determine these parameters. Ross et al. [174] sample the image do-
main to detect the most likely fissure surface based on Hessian eigenvalues and a maximum
a posteriori estimation. Their technique requires a lobe boundary shape model based on
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manually segmented data to improve their fissure discrimination. The method is similar to
the formulation of van Rikxoort et al. [222], which requires prior knowledge of manually
labelled voxels to build a classifier. Manual annotation of data is time consuming and im-
practical in routine clinical practice. Moreover, it does not follow that a training dataset built
on a single set of scans will generalise to a new cohort derived using different scanners, with
varying reconstruction kernels. Such a constraint is also apparent in the likelihood function
of Lassen et al. [109]. Our technique however learns the necessary model parameters from
the volume being segmented, permitting the development of a robust segmentation tool,
applicable across a broad range of datasets.
The use of prior knowledge derived from population models has increased in popularity
[174, 150, 221, 254]. Zhang et al. [254] perform lobe segmentation using a single atlas
search initialisation. The average fissure surface from a training set is exploited in a fuzzy
reasoning system to segment the fissures and the lobes. An alternative multi-atlas selection
mechanism has been proposed by van Rikxoort et al. [220]. This selects the most similar
atlas to the patient by comparing the patient fissure segmentation to the atlas and exploits a
transformation to combine atlas lobe labels with an approximate lobe segmentation. Ross
et al. [174] exploit a deformable model in fissure surface extraction. The ability to exploit
prior knowledge is an implicit advantage of atlases. However, if the training data is not
large enough, this may not correctly model the shape variation within the population. These
methods described all require complete segmentations prior to model building, which is a
laborious task. I aimed to build a simple population model of the fissures negating the need
for prior manual labelling without requiring complete fissure segmentations.
The limitations associated with the dependence on manually segmented data, either
to train classifiers or build atlases was a major motivation of the work presented. When
considering fissure segmentation, there is sufficient data within a single scan to detect the
fissures when visible whilst rejecting most false-positives. In view of large-scale studies
such as COPDGene [167], CT scans can also be pooled together to produce a prior, which
negates the need for complete manual segmentations.
4.2 Methods
I present an automatic lobe segmentation algorithm (Figure 4.2) based on a probabilistic
segmentation of the fissures (Section 4.2.2) and the construction of a groupwise fissure
model (Section 4.2.3). Our study aimed to construct a fissure model (Section 4.2.3) using
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complete and incomplete fissures to generate a confidence region based on a population. In
the context of routine clinical care, new scans can be iteratively added if necessary to help
strengthen the population model.
The main technical contributions of the algorithm are: a) unsupervised probabilis-
tic segmentation of the fissures with iterative false-positive removal, b) the simultaneous
construction of a groupwise prior without need for complete manual segmentations and c)
post-processing of the airway segmentation to correct errors in seed labelling. An overview
of the segmentation is shown in Figure. 4.2. The lungs, vessel and airway tree are first
segmented. This is followed by a segmentation of the fissures using auxiliary tree structures
as anatomical priors in a probabilistic setting. The segmented fissures are then combined
using a groupwise registration framework to produce a population prior. The anatomical
information, the segmented fissure and the groupwise fissure prior are then combined as a
cost image for a watershed segmentation.
4.2.1 Data pre-processing
Lung masks are obtained with the algorithm of Hu et al. [100]. The vasculature is seg-
mented by considering multi-scale vessel filtering [172]. The airways are segmented using
region growing via evolution of a wavefront, which iteratively corrects for leakage across
the airway wall [54]. It is assumed that the remaining structures after segmentation are the
fissures and the parenchyma. A skeletonisation of the airways reveals the branching struc-
ture, used to label the lobar bronchi to generate surface fitting seeds. All pre-processing is
performed using the Pulmonary Toolkit1with standard parameter settings.
4.2.2 Probabilistic fissure segmentation
I propose an unsupervised fissure segmentation framework that does not require any training
data to classify fissure-voxels whilst negating the need to empirically determine algorithm
parameters. I present a simple fissure enhancement filter that does not require any manual
observations to set the parameters. I then construct a probabilistic framework to segment the
fissures based on this enhancement filter. I assume a generative model between the observed
filter result and the underlying segmentation of the lung and that these hidden segmentations
exhibit separate Gaussian distributions. This is motivated by the work of Ha¨me et al. [84]
who first used mixture modelling with a hidden Markov Measure Field Model to segment
normal parenchyma and emphysametous regions of the lung. The proposed model assumes
1https://github.com/tomdoel/pulmonarytoolkit
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Figure 4.2: Lobe segmentation algorithm for processing a set of T patients, given by I =
{I1,I2, · · · ,It , · · · ,IT}. The lung mask, airway and vascular tree are segmented as
preprocessing steps. Anatomical information (pit,k, k = (fissure, tissue)) is derived from
the airway and vascular tree. A probabilistic segmentation of the fissures based on a
filter (Ft) exploits the anatomical information. This yields fissure segmentations (St )
for each patient t. For a given cohort (I = {I1,I2, · · · ,IT}), a groupwise space is con-
structed yielding the set of transformations ϕI,Iˆ to the common space Iˆ. This space
is exploited to construct an average model of the fissures (Sˆavg). This is combined
with the segmented fissures St and the patient-specific anatomical information (pit,k)
in a cost function for non-parametric surface fitting. Final lobe segmentations (L =
{L1,L2, · · · ,LT}) are obtained for each patient (t) in the cohort (I = {I1,I2, · · · ,IT}).
© 2017 IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe seg-
mentation with probabilistic segmentation of the fissures and a groupwise fissure prior,
IEEE Transactions on Medical Imaging, 2017.
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that the filtered image is generated by a two-class Gaussian mixture model (GMM), where
the fissures and the parenchyma are the hidden segmentations that have generated the ob-
served enhancement filter. Parameters of the GMM and the underlying segmentation are
determined through application of the Expectation-Maximisation (EM) algorithm.
4.2.2.1 Multi-scale fissure enhancement filter
This filter aims to distinguish fissure-like voxels from surrounding structures. If one con-
siders an image volume It from the set of images I = {I1,I2, · · · ,IT}, the Hessian matrix
(Ht) at a scale σ is obtained by considering the second derivative of It convolved with a
Gaussian kernel G(σ).
The width of the pleural cavity is likely to vary. The filter is embedded in a multi-scale
framework to capture this variation. A voxel-wise eigen-analysis of Ht (It ;σ) yields scale-
dependent eigenvalues λ1, λ2 and λ3, which are, ordered based on their magnitude such that
|λ1| ≤ |λ2| ≤ |λ3|, with respective eigenvectors uˆ1, uˆ2 and uˆ3. I adapted the vesselness filter
of Frangi et al. [172] to capture voxels exhibiting a fissure-like shape.
As a sheet-like structure, a candidate fissure voxel will ideally be represented by a
very large |λ3|>> 0 with λ2 ≈ λ1 ≈ 0. The aim of the filter is to enhance voxels with this
relationship whilst suppressing other auxiliary structures using the following parameters:
Ra = |λ1|√|λ2λ3| (4.1)
Rb = |λ2||λ3| . (4.2)
The parameter Ra helps differentiate spherical structures from plate-like and tubular
structures. To differentiate plates from tubes,Ra is combined with the parameterRb, which
seeks to enhance structures exhibiting a plate-like aspect ratio. A scale dependent filter (Eq.
4.3) is obtained by combining both terms:
Ft(σ)=I(λ3(σ)) ·
{
exp(−Ra(σ)
2
A
) · exp(−Rb(σ)
2
B
)
}
(4.3)
where I(λ3(σ)) is an indicator function such that I(λ3(σ)) = 0 when λ3(σ) > 0 to seek
only bright features. The parameters A and B control the sensitivity of each parameterRa,b.
Small values of A and B (≈ 0) will only be sensitive to voxels with ideal values for the filter
parameters (Ra,b → 0). Larger values for A and B (→ 0.5) will enhance voxels with less
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ideal relationships with the caveat of enhancing more false positives (Section 4.4.1). A final
value of Ft is found by computing the scale σ which maximises Ft at a voxel x:
Ft(x) = max
σmin≤σ ≤σmax
F(x;σ) . (4.4)
There is a deviation from the ideal plate-like eigenvalue relationship in the presence
of partial-volume effects, image noise and patient motion, which may result in a loss in the
discriminating power of Ft . We assume that both tissue classes are hidden segmentations
that generate a range of values stemming from Gaussian distributions. I aim to capture these
class distributions to accurately segment the fissures, even when the filter response is poor
at a fissure voxel by considering local neighbourhood properties.
4.2.2.2 Fissure segmentation using a Gaussian Mixture Model
The output of the filter Ft is parameterised by a two-class GMM. The two underlying distri-
butions in the signal correspond to the fissures and all other remaining structures. I assumed
that the fissures and lung tissue are hidden segmentations (z) that give rise to the observed
values y of Ft . The segmentation can be modelled as a random process with a probabil-
ity density function f (z |Φz) with parameters Φz. The total filter signal has a probability
density function f (y |z,Φy) parameterised by the model parameters Φy. The goal is to es-
timate the segmentation z by the parameters Φ = {Φy,Φz}. This is performed using the
EM algorithm by estimating the maximum-likelihood parameters Φˆ via maximisation of
the log-likelihood
Φˆ= arg max
Φ
log f (y |Φ). (4.5)
I considered the image model of Van Leemput et al. [219]. The index of a voxel x is i∈
{1,2, ...,n} where n is the number of voxels within the lung mask. There are K = 2 classes
(fissure and tissue). The class of the ith voxel is defined as zi = ek. The variable ek represents
the class membership e.g. ek=1 defines the fissure class and ek=2 is the surrounding lung
parenchyma. The response of the filter at voxel xi is yi. The filter values belonging to each
class k are assumed to be normally distributed after log transformation with mean µk and
standard deviation σk such that φk = {µk,σk}. The vector Φy = {φk=1,φk=2} represents the
model parameters for both tissue classes. The overall probability density for yi is defined as
a mixture of normal distributions,
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f
(
yi |Φy
)
=∑
k
Gσk (yi−µk) f (zi = ek) (4.6)
where Gσk represents the k
th class zero-mean normal distribution with standard deviation
σk and f (zi = ek) is the class prior probability of a voxel xi. By assuming statistical inde-
pendence over all voxels x ∈ I, the overall joint probability density is given by
f (y |Φy) =∏
i
f (yi |φy). (4.7)
The maximum-likelihood estimates for Φy are found using Eq. 4.5 by seeking the
parameters that maximise Eq. 4.7, giving the following update equations for the model
parameters
µ(m+1)k =
∑i p
(m+1)
ik yi
∑i p
(m+1)
ik
(4.8)
(
σ (m+1)k
)2
=
∑i p
(m+1)
ik
(
yi−µ(m+1)k
)2
∑i p
(m+1)
ik
(4.9)
where
p(m+1)ik =
f
(
yi |zi = ek,Φ(m)y
)
f (zi = ek)
∑Kj=1 f
(
yi |zi = e j,Φ(m)y
)
f
(
zi = e j
) (4.10)
is a probabilistic estimation of the hidden data zi of class k at voxel xi given the filter value
yi. The class k is iterated with the class index j and m denotes the EM iteration number.
The segmentation resulting from Eq. 4.10 can be sensitive to noise, image artefacts
and false positives as the segmentation is only based on y. Priors (pit,ik) that incorporate
probabilistic information about the segmentation are typically added to the model [219,
28]. In the context of this work, the likelihood of the fissure location (Figure 4.4b) can be
quantified based on the vessel and airway tree. I computed the vessel density (vd) [54],
which is obtained by applying a strong (10mm isotropic) Gaussian filter to the vesselness
filter of Frangi et al. [172]. This measure is inverted and scaled in the range [0,1] using
min-max scaling such that regions of low vessel density are close to 1. Airway density (ad)
is estimated by computing the Euclidean distance transform to the airway segmentation and
is normalised using min-max scaling to the range [0,1] such that regions of high distance
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to the airways are close to 1. The fissure likelihood measure is defined as pit,ik=1 = (ad+vd)/2
and the tissue likelihood is pit,ik=2 = 1− pit,ik=1. The subscript t is dropped in Eq. 4.11
and 4.12 for convenience. The anatomical information is integrated into Eq. 4.6 by setting
f (zi = ek) = piik.
Information about lung structure, spatial smoothness and morphology can be also be
enforced by considering a Markov Random Field (MRF) regularisation term (UMRF). The
probability of a voxel i belonging to tissue class k is now dependent on the first-order neigh-
bours Ni. The neighbourhood system at a voxel xi is defined as Ni = {N xi ,N yi ,N zi } in the
face-connected neighbourhood. The likelihood term (pi) is now augmented with an MRF
that is dependent on the probability and curvature of neighbouring voxels. By employing
the formulation of Van Leemput et al. [219], Eq. 4.10 is updated to
p(m+1)ik =
f
(
yi |zi = ek,Φ(m)y
)
f
(
zi = ek | p(m)Ni ,Φ
(m)
z
)
∑Kj=1 f
(
yi |zi = e j,Φ(m)y
)
f
(
zi = e j | p(m)Ni ,Φ
(m)
z
) (4.11)
with
f
(
zi = ek | p(m)Ni ,Φ
(
zm)
)
=
piike
−βiUMRF
(
ek | p(m)Ni ,Φ
(m)
z
)
∑Kj=1pii je
−βiUMRF
(
e j | p(m)Ni ,Φ
(m)
z
) . (4.12)
where the MRF term UMRF
(
zi | pNi ,Φz
)
is an energy function dependent on Φz = {G}
and the MRF weight βi is kept constant for all voxels i.
Structure in the segmentation is enforced by considering neighbourhood probabilities
(pN ) and constraints on the curvature of the surface ( fdotk ) (Figure 4.3b). The fissure sur-
face exhibits low local curvature, which will be captured in the eigenvector uˆ3. A weight
in the MRF energy term is introduced based on the dot product of the eigenvectors of a
neighbouring voxel xl with the center voxel xi such that
fdot(xl,xi)k =

1− exp
(
−(|uˆxl ,3·uˆxi ,3|)
6
0.25
)
if k = 1
exp
(
−(|uˆxl ,3·uˆxi ,3|)
6
0.25
)
if k = 2
(4.13)
When considering the fissure class (k = 1), the weight will tend to 0 as dissimilarity
in the local curvature increases (1− exp(−|uˆl,3 · uˆi,3|)→ 0). If neighbouring voxels xl and
xi have similar curvature, fdot(xl,xi)k=1 will tend to 1. The goal of this function is to force
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candidate fissure voxels to have approximately equal curvature whilst negatively weighting
the probabilities of false-positives with non-equal local curvature. The shape of the function
within Equation 4.13 was chosen to have a highly non-linear form such that only voxels with(|uˆxl ,3 · uˆxi,3|)> 0.90 had a value of fdot(xl,xi)k equal to 0.90 or above.
The possibility of anisotropic voxel sizes and slice spacing is considered with the
connection-strength factor (s) introduced by Cardoso et al. [28], defined as s= {sx,sy,sz}=
{1/dx, 1/dy, 1/dz} based on real-world distances between the centre of neighbouring voxels.
Closer voxels will yield higher weights in the MRF. The total energy (UMRF ) (Figure 4.3)
for a face-connected neighbourhood Ni centered at voxel xi in Eq. 4.12 is defined as
UMRF
(
ek | p(m)Ni ,Φ
(m)
z
)
=
K
∑
j=1
Gk j(
∑
l∈N xi
sx · fdot(l, i) j · pl, j +
∑
l∈N yi
sy · fdot(l, i) j · pl, j +
∑
l∈N zi
sz · fdot(l, i) j · pl, j)
(4.14)
where G represents a K by K matrix whose elements Gk j represent the transition energy
between tissue classes k and j and the the subscript l denotes the neighbourhood iterator in
each direction x,y,z. Since this is a two-class problem, the matrix G is set up with diagonal
elements equal to 0, off-diagonal elements set to 1 and is a constant in our framework.
Initial parameters for the mixture model (Eq. 4.8 and 4.9) are set to µ(m=0) =
{0.10, 0.90} on the assumption that both class distributions are significantly different. The
class standard deviations are initialised as the original standard deviation of the image filter
(σ2(m=0) = {σ2(Ft),σ2(Ft)}). Initial values for the MRF energy weights (Eq. 4.12) are set
to an even split of 0.5. A termination criteria based on the ratio of likelihood change is set
to ε = 10−3.
The parameter β in Eq. 4.12 controls the regularisation strength. To mitigate depen-
dence of the segmentation on a user-defined choice, the segmentation is performed itera-
tively whilst increasing the strength of β . The percentage of high probability fissure voxels
(pi,k=1 ≥ 0.75) with respect to the number of voxels n is quantified. This percentage de-
creases as β rises leading to a fall in false-positive fissure voxels. The initial regularisation
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Figure 4.3: Illustration of the local neighbourhood Ni used in Eq. 4.14. The index l iterates over
each component in Ni whilst j is the tissue class iterator. The real-world distances are
represented by sx and sy, both measured in mm. © 2017 IEEE. Reprinted, with per-
mission from F. Bragman et al., Pulmonary lobe segmentation with probabilistic seg-
mentation of the fissures and a groupwise fissure prior, IEEE Transactions on Medical
Imaging, 2017.
(a) It (b) pit (c) Ft (d) Pt,fissure
Figure 4.4: Given a patient It (a), an anatomical prior (pit ) (b) is derived from the vessel density
and airway tree distance transform. A multi-scale filter is applied to It to yield Ft (c).
Gaussian mixture modelling with an MRF yields a probabilistic segmentation (d) of
the fissures Pt,fissure. © 2017 IEEE. Reprinted, with permission from F. Bragman et
al., Pulmonary lobe segmentation with probabilistic segmentation of the fissures and a
groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
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is β = 0.75. The EM framework is run and the percentage high probability voxels is quan-
tified. If there is a convergence of this percentage, the segmentation framework terminates.
Otherwise, the regularisation is automatically increased by 0.50. Convergence is defined
when the percentage has not fallen by at least 2% in 5 successive iterations. The output of
the framework after convergence yields probabilistic fissure (Pt,fissure) and tissue (Pt,tissue)
maps for each image It . To obtain a binary segmentation of the fissures (St), a two-pass
analysis is performed. A connected component analysis of Pt,fissure using a face-connected
neighbourhood is performed. Firstly, all components with a median probability below 0.50
are removed then all components below a volumetric threshold of 0.50mL are discarded.
4.2.3 Groupwise fissure prior
In a given patient cohort, there will be a range of cases with incomplete fissures, which will
complicate the segmentation of the lobes. The goal is to combine all segmented fissures into
a groupwise space to create an average fissure model to help guide the lobe segmentation in
problematic cases.
4.2.3.1 Groupwise registration
Given a set of T patients I={I1,I2, . . . ,IT}, a common average space ΩIˆ is computed by
iteratively registering the set of patients I to the Freˆchet mean. The output is an average
image Iˆavg and a set of forward and backward transformations (ϕIT ,Iˆ and ϕIˆ,It ) such that
ϕIt ,Iˆ : ΩIt →ΩIˆ and ϕIˆ,It : ΩIˆ →ΩIt .
The registration is performed using the NiftyReg software package [139]. The algo-
rithm is motivated by the work of Ashburner et al. [8]. All patients in I are initially regis-
tered to an initial template image Iˆ(n=0)avg , which is chosen at random from the set of images
I. The initial average space is created using a rigid registration. This prevents the atlas from
being biased by the geometry of the initial template image. A set of n1 affine registrations
using symmetric block-matching [135] are then performed followed by a set of n2 non-rigid
registrations. The non-rigid registration uses a stationary velocity field, which is parame-
terised by a cubic B-spline with a 12mm spacing. The locally normalised cross-correlation
is used as the similarity with a Gaussian kernel of 50mm. The number of iterations was
determined in a pilot experiment by computing the sum of squared differences similarity
between successive average images Iˆ(n)avg and Iˆ(n+1)avg at iterations n and n+1. Convergence
of similarity measures occurred after n1 = 5 and n2 = 5 affine and nonrigid registrations.
At each iteration (n) of the algorithm, all patients are registered to the average im-
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age Iˆ(n−1)avg . In order to create the new average image Iˆ(n)avg and the new space ΩIˆn , the
average transformation from all patients is computed in the log-Euclidean space, which is
used to demean each patient transformation. All patients are subsequently resampled using
the demeaned transformations to create Iˆ(n)avg. This new average image Iˆ(n)avg is obtained by
averaging all the resampled images.
(a) Iˆ (b) Sˆavg (c) Iˆ (d) Sˆavg
Figure 4.5: Average fissure in the groupwise space ΩIˆ . The average of the right (a-b) and left (c-
d) lung with the respective average fissures can be seen. © 2017 IEEE. Reprinted, with
permission from F. Bragman et al., Pulmonary lobe segmentation with probabilistic seg-
mentation of the fissures and a groupwise fissure prior, IEEE Transactions on Medical
Imaging, 2017.
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4.2.3.2 Construction of the population prior
The set of patients I={I1,I2, . . . ,IT} will have a corresponding set of binary fissure vol-
umes S={S1,S2, . . . ,ST}. The transformations resulting from the groupwise registration
(ϕIt ,Iˆ and ϕIˆ,It ) are exploited to build the fissure prior (Sˆavg). Each fissure segmentation
St is resampled into the groupwise space (ΩIˆ) using the respective forward transformation
ϕIt ,Iˆ to yield Sˆt . All resampled fissures (Sˆ = {Sˆ1, Sˆ2, . . . , SˆT}) are averaged in the group-
wise space to create the average fissure Sˆavg (Figure 4.5). In order to exploit this information
to help segment the lobes, the average fissure is resampled using the backwards transforma-
tion ϕIˆ,It into each patient space (ΩIt ) resulting in Πt . This prior is normalised to the range
[0,1] for each patient and is subsequently smoothed using a Gaussian kernel (σ = 2.5mm).
This produces a prior in the space of each patient, denoting a region where the fissure is
expected (Figure 4.6).
(a) It (b) Πt (c) Πt ∗ G(σ)
(d) It (e) Πt (f) Πt ∗ G(σ)
Figure 4.6: Groupwise prior in the patient space ΩIt . a) The patient volume (It ), b) the resampled
average fissure (Πt ) and c) the smoothed prior (Πt ∗ G(σ)). Within this example, the
right lung can be viewed in (a), (b) and (c) whilst the left lung is in (d), (e) and (f). ©
2017 IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe seg-
mentation with probabilistic segmentation of the fissures and a groupwise fissure prior,
IEEE Transactions on Medical Imaging, 2017.
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4.2.4 Watershed surface fitting
The segmented fissure, the groupwise fissure prior and anatomical information are com-
bined into a cost image inspired by the formulation of Lassen et al. [109]. They created
a cost function by combining information from the vessel and airway tree, the segmented
fissure and the voxel intensities. I built on this work by extending the cost function to utilise
a fissure groupwise prior derived from the population that needs to be analysed.
4.2.4.1 Watershed cost function
The population prior (Πt) is first combined with the segmented fissure (St). The aim of this
step is to produce an initial cost function, with regions of complete and incomplete fissures
accentuated using information from the segmentation St and the population prior Πt . The
inverted Euclidean distance function is applied to St to help deal with minor gaps in the
segmentation. It is normalised with min-max scaling to the range [0,1] with a value of 1
at the fissure. Only regions in the distance map ( fdist (St)) within 2.5mm of the fissure are
considered. The distance map and the population prior are averaged and convolved with a
small Gaussian kernel (σ = 1.0mm) to produce a smooth map in Eq. 4.15. The magnitude
of c1 will be strongest when fdist (St) and Πt are in the same anatomical location. When
there are large gaps in St due to fissure incompleteness, Πt will provide a local maxima.
ct,1 =
(
fdist (St)+Πt
2
)
∗G(σ) . (4.15)
This is then combined with the anatomical information (pit,ik=1∀i→ pit,k=1) and the
binary segmentation (St):
Ct =
(
ct,1+pit,k=1+St
3
)
(4.16)
The fissure likelihood based on the vessel and airway tree (pit,k=1) provides a satis-
factory estimate for regions of low and high fissure probability and helps guide the seg-
mentation into regions of low vessel and airway density. In addition to c1, the original
segmentation (St) is reintroduced. This is performed to produce a high value in Ct at the
segmented fissure since this is the true location of the lobar border.
4.2.4.2 Lobe seed labelling
I used the method used by Doel et al. [54] to generate initial lobe seed labels from the
segmented airway tree. The seed labels are dilated and allowed to grow according to the
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vessel density map for a limited amount of iterations using the watershed algorithm.
4.2.4.3 Lobe seed labelling post-processing
The segmentation is dependent on the initial seed labels. The quality of the initial labelling
can be affected by segmentation failures and errors in the bronchial labelling. If a lobe
seed is incorrectly labelled, the resulting segmentation will be erroneous despite successful
segmentation of the fissures. To improve the robustness of the pipeline with respect to the
airway tree segmentation, the following errors are accounted for: 1) mislabelled branches
and 2) unsegmented branches.
A. Seed label correction - labelling errors
To detect and remove mislabelled branches (Figure 4.7), the centre of mass (CoM) of
each set of label seeds is quantified. For each label set, the intra-label distance of each
component to the label CoM is computed. The inter-label distance of the components
to all other label CoMs are also quantified. The dilated components are removed iter-
atively to minimise the amount of deleted seeds. A seed is marked for removal if its
inter-label distance is smaller than its intra-label distance. The seed with the small-
est inter-component distance of all candidate components is marked for removal. This
component is discarded if its removal does not cause the number of components for that
label to fall below a threshold (rthreshold = 4). If this threshold is met, the component
with the next smallest distance is considered. Once a component is removed, the above
method is repeated until removal is no longer possible. This enforces maximum sepa-
rability between the seeds and removes all potentially erroneously labelled seeds. An
example of the algorithm can be viewed in Figure 4.8.
B. Seed label correction - airway segmentation errors
If the airway tree segmentation fails (Figure 4.9), labelling of the branches will not yield
the necessary seeds to segment all lobes. In this instance, the anatomical information
(pit,k=1) and its distribution in non-fissure regions (4.17) is considered. The threshold is
considered by analysing the distribution of the prior (pit,k=1) at the fissure St :
pit,threshold = µ
(
pit,k=1 ∈ St
)−2σ (pit,ik=1 ∈ St) (4.17)
The low minima regions of pit,k=1 are defined as pit,k=1 < pit,threshold . These correspond to
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Figure 4.7: Labelling error in the lobe seeds in the left lung. A lower left lobe seed has been incor-
rectly labelled as upper left lobe.
(a) Iteration 1 (b) Iteration 2 (c) Iteration 3
Figure 4.8: Schematic of the seed label correction algorithm. There are labelled components for the
upper right lobe (black), middle right lobe (blue) and lower right lobe (red). The centre
of mass of the components per lobe are denoted by the filled circles whilst the centre of
mass of each component is an unfilled circle. The solid lines denote the connections that
calculate intra-label distances whilst the dashed lines represent the inter-label distances.
As the algorithm iterates, two erroneous lower right lobe seed label components (top of
figure) are automatically removed in (b) and (c) causing the centre of mass of the lower
lobe component to move away from the other lobes.
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regions of high vessel and airway branching density. A mask of these regions is created
and a connected component analysis is performed to extract the regions of local minima
(Figure 4.10). These regions are analysed based on their position within the lung and
are exploited to generate new seed labels should the airway tree segmentation fail.
Figure 4.9: Three-dimensional reconstruction of a segmented airway missing the branches in the
right lung.
C. Final lobe segmentation
Segmentation of the lobes (Lt) is obtained by combining the cost image Ct and the pro-
cessed seed labels in a watershed segmentation. The lobar boundaries are smoothed to
deal with minor artefacts in the segmentation. This is performed by normalised convo-
lution with a 4.0mm3 Gaussian kernel.
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(a) Vessel density map (b) Binary mask after thresholding
Figure 4.10: Seed label generation by analysis of the vessel density map for the airway tree in Figure
4.9. a) Analysis of the vessel density map using the fissure segmentation with Equation
4.17 facilitates a data-driven way to threshold the vessel density map into regions of
low vessel density. b) The creation of a binary mask using the thresholding allows one
to generate candidate regions in the lung for the lobe seeds in cases with no segmented
airway branches.
4.3 Data
4.3.1 Dataset 1
Dataset 1 was based on the LObe and Lung Analysis 2011 (LOLA11) challenge [99]. It
consists of 55 volumetric chest CT scans originating from a variety of source with a range
of scans containing serious pathology and abnormalities. The inplane resolution is between
0.53mm and 0.78mm whilst the slice thickness ranges from 0.3 to 1.5mm. The organisers
manually segmented the lobes on 9 coronal slices with two human observers and were
instructed only to label when the boundaries were visible. The inter-observer agreement
between the lobar borders was 1.50mm ±1.28mm.
4.3.2 Dataset 2
Dataset 2 was used to quantitatively and qualitatively validate the framework on patients
with COPD from the COPDGene study [167]. I created a quantitative (Nquant = 30) and
qualitative set (Nqual = 50) by randomly selecting patients from the study. Minimum thresh-
olds (> 10%) for the level of emphysema in the inspiration scan and gas trapping in the
corresponding expiration scan were set in the qualitative cohort to capture cases with sig-
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nificant pathology. The quantitative set averaged 12.8%± 11.12% emphysema whilst the
qualitative set averaged 22.50%±3.60% emphysema.
Analysed scans stem from GE Medical Systems (LightSpeed 16, Lightspeed VCT),
Siemens (Sensation 16, Sensation 64 and Definition) and Philips (Brilliance 64) scanners.
Scans with the STANDARD (GE), AS+ B31f and B31f (Siemens), and 64 B (Philips) re-
construction algorithms were analysed. Information about the scanning protocols can be
viewed at the COPDGene website2. The slice thickness of the scans range from 0.62mm to
1.00mm with in-plane dimensions ranging from 0.52 to 0.90mm.
The quantitative cohort was built by manually tracing the fissures in every fifth sagittal
slice using ITK-SNAP [252]. The radiologist was asked to manually trace the fissures using
three labels. Label 1 was used when the fissures were visible. Label 2 was employed in cases
where extrapolation was possible. Label 3 was used in areas of high fissure uncertainty.
The manual segmentation provided an approximate estimate of fissure incompleteness
with an average of 12.4%± 8.3% across the quantitative set. This was computed by consid-
ering the percentage of voxels labelled 2 and 3. Intra-observer variability was obtained by a
repeated segmentation of 3 datasets with varying degrees of fissure incompleteness (6.7%,
23.0% and 31.3%). These were performed 14 days after to minimise recall bias. The intra-
observer agreement for all lobar boundaries across all patients was 1.54mm ±0.45mm.
4.4 Experiments and results
4.4.1 Fissure segmentation evaluation
I investigated the effects of parameters A and B (Eq. 4.3) and the performance of our
segmentation framework on the quantitative set of dataset 2 using label 1 of the reference
set.
I used the method presented by Xiao et al. [242] to evaluate our fissure segmentation.
I did not define a volume of interest (VoI) using a 40mm width band around each reference
as this ignores potential false positives in the validation. The F1-score was used as quan-
titative index of performance. It is defined as 2 · (Precision ·Recall)/(Precision+Recall).
The magnitude of F1 reflects the similarity between the segmentation and the reference.
Precision and Recall are defined respectively as T P1/(T P1+FP) and T P2/(T P2+FN)
[242]. Precision was quantified by considering the overlap of the binary result (S) with
2copdgene.org/sites/default/files/COPDGene%20MOP%2006.19.2009.pdf
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the reference. A 3mm tolerance band was defined around the reference segmentation as
performed by Xiao et al. [242]. Voxels of S are classified as true positive (T P1) if they
fall within the 3mm band and false positive (FP) if otherwise. Recall was computed by
defining a 3mm band around the binary result (S). Reference voxels within this band were
classified as T P2 and those outside as false-negative (FN).
I segmented the fissures using parameters A,B ∈ [0.05,0.50]. I illustrate the perfor-
mance of the segmentation for a subset of the parameter B ∈ [0.05,0.10,0.15,0.25] with
A ∈ [0.05,0.50] in Figure 4.11. The best performance over all datasets was achieved with
parameters A = 0.25 and B = 0.10 with a median F1-score of 0.90 with median False-
Discovery Rate and False-Negative-Rate of 0.08 and 0.13 respectively. The F1-score re-
mained relatively stable when set in the range A∗ = B∗ ∈ [0.10,0.35] (Figure 4.11). The
mean F1-score over all combinations (A∗ B∗) was 0.87± 0.02 demonstrating stability
in algorithm performance. The mean F1 over all values of A for increasing values of
B is 0.87± 0.03 (Figure 4.11a), 0.87± 0.03 (Figure 4.11b), 0.86± 0.04 (Figure 4.11c),
0.83± 0.08 (Figure 4.11d). At higher values of B, this drops to 0.82± 0.09 (B = 0.30),
0.81± 0.10 (B = 0.35), 0.79± 0.12 (B = 0.40), 0.78± 0.14 (B = 0.45) and 0.77± 0.15
(B = 0.50). This is expected as higher values decreases the separation between the tissue
and fissure-class distributions.
4.4.2 Lobe segmentation validation
Algorithm parameters quoted within Section 4.2 were used in the validation of dataset 1 and
2. The fissure filter parameters used were A = 0.20 and B = 0.20.
4.4.2.1 Dataset 1 - LOLA11
I evaluated our algorithm on the LOLA11 cohort and submitted our results for evaluation
[99]. The LOLA11 evaluation metric is the volume overlap between the submission and the
reference segmentation of one observer. The organisers defined a 2mm slack border around
the borders of the lung and lobes to account for inter-observer variability. Voxels within this
border were not accounted for during evaluation. The overlap is calculated for each lobe
across all patients. I report the mean ± standard deviation, first quartile (Q1), median and
third quartile (Q3) of the scores across all 55 patients. The LOLA score is calculated as
the average of all average overlaps over all lobes. Table 4.1 shows the score for our lobe
segmentation and those of van Rikxoort et al. [220] and Lassen et al. [109].
Five algorithms have been validated for lobe segmentation on this cohort. However, I
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(d) B = 0.25
Figure 4.11: Boxplots of the fissure segmentation with increasing values of B whilst varying con-
stant A of the multiscale filter (Eq. 4.3). © 2017 IEEE. Reprinted, with permission
from F. Bragman et al., Pulmonary lobe segmentation with probabilistic segmentation
of the fissures and a groupwise fissure prior, IEEE Transactions on Medical Imaging,
2017.
have restricted our comparison to van Rikxoort et al. [220] and Lassen et al. [109] as they
are fully automatic and do not require interactive post-processing to correct segmentations.
I achieved the highest automatic average lobe score of 0.884 and the second highest average
median overlap of 0.950 (Table 4.1).
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Table 4.1: LOLA 11 lobe segmentation results. LUL=left upper lobe, LLL=left lower lobe,
RUL=right upper lobe, RML=right middle lobe and RLL=right lower lobe. © 2017
IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe segmenta-
tion with probabilistic segmentation of the fissures and a groupwise fissure prior, IEEE
Transactions on Medical Imaging, 2017.
Lobe Mean ± STD Q1 Median Q3
LUL 0.906±0.202 0.946 0.975 0.988
LLL 0.880±0.243 0.919 0.962 0.980
RUL 0.928±0.071 0.888 0.960 0.980
RML 0.799±0.235 0.759 0.891 0.941
RLL 0.908±0.194 0.937 0.961 0.976
Our method 0.884 0.950
Lassen et al. [109] 0.881 0.951
van Rikxkoort et al. [220] 0.851 0.943
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(a) lola11-40 (b) lola11-01 (c) lola11-30 (d) lola11-41 (e) lola11-29 (f) lola11-28
(g) lola11-55 (h) lola11-21 (i) lola11-14 (j) lola11-25
Figure 4.12: Illustration of the segmentation on a variety of cases from dataset 1 with complete and incomplete fissures in addition to various levels of pathology.
© 2017 IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe segmentation with probabilistic segmentation of the fissures and a
groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
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4.4.2.2 Dataset 2 - Quantitative COPDGene
I assessed the performance of our algorithm quantitatively on dataset 2 using the mean,
maximum and root-mean square error (RMSE) distance from the manual reference to the
automatic boundary. This was performed by calculating the three-dimensional Euclidean
distance between the reference voxels and the closest point on the automatic segmentation.
I assessed the segmentation for each label (Table 4.2). The algorithm achieved a mean
of 2.01mm ± 6.24mm when the fissures were visible (label 1). In cases where fissure
extrapolation was possible (label 2), a mean of 5.16mm ± 6.12mm was achieved. The
performance dropped to 7.31mm ± 4.88mm in regions of highest uncertainty (label 3). In
one case, the right lobe segmentation failed and in a second case, segmentation of the right
and left lobes failed. The failure was due to major errors in the airway branching labelling,
which could not be corrected using our methodology. With a 2mm slack border, the mean
distances were 1.65±3.28mm (label 1), 3.31±5.93mm (label 2) and 6.18±4.70mm (label
3). Errors were due to instances where the groupwise fissure was significantly different from
label 2 and 3 of the reference or slightly biased the segmentation of label 1. Further typical
errors were in cases where emphysametous bullae appearing as fissures lead to isolated
errors in the lobe boundary segmentation.
The performance of my algorithm was also assessed against approximate fissure in-
completeness. The correlation between the mean error (distance to the reference) and fis-
sure incompleteness was calculated. The relationship between the standard deviation of the
errors and fissure incompleteness was also calculated. This was performed with Pearson’s
correlation coefficient (ρ) and processed for each lobar boundary. Weak and moderate re-
lationships were observed between the mean distance and the degree of fissure incomplete-
ness for each boundary (right minor: ρ = 0.47(p < 0.05), right major: ρ = 0.66(p < 0.05)
and left major: ρ = 0.35(p > 0.05)). Similar findings were observed in the standard de-
viation (right minor: ρ = .46(p < 0.05), right major: ρ = 0.61(p < 0.05) and left major:
ρ = 0.23(p > 0.05)).
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Table 4.2: Quantitative Results - Fissure Metrics. © 2017 IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe segmentation with probabilistic
segmentation of the fissures and a groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
average of patient mean (mm) average of patient max (mm) average of patient rmse (mm)
Label 1
Right Major 1.66±3.61 15.42±14.91 2.72±5.67
Right Minor 2.31±11.10 18.60±20.10 3.32±12.82
Left Major 2.07±4.03 28.50±27.89 3.95±6.85
Total 2.01±6.24 20.85±20.96 3.33±8.44
Label 2
Right Major 5.44±5.55 14.22±14.45 6.69±6.98
Right Minor 5.39±8.50 18.65±18.96 7.23±8.48
Left Major 4.65±4.30 16.15±16.75 6.01±5.81
Total 5.16±6.12 16.34±16.72 6.64±7.09
Label 3
Right Major 7.21±4.18 20.95±21.02 8.65±6.15
Right Minor 7.56±5.49 19.05±17.62 8.44±7.28
Left Major 7.16±34.96 23.23±23.23 9.78±5.58
Total 7.31±4.88 21.08±20.62 8.95±6.34
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(a) Qual. 1 (b) Qual. 2 (c) Qual. 3 (d) Qual. 4 (e) Qual. 5 (f) Qual. 6
(g) Quant. 1 (h) Quant. 2 (i) Quant. 3 (j) Quant. 4 (k) Quant. 5 (l) Quant. 6
Figure 4.13: Illustration of the segmentation on examples from the qualitative set of dataset 2 and the quantitative set (bottom row) at various levels of COPD severity.
© 2017 IEEE. Reprinted, with permission from F. Bragman et al., Pulmonary lobe segmentation with probabilistic segmentation of the fissures and a
groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
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4.4.2.3 Dataset 2 - Qualitative COPDGene
The radiologist qualitatively assessed (Table 4.3) my algorithm on 50 patients with ad-
vanced disease using an adapted scoring system of van Rikxoort et al. [222], which scores
the segmentations out of five. The radiologist assessed each lobe segmentation on the sagit-
tal plane. The highest score (5) corresponded to a segmentation error below 3mm. A score
of 4 reflected a segmentation error at any location between 3mm and 12mm. A score of
3 reflected a segmentation error greater than 12mm but where the overall lobe segmenta-
tion remained acceptable for analysis. The lowest scores (2 and 1) were awarded when the
maximum segmentation error was greater than 12mm and segmentation quality was either
equivocal or unusable. Scores were assigned to both complete and incomplete fissures.
The algorithm showed good performance across complete (3.9 ± 0.3) and incomplete
fissures (3.8 ± 0.5). There was one notable failure (score = 2) to segment the right major
fissure in a case with a complete fissure and one failure (score = 1) of a segmentation of
a right major fissure when it was grossly incomplete. Across cases with complete and
incomplete fissures, the most commonly awarded score was 4. Only a small proportion
of cases had maximum errors < 3mm (22% and 12.5% for complete and incomplete right
minor fissures whilst 0% and 7.3% for complete and incomplete right major fissures).
4.4.3 Effect of the groupwise prior
I assessed the performance of the algorithm with and without the groupwise prior (Π) on
dataset 2. I computed the mean of the distances from the automated segmentation to the
reference and compared this to results using the prior. I did not include the boundaries
that failed in the quantitative analysis of Section 4.4.2.2 as these boundaries also failed
without using the groupwise prior. I omitted cases with minor fissure incompleteness in the
analysis. This was defined when a lobar boundary had less than 1% fissure incompleteness.
This led to 19 analysed patients for the right major fissure, 23 for the right minor and 19
for the left major. There was 9.72%± 8.66% fissure incompleteness in the right major,
36.44%± 18.91% for the right minor and 11.61%± 9.81% for the left major in the new
cohort. We calculated the cohort average for each boundary and for the segmentation labels
of fissures not visible in CT, delineated as label 2 and 3. I performed a two-sample t-test
under the null hypothesis that the mean results of the segmentation with and without the
groupwise prior are significantly different.
I found a general increase in the distance to the reference for label 2 (5.87mm±
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Table 4.3: Qualitative COPDGene results. © 2017 IEEE. Reprinted, with permission from F. Brag-
man et al., Pulmonary lobe segmentation with probabilistic segmentation of the fissures
and a groupwise fissure prior, IEEE Transactions on Medical Imaging, 2017.
(a) Complete fissures (label 1)
Score Right Major Right Minor Left Major Total Score
% 5 0.0 22.0 0.0
3.9 ± 0.3
% 4 82.4 58.0 76.5
% 3 15.6 20.0 23.5
% 2 2.0 0.0 0.0
% 1 0.0 0.0 0.0
(b) Incomplete fissures (label 2 and 3)
Score Right Major Right Minor Left Major Total Score
% 5 7.3 12.5 2.4
3.8 ± 0.5
% 4 68.3 50.0 70.7
% 3 22.0 37.5 26.8
% 2 0.0 0.0 0.0
% 1 2.4 0.0 0.0
3.72mm to 7.60mm± 6.49mm) and label 3 (7.10mm± 3.67mm to 8.59mm± 5.77mm)
when excluding the groupwise prior. I did not find a significant difference between the sets
of mean distances for each lobar boundary stratified by reference label (Table 4.4). This is
due to the fact there may be extreme differences due to failures without the prior, smaller
improvements using the prior but also cases where the prior negatively affects extrapolation
of the fissure.
In areas of significant fissure incompleteness, the groupwise prior may help avoid leak-
ing of the seed labels during the surface fitting whilst guiding the segmentation to the most
probable location based on the population and the patient anatomy. This occurred in several
cases (Figure 4.14 a and b) where either the left major border or the right major border
failed without the prior. Within this cohort, the right minor fissure had the highest level of
fissure incompleteness. In various cases (Figure 4.14 c and d), the prior helped drive the
lobar border towards the reference. However, there are several modes of variation in the
right minor fissure (Figure 4.5). The patient anatomy may differ greatly from the popula-
tion mean. The prior may negatively affect the final segmentation in areas of incomplete
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fissures. This led to a smaller difference in the population means in the right minor fissure
(6.28mm to 6.51mm in label 2 and 6.41mm to 6.50mm in label 3). Despite this limitation,
I can conclude that the groupwise fissure prior, constructed from the same cohort using a
combination of complete and incomplete segmented fissures is advantageous.
Table 4.4: Quantitative Results - Fissure Metrics with and without Groupwise Prior. © 2017 IEEE.
Reprinted, with permission from F. Bragman et al., Pulmonary lobe segmentation with
probabilistic segmentation of the fissures and a groupwise fissure prior, IEEE Transac-
tions on Medical Imaging, 2017.
WITH (mm) WITHOUT (mm) p-Value
Label 2
Right Major 5.29±3.00 5.71±2.75 p=0.65
Right Minor 6.28±3.52 6.51±3.51 p=0.83
Left Major 6.05±4.64 10.59±16.32 p=0.25
Total 5.87±3.72 7.60±6.49 -
Label 3
Right Major 6.94±3.24 8.18±4.28 p=0.34
Right Minor 6.41±2.81 6.50±2.84 p=0.92
Left Major 7.94±4.95 11.09±10.19 p=0.67
Total 7.10±3.67 8.59±5.77 -
4.5 Discussion and conclusion
I have presented a novel lobe segmentation algorithm based on an unsupervised segmenta-
tion of the fissures with iterative false-positive removal, the creation of a groupwise fissure
prior and a cost function combining patient and population information. Our algorithm
does not require prior training or manual labelling to segment the fissures and build a pop-
ulation prior of the fissures. Fissure probabilities were obtained by parameterising a fissure
enhancement filter with a Gaussian Mixture Model (GMM). Smoothness and curvature con-
straints were enforced in the segmentation by considering a Markov Random Field (MRF)
regularisation. This led to rejection of most false-positives leading to high maximum F1-
score of 0.90. A method to construct a groupwise fissure prior given complete and incom-
plete fissures in a population was presented. I evaluated its role in identifying incomplete
fissures whilst minimising potential segmentation failures. The method was validated on 55
cases from the LOLA11 study [99] and on 80 datasets from the COPDGene study [167]. I
illustrated its applicability in correctly segmenting the lobes of patients with varying levels
of disease severity and fissure incompleteness.
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(a) Example 1 - correction in left major
(b) Example 2 - correction in right major
(c) Example 3 - correction in right minor
(d) Example 4 - correction in right minor
Figure 4.14: Lobe segmentation results without and with the groupwise prior (Π) in four different
patients. The reference for non-visible fissures (label 2 and 3) is overlaid on the lobe
segmentation. The colour of the reference was chosen to aid the visualisation and is
not representative of the segmentation label. © 2017 IEEE. Reprinted, with permission
from F. Bragman et al., Pulmonary lobe segmentation with probabilistic segmentation
of the fissures and a groupwise fissure prior, IEEE Transactions on Medical Imaging,
2017.
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Correct removal of false-positive fissures is necessary to accurately segment the fis-
sures. Whilst supervised filter techniques have been utilised to segment the fissures
[223, 118, 174], they require a training dataset to perform the classification. Manual la-
belling of voxels is laborious and may not always be practicable in a clinical setting. The
fissure segmentation used by van Rikxoort et al. [221] required a training set as part of
their algorithm and can only be employed when manual labelling is possible by an expert.
Moreover, the applicability of a training set built on an independent set of scans applied to
those acquired on different scanners is debatable.
Ross et al. [174] exploited a deformable model to identify the fissure surfaces, which
may fail when the patient anatomy cannot be modelled by the atlas. The fissure enhance-
ment applied by Lassen et al. [109] required experimentation to yield optimal ranges for
the Hessian eigenvalues. Applying pre-existing thresholds to new datasets and those ac-
quired at lower doses can be problematic and may cause undesirable drops in algorithm
specificity. Applying hard-constraints on eigenvalue magnitudes in new scans may not be
beneficial. The eigenvalue range may differ whilst the ratio is expected to remain constant.
This is because the ratio will model different orientation patterns unique to various struc-
tures (spherical, tubular and sheet-like). This may cause an over-segmentation with too
many false positives. The limitation of pre-existing threshold can also be applied to the
filter of Wiemker et al. [238], who developed a weighting term based on the expected inten-
sity of the fissures. It requires specific knowledge about the HU of the fissures to determine
parameters unique to scans. Finding optimal parameters that yield a robust filter across a
broad range of datasets is difficult and not desirable.
Our segmentation framework requires little prior knowledge regarding algorithm pa-
rameters and will be more robust than methods requiring prior training. Our fissure en-
hancement filter is based on ratios of Hessian eigenvalues. Given a set of new scans, sep-
arability between class distributions will exist since relationships between the eigenvalues
should remain constant. Since we learn model parameters of the GMM, the segmentation
of the fissures will be flexible when processing new scans. Classifying voxels by learn-
ing the underlying class distributions will capture a range of filter values; which can vary
for each dataset. The integration of the MRF regularisation increases the robustness of the
segmentation to noise. A voxel with a poor filter response can still receive a high fissure
class probability when considering neighbourhood constraints on pairwise probabilities and
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Hessian eigenvectors.
I showed in Section 4.4.1 that our method achieved a high median F1-score of 0.90
and insensitivity to the filter input parameters. These parameters govern the separability
of the class distributions and do not rely on knowledge of specific CT features. There is
a minor dependence on the initialisation of the model parameters in the GMM. However,
the iterative framework for increasing the MRF regularisation means no user-interaction is
required. The iterative increase also deals with false-positive rejection as constraints on
neighbourhood properties are given more weight until algorithm convergence. Performance
of the fissure segmentation could be improved in future work by modelling the signal as a
mixture of skew-normals akin to the work of Ha¨me et al. [84] since I chose a GMM for
mathematical simplicity.
I evaluated our algorithm on the LOLA11 dataset [99], which enabled direct compar-
ison with the work of Lassen et al. [109] and van Rikxoort et al. [220]. I achieved the
highest score of 0.884 in comparison to Lassen et al. [109] (0.881) and van Rikxoort et
al. [220] (0.851). Both algorithms used superior lung segmentation algorithms (0.947 (our
method) versus 0.962 [220] and 0.971 [109]), which may have had detrimental effects on
our lobe segmentation scores in the most challenging cases (e.g. Figure 4.12g, h and j).
The quantitative experiment on dataset 2 highlighted the accuracy of the algorithm
in areas with varying fissure visibility (Table 4.2). The high standard deviation associated
with the segmentation of the right minor fissure was due to the failure of lobar segmentation
in 2/30 cases. In these two cases, post-processing of airway labelling errors could not
be automatically corrected. The respective fissure means and standard deviations were:
1.52mm ±1.49mm, 46.06mm ±30.74mm and 1.33mm ±2.06mm for the right major and
minor fissures and and left major fissure respectively, which displays the isolated error. The
large maximum errors in certain cases with low mean distances occurred in isolated areas
close to the ribcage and near the lung hila where the automated segmentation disagreed
significantly with the radiologist.
Qualitative testing (Table 4.3) highlighted the ability of the algorithm to produce good
segmentation results in cases with higher severities of disease. The low proportion of lobar
boundaries scoring 5 (errors < 3mm) in cases with complete fissures (Table 4.3a) are a
result of the narrow boundary definitions of the scoring system. The scoring system may
not adequately reflect the performance of the algorithm since an isolated error will reduce
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the score to 4 when it would otherwise be graded as 5. Most of these errors were less
than 6mm from the reference fissure line and occurred in isolated regions prone to artefacts
such as close to the rib-cage, the lung hila and the intersection between the right major and
minor boundaries. Importantly, the algorithm was able to interpolate incomplete fissures
(Table 4.3b) and demonstrated equivalence in performance to cases with complete fissures.
The findings highlight the ability of the groupwise prior in conjunction with information
from the vessel and airway tree to successfully guide fissure segmentation towards correct
locations as defined by the reference standard.
My work bears many similarities with the implementation of Lassen et al. [109]. They
also exploited information from auxiliary structures by combining the airway and vessel
tree with the segmented fissures to create a cost image for watershed segmentation. Our
algorithm differs primarily in the fissure segmentation and in the inclusion of population
information in the cost image. Priors dependent on the segmentation of the vessel and
airway tree might not always be fully informative. Airway tree segmentation is challenging
and may not be sufficiently segmented to provide enough information about the location
of lobar borders. The vessel tree may also not provide sufficient information in areas of
largely incomplete fissures. The additional information provided by the groupwise fissure
prior helps mitigate these issues. Within the LOLA11 dataset, the effect is marginal on
the overall scores (0.884 versus 0.881). The dataset included many highly irregular scans,
which made it difficult to create an accurate population model. The effect of the groupwise
prior was more noticeable in dataset 2 from the COPDGene study (Figure 4.6 and 4.14)
where I demonstrated the utility of the groupwise fissure.
The technique by which I construct the groupwise prior has the advantage of not requir-
ing any pre-existing data. This does not require an expert to manually delineate complete
fissures including visible and non-visible fissures. Since I construct the prior on the current
set of data, it is not biased towards particular types of imaging data. The groupwise prior
acted as a guide or region of confidence within the patient space rather than rigidly guiding
the segmentation based on shapes in the training set, facilitating the segmentation of lobes
of varying shape. Its effect was demonstrated on dataset 2 (Table 4.4) and visualised in Fig-
ure 4.14. Our method for constructing the groupwise prior suffers from a lack of flexibility
in comparison to deformable models. A prior created by averaging all segmented fissures
in the groupwise space may be over simplistic. Despite the simplicity of its construction,
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the application can bias the results in certain cases. This was seen in the relationships cal-
culated between segmentation errors and fissure incompleteness (Section 4.4.2.2) but also
when quantifying the effect of the prior (Section 4.4.3). Since the average fissure is directly
added within the patient space, it does not take into account the shape of the segmented
fissure. This introduces a bias if the patient anatomy differs significantly from the mean.
This occurred mostly in the right minor fissure, where several modes in the population exist
(Figure 4.5). This led to a smaller average increase in the errors when testing algorithm
performance without the prior (Table 4.4).
The dependence of our work on the construction of a groupwise space is a limitation.
Groupwise registration is computationally expensive and measuring registration accuracy
of inter-patient registration is difficult. Errors in the registration may be present, which can
decrease the strength of our calculated groupwise prior. The work of Li et al. [112] used an-
notated landmarks from the airway tree to drive inter-patient landmark and intensity-based
registration, indicating the applicability of detecting landmarks in inter-patient registration.
Inclusion of the vessel density map in a multi-modal registration scheme to construct our
groupwise space may then produce a more accurate fissure prior. Improving the inter-patient
registration is then likely to increase the flexibility of the fissure prior. The transformation
between the average space and the patient space acts as a deformable model. A more accu-
rate mapping; obtained by including extra morphological information will help deform the
groupwise prior to more unusual geometries.
The need to segment the airway tree may also decrease the applicability of our frame-
work. Segmentation of the bronchial tree is an important determinant in the success of our
algorithm as demonstrated by several failures in dataset 2. The vessel density map produces
a good approximation of the fissure location, which may negate the need to use the airway
tree in the fissure segmentation and cost function. However, initial seed labelling for the
watershed still relies on the airway tree. Whilst I developed post-processing methods to
make the method more robust to the quality of the airway segmentation, errors can lead to
failures. A combination of the groupwise framework and the labelling method described in
Section 4.2.4.3 may help generate better seeds without needing the airway tree.
The segmentation of incomplete fissures remains one of the biggest challenges in lobe
segmentation. I presented the simultaneous construction of a groupwise prior to address this
challenge. When the fissures are not-visible on CT, this is because they may be congenitally
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absent or destroyed by inflammatory disease processes. The segmentation may therefore be
creating an artificial division between lobes. In reality, the anatomical boundary between
the lobes has either been destroyed or is absent. This is seldom mentioned in the lobe seg-
mentation literature. When comparing our results with the label 3 reference, it is therefore
important to note I am comparing algorithm extrapolation with the educated guess of an
expert. Furthermore, it is not yet known what accuracy is needed in the segmentation of
incomplete fissures to produce regional markers of disease that are clinically useful.
Despite the ability to correctly guide the segmentation in regions of incomplete fissures
in most cases, the application of the groupwise prior requires further work. There may
be issues when the mean of the population deviates significantly from the patient being
segmented. In order to fully exploit the power obtained by fusing complete and incomplete
segmentations, it is necessary to dynamically weight the groupwise prior in regions when it
is needed and regions where information stemming from the patient is sufficient. Another
solution may lie in creating various fissure models using different sets of patients from the
population to mimic multi-atlas selection.
In conclusion, I have presented a lobe segmentation algorithm, which requires no prior
training or manual labelling to both segment the fissures and build a population prior of the
fissures. I have tested the method on 135 different datasets with varying levels of disease
severity and complexity. The presented algorithm can be used in large studies to perform
accurate regional quantification of disease progression and shows great promise to be inte-
grated within a clinical setting.
Chapter 5
Manifold learning of COPD
The work presented in this chapter is based on and reproducted, with permission from F.
Bragman, J. McClelland, J. Jacob, J. Hurst and D. Hawkes (2017)∗. “Manifold Learning
of COPD”. In: Medical Image Computing and Computer Assisted Interventions - MICCAI
2017. Edited by M. Descoteaux, L. Maier-Hein, A. Franz, P. Collins and S. Duchesne.
Lecture Notes in Computer Science, vol 10435, pp. 586-593. © 2017 Springer Nature.
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Abstract
In this chapter, I build on the framework proposed in Chapter 3 to better quantify
the pathology and pathophysiology of COPD. The aim was to develop a method
that better quantifies the spread of disease throughout the lung and captures its
effect on lung deformation. Current methods for quantifying disease extent in
the lung rely on global averages and lobar averages when lobe segmentations are
possible. By extending the local sampling framework of Chapter 3 to measure
the spread of emphysema, functional small airways disease (fSAD) and variations
in local volume change, a simple and clinically intuitive method for phenotyping
COPD from CT could be developed.
I present local disease and deformation distributions in this chapter. The disease
distribution aims to quantify two aspects of parenchymal damage: locally dif-
fuse/dense disease and global homogeneity/heterogeneity. The deformation dis-
tribution aims to link parenchymal damage to local volume change. These distri-
butions can be exploited in various ways to study COPD. The distributions were
exploited to quantify accurate inter-patient differences in large cohort of patients
from COPDGene. A framework originally applied to study neonatal brain de-
velopment was implemented to investigate the progression of the distributions.
Manifold learning was applied to seek a low-dimensional embedding based on the
distributions whilst fusion of the learned embeddings was employed to combine
distinct aspects of COPD into a single model. I demonstrated the utility of the
framework by comparing associations between learned embeddings and measures
of severity. I have also illustrated the potential to identify trajectories of disease
progression in a manifold space of COPD.
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5.1 Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a complex disorder arising from various
pathological processes including emphysema and functional small airways disease (fSAD).
The extent of emphysema and fSAD that make up overall disease burden in an individual
patient can vary, which can affect lung physiology and the clinical manifestations of a pa-
tient [82, 104, 162, 206, 157, 180]. Both components of COPD can progress at different
rates and can complicate prognostication. Optimising the quantification of disease extent in
COPD may improve the precision of disease staging and monitoring.
Analysis of lung disease from Computed Tomography (CT) has typically relied on the
use of global averages. Such metrics cannot capture the anatomical distribution of disease.
Several methods have attempted to capture regional manifestations with varying results in
the literature. Tanabe et al. [205] employed the fractal exponent D to quantify the size dis-
tribution of emphysema clusters. They showed through model simulations that a spatially
heterogeneous progression of emphysema may occur as a result of smoking [205]. They fur-
ther showed in a separate study that a more homogeneous distribution of emphysema con-
tributes more to FEV1 decline. In a similar longitudinal study, focusing on α1-antitrypsin
deficiency, Parr et al. [157] showed that basal emphysema was associated with stronger
progression in gas exchange impairment yet that apical emphysema associated better with
FEV1 decline.
Heterogeneity between the upper and lower lobes was assessed by Ju et al. [104]
who proposed a heterogeneity index (HI) to quantify apical and basal emphysema subtypes.
They found that patients with apical emphysema in contrast to Parr et al. [157] had sig-
nificantly better lung function. Gietema et al. [75] found a negative correlation between
pulmonary function and apical predominant emphysema although they note that it may not
be statistically strong enough to be of clinical utility. Although not applied to COPD, a first
attempt at quantifying intra and inter-lobar differences in emphysema was performed by
Yilmaz et al. [246]. They quantified lobar fractional tissue volume and found associations
between inter and intra-lobar distributions of emphysema and pulmonary function.
These methods are all attempts at better measuring COPD. However, considering the
complex nature of the lung anatomy and its variation in the population, quantifying inter-
patient differences with these metrics may not be accurate enough. In contrast to neu-
roimaging where groupwise studies are plentiful [212], with methods such as voxel-based
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morphometry [130], population-wide studies of COPD and other lung diseases have largely
been limited to using these simple metrics that may not be fully illustrative of the disease
process.
The work of Feragen et al. [65] addressed the complexity of the airway tree by intro-
ducing a family of kernels for comparing anatomical trees endowed with vector attributes.
These were exploited to statistically test that COPD diagnosed airway trees come from
different distributions than healthy airway trees. Importantly, they showed that COPD clas-
sification improved when using airway wall area percentage kernels instead of traditional
methods that compute an average across airway branch generations [83]. The need for a
more complex quantification of the lung anatomy is seen in classification methods that ex-
ploit regions of interest (ROI) measured throughout the lung [42, 77, 192, 193]. Sørensen et
al. [192] developed a new distance metric based on bipartite-graph matching between two
collections of ROIs, which outperformed classification using average emphysema. This is
corroborated in the work of Cheplygina et al. [42] who approached COPD classification
as a Multiple Instance Learning (MIL) problem. Within MIL, the goal is to build a classi-
fier for a collection of feature vectors, referred to as instances. This idea extends naturally
to COPD, where a patient may experience positive instances of disease (emphysematous
regions), and false positive instances (healthy regions).
In this chapter, I present a new method that quantifies the spread of disease throughout
the lung and, which goes beyond the global extent of disease to quantify various aspects
of pathological tissues destruction. It can be applied to any imaging features such as lung
deformation to quantify links between structural damage and lung deformation. The frame-
work can be exploited to quantify inter-patient differences in a large patient cohort to ex-
amine disease progression in a cross-sectional cohort. This bypasses the need to construct
a groupwise space to compare lung texture. It is based on locally quantifying tissue clas-
sification results and lung deformation to capture heterogeneity or homogeneity across the
lung. The outcome of the method is a distribution that quantifies various aspects of lung
pathophysiology that can be modelled with manifold learning to test associations with clin-
ical hypotheses. This work builds on the framework presented in Chapter 3. The lung is
composed of a collection of regions with different pathological and healthy characteristics.
The distribution of ROIs is unique to the patient, represents a signature of the disease state
and may potentially be used as a marker of disease progression.
5.2. Methods 106
5.2 Methods
5.2.1 Lung deformation and tissue classification
The deformation between paired breath-hold CT scans acquired at forced residual capacity
(Iexp, Ω∗) and total lung capacity (Iins, Ω) can be obtained using nonrigid registration. The
output is a transformation ϕ mapping each coordinate x ∈ Ω→ x∗ ∈ Ω∗. Local volume
change on a voxel-wise basis is measured using the determinant of the Jacobian matrix: J =
det(∇xϕ ). A Jacobian determinant equal to 1 represents no volume change, compressive
change occurs at J < 1 whilst J > 1 represents expansion.
Parametric Response Mapping (PRM) [70] is used to classify lung tissue into emphy-
sema (PRMemph) and functional small airways disease (PRM f SAD). It is a simple technique
that requires no training or manual labelling for the classification, which makes it particu-
larly attractive in the studies with large cohorts of patients. The value of PRM f SAD is not
a direct measurement of functional small airways disease. The smaller airways cannot be
directly measured since their dimensions fall below the resolution of modern CT scanners.
It is an indirect measure as it classifies areas of gas trapping in Iexp, which are not emphy-
sematous in Iins.
To perform the classification, PRM requires the transformation (ϕ ) resulting from the
registration of Iexp to Iins. For all voxels xi ∈ Iins, the tissue class zi is obtained by applying
the following Hounsfield Unit (HU) thresholds in Iins and the registered Iexp:
zi =

PRMemph if Iins(xi)≤−950 and Iexp(ϕ (xi))≤−856
PRM f SAD if Iins(xi)>−950 and Iexp(ϕ (xi))≤−856
(5.1)
The contribution of the airway walls and the vasculature is minimised by only consid-
ering voxels with an HU between −500HU and −1024HU in both scans. Equation 5.1 is
applied to all voxels xi ∈ Iins to yield the classified volume Z (Figure 5.1).
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(a) Iins (b) Z (c) Z = PRMemph (d) Z = PRM f SAD
(e) Iins (f) Z (g) Z = PRMemph (h) Z = PRM f SAD
Figure 5.1: Example of Parametric Response Mapping classification. The map for voxels classified
as normal (PRMnormal), which are green voxels in Z , is not displayed.
5.2.2 Local disease and deformation distributions
I present the concept of local feature distributions (Figure 5.2 and 5.3). The aim is to
quantify local abnormalities in lung physiology and pathology to define a signature unique
to a patients disease state. I introduce two models: 1) local disease distributions (Figure
5.2) and 2) local deformation distributions (Figure 5.3). The disease distributions model
the spread of emphysema and fSAD whilst the deformation distribution characterises local
volume change across the lung. They are created by locally sampling regions of Z and J
in a Cartesian grid using local regions of interest Ωk (ROI) where k = 1 · · ·K indexes the
center voxel of the ROI. The size (r× r× r) of the ROI governs the scale of the sampling.
The local disease distributions model two properties of disease spread: 1) locally dif-
fuse/dense disease and 2) global homogeneity/heterogeneity. For each ROI centered at
zk where z ∈ Ωk, I computed the fraction of PRMemph and PRM f SAD voxels; defined as
vk(emph) and vk( f SAD). Dense disease occurred when vk(·)→ 1 whilst diffuse disease
was present when vk(·)→ 0. The deviation of diffuse and dense regions in the lung defined
the heterogeneity/homogeneity of disease spread.
A distribution f (v(·)) for each feature was built by sampling K regions. The shape of
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the distribution is governed by the two disease properties (Figure 5.4). It provides informa-
tion on the nature of local disease spread (diffuse or dense), whether it is homogeneous or
heterogeneous. Additionally, it also captures whether the distribution is bimodal.
Expansion of the lung is dependent on local biomechanical properties (emphysema)
and airway resistance (functional small airways disease). Both these processes will affect
lung deformation locally. The local deformation distribution captures volume change on
a local basis whilst modelling potential homogeneities or heterogeneities (Figure 5.3). To
measure volume change on a local basis, the Jacobian map (J) was sampled by calculating
the mean Jacobian (µ(J)k) for all Ωk. A distribution f (µ(J)) of these measurements was
built to capture local volume change throughout the lung using the same process as for the
disease distribution.
(a) Local sampling of Z
(b) Iins (c) Z (d) v(PRMemph) (e) v(PRM f SAD)
Figure 5.2: Local disease distribution quantification. © 2017 Springer Nature. Reprinted, with per-
mission from F. Bragman et al., Manifold learning of COPD, Medical Image Computing
and Computer Assisted Interventions, 2017.
5.2.3 Manifold Learning of COPD distributions
The goal of manifold learning lies in learning a low-dimensional representation to model
variability in the data. In this chapter, I have presented the concept of local disease and
local deformation distributions. It is possible that one aspect in the heterogeneity of COPD
is due to the different mechanisms of emphysema and fSAD and its effect on local lung
biomechanics. The presented distributions were developed to capture these processes. I
used manifold learning to model variations of the distributions in a large population of
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Figure 5.3: Local deformation distribution quantification. © 2017 Springer Nature. Reprinted, with
permission from F. Bragman et al., Manifold learning of COPD, Medical Image Com-
puting and Computer Assisted Interventions, 2017.
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Figure 5.4: Local disease distributions for patient with equal levels of emphysema in the lung
(µ(PRMemph=30%). Top row patient: FEV1%predicted=28.3 and bottom row patient:
FEV1%predicted=33.8
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COPD patients. This led to separate embeddings for emphysema, fSAD and volume change.
Fusion of these embeddings was then performed to create a single model of these processes
to analyse COPD progression.
5.2.3.1 Distribution distances
Inter-patient differences can be computed by considering the distance (L) between two fea-
ture distributions ( f1(v) and f2(v)). As the distance metric employed is an important deter-
minant in comparing distributions, I considered the following: 1) the L1-norm, 2) the L2-
norm, 3) the Earth-Movers Distance (LEMD) and 4) the Quadratic-Chi histogram dissimilar-
ity (LQC). The first two are bin-to-bin distance measures and the latter are cross-bin metrics.
The local distributions ( f1(v) and f2(v)) are quantised into histograms (H(v),K(v) ∈ RNb)
with Nb bins. These histograms are normalised such that they sum to one. They have equal
mass and are probability mass functions on equal intervals ([0,1]). The probability mass at
a bin i for the histograms H and K are defined as hi and ki.
Lp Distances The L1 and L2-norm are defined as follows:
Lp(H,K) =
(
Nb
∑
i
|hi− ki|p
)1/p
(5.2)
with p = 1 and p = 2 corresponding respectively to the L1 and L2-norm. They are
considered bin-by-bin measures as the distances are computed by matching bins at the
same index. A drawback of Lp-style distances is their dependence on the bin number.
If the number of bins is low, the resulting histogram will not be discriminative. If the
number of bins is too high, quantisation of the data into bins with small widths can
yield undesirable discontinuities in the histogram leading to a non-robust distance.
Earth-Movers Distance The Earth-Movers Distance (LEMD) [175] is a metric based on
the principle of optimal transport. It measures the minimum amount of work needed
to transform one distribution into another. The EMD operates on signatures of his-
tograms s j = {m j,w j}, which represents a set of feature clusters. Each cluster is
represented by its mean m j and by the fraction of w j of voxels that belong to that
cluster. The Earth-Movers distance is defined as
LEMD(H,K) =
min
{ fi, j}
(∑i, j fi, jdi, j)
∑i, j fi, j
(5.3)
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where di, j is the ground distance and fi, j is the flow between histogram bins i and
j. The aim of LEMD is to find the minimal flow from H to K. Importantly, if one
assumes that the histograms are one-dimensional, have equal mass and have equal
number of bins, the EMD has a closed-form solution equivalent to the L1-norm on
the cumulative distribution function of P(H) and P(K) [110] such that
LEMD(H,K) = L1(P(H),P(K)) (5.4)
Quadratic-Chi Distance The Quadratic-Chi distance LQC is another example of a cross-
bin distance measure [160]. It combines the Quadratic-Form distance (LQF ) and the
Chi-squared distance (Lχ2) such that
LQF(H,K) =
√
(H−K)T A(H−K) (5.5a)
Lχ2(H,K) =
1
2∑i
(hi− ki)2
(hi+ ki)
(5.5b)
LQC(H,K) =
√√√√∑
i, j
(
(hi− ki)
(∑c(hc+ kc)Ac,i)m
)(
(h j− k j)
(∑c(hc+ kc)Ac, j)m
)
Ai, j (5.5c)
where A is a bin-to-bin similarity matrix and m is a normalisation factor. The au-
thors [160] recommend m = 0.9 for best results. In the context of the Quadratic-Chi
distance, the similarity matrix is defined as:
Ai, j = 1− Di, jmax
i, j
(Di, j)
(5.6)
where D is a distance matrix between histogram bins.
The Quadratic-Chi distance exploits advantages of bothLQF andLχ2 . The Quadratic-
form distance takes cross-bin relationships through the similarity matrix A whilst
the χ2 distance reduces the effects of bin-to-bin distances caused by bins with large
values.
5.2.3.2 Manifold Learning and fusion
Manifold learning is used to model emphysema, fSAD and Jacobian distributions. The
aim is to capture variations in the distributions in a population of COPD patients. The
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progression of emphysema and fSAD occur synchronously yet the pathological processes
are distinct. Their combination is likely to affect the lungs ability to deform. The aim
is to capture both processes and their effect on lung deformation to analyse COPD. The
manifold fusion framework presented by Aljabar et al. [4] is employed to create a single
representation of these processes (Figure 5.5).
For P subjects, the classified volumes Z1, · · · ,ZP and their respective Jacobian deter-
minant maps J = J1, · · · ,JP are obtained. The local disease and deformation distributions are
created and quantised using Nb bins into their respective histograms hp,v(emph), hp,v( f SAD) and
hp,J . Pairwise measures in the population are obtained using any of the distance functions
L discussed above in Section 5.2.3.1. This yields the pairwise matricesMemph,M f SAD and
MJ for emphysema, fSAD and the Jacobian respectively.
The pairwise matrices can be visualised as connected graphs where each node repre-
sents a patient and the edge length between nodes is the distance L. Various linear and
non-linear dimensionality reduction methods can be applied to the matrices M(·). Since
the edge-weights inM(·) are distances, the Isomap algorithm [209] is a natural choice as it
interprets edge-weights inM(·) as distances.
Th goal of Isomap is to find the mapping function f : M(·)→ Rd , whereM(·) ∈ RD
such thatM(·) is projected to a low-dimensional space Rd . The main assumption of Isomap
is that f is an isometric chart, which means the distances are preserved as they are mapped to
the new space. If xi and x j are points on the manifold and D(xi,x j) is the geodesic distance
between them, the following relationship is obeyed:
∥∥ f (xi)− f (x j)∥∥=D(xi,x j) (5.7)
A further assumption of the Isomap algorithm is that the geodesic distance between
nearby points is linear and can be approximated by the Euclidean distance. For points
which cannot be approximated by a linear function, the Euclidean distance will not be a
valid approximation. A different approach is therefore needed to compute the distance be-
tween these points. The Isomap algorithm first constructs a sparse representation ofM(·)
by searching for the K-nearest neighbours (k-NN) weighted by Euclidean distances be-
tween each node. Local structure can thus be modelled by an appropriate choice of the
parameter k. To estimate the manifold structure, a full pairwise geodesic matrix D is es-
timated by identifying the shortest path in the k-NN graph of M(·). This is performed
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using Djikstra’s shortest-path algorithm [51]. Given the matrix D(·), Isomap then seeks the
lower-dimensional embedding coordinates y(·)p , p = 1, · · · ,P that satisfies Equation 5.7 by
minimising the cost function:
min∑
p, j
(
D(·)p, j−
∥∥∥y(·)p − y(·)j ∥∥∥)2 (5.8)
using Multi-Dimensional Scaling. The Isomap algorithm is applied separately to
Memph, M f SAD and MJ , which yields the respective embeddings ye, y f and yJ with di-
mension de, d f and dJ that need to be selected (Figure 5.5).
The coordinates y(·) can boe fused together in any combination to create various models
and investigate different combinations of features implicated in COPD. For simplicity, I
consider the fusion of all embeddings. The coordinates are uniformly scaled with scaling
factors se, s f and sJ such that the first component of each embedding y(·)p,1 has a unit variance.
These are concatenated to yield the new set Yp = (seyep,s
f y fp,sJyJp)with dimension d
e+d f +
dJ . A new distance matrix Dc is obtained by calculating the Euclidean distance between all
pairs of coordinates in Y . A second Isomap step is applied to yield the combined coordinate
embedding yc with dimension dc (Figure 5.5). The new embedding coordinates (yc) can then
be used in a classification framework to find clusters of patients with similar presentations
or in regression to test associations with various clinical metrics and outcomes.
5.3 Experiments and results
5.3.1 Histogram quantisation and pairwise distances
There are various parameters that need to be set to run the framework. In the analysis of
local disease and deformation distributions, quantisation of the distributions into probabil-
ity mass functions is necessary to compute pairwise distances. Pairwise distances between
patients provides a metric that quantifies potential differences in textural damage and de-
formation. The choice of distance measure will affect the accuracy of the measurements
and any ensuing analysis. The choice of bin size will affect the shape of the mass func-
tion (Figure 5.6) and will affect the ensuing distances. Adaptive binning techniques exist
[153], which can be approximated as Nb =
3√Ns where Ns is the number of sampled ROIs.
However, Ns varies for each patient and an equal Nb is necessitated to use the closed-form
solution of the LEMD (Equation 5.4). It is noteworthy that the choice of distance function
(L) could be learnt in the training phase of the algorithm when considering classification
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· · ·
· · ·
· · ·
ye
yf
yJ
yc
Figure 5.5: Overview of manifold learning and fusion of local disease and deformation distribu-
tions. Individual embeddings ye, y f and yJ are quantified for each set of distributions
( f (·)) obtained by sampling emphysema (Z = PRMemph), fSAD (Z = PRM f SAD) and
Jacobian determinant maps (J). A final combined embedding (yc) is obtained by fusion
of the individual coordinates.
[193].
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(e) Nb = 40
Figure 5.6: Effect of Nb on the distribution.
Within this experiment, I examined the robustness of pairwise distances on the four
distance metrics (L1,2,EMD,QC, Section 5.2.3.1) with respect to the number of bins. The aim
was to determine the distance measure that is most robust to quantisation, an approxima-
tion of the optimal number of bins and choose the distance measure, which best matched
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perceptual differences.
5.3.1.1 Effect of Nb on the distance metric
I created local-disease distributions (emphysema and fSAD) for 198 COPD patients (GOLD
≥ 1) from the COPDGene cohort [167]. These were created using a local sampling neigh-
bourhood size of r = 20mm. The distributions were created by a dense sampling of 5mm in
the x, y and z directions. This led to an average Ns = 44,251±11,572 number of sampled
regions. Histograms were created by iteratively increasing the number of bins by 10 at each
iteration within the range: Nb(i) ∈ [5,255]. Pairwise matrices (MeL(·)(i) andM
f
L(·)(i)) were
created at each iteration Nb(i) by considering the four proposed distance metrics.
In order to compare how the pairwise distances change with bin size, I first normalised
the pairwise distances by the maximum of all pairwise distances at each iteration. Since
the pairwise matrices are symmetric, I only considered the upper triangular matrixM :=
U(M). The effect of Nb on the pairwise distances was then measured with the absolute
percentage change of the normalised distances:
∆
(
M(·)L(·)(i)
)
=
∣∣∣M(·)L(·)(i)−M(·)L(·)(i−1)∣∣∣
M(·)L(·)(i−1)
(5.9)
where M(·)L(·)(i) and M
(·)
L(·)(i− 1) are the pairwise distances at bins i and i− 1 for
any feature and choice of distance function. Assessing the relationship between M(·)L(·)(i)
and Nb(i) for each distance function provides an indication of the effect of Nb on pairwise
measures in the cohort of patients.
For each bin iteration Nb(i), I calculated the mean and standard deviation ofM(·)L(·)(i)
(Figures 5.7 and 5.8). I also computed the maximum change ofM(·)L(·)(i) (Figure 5.9). The
biggest change in the pairwise distances occurred at low bin numbers (Nb ∈ [5,45]). This
is expected as the distribution is likely to vary significantly when increasing the number of
bins from a very coarse distribution (Figure 5.6). At higher values of Nb (> 40), changes
in histogram distances became less pronounced (Figures 5.7 and 5.8). However, I noticed
a difference between the bin-to-bin (Lp) and cross-bin (LEMD and LQC) measures. In the
former, despite convergence of the pairwise distances, there was still a large variability
with increasing bin size. Conversely, the cross-bin measures saw greater robustness (in
particular the LEMD) with regards to the bin number (when Nb > 30). This was specifically
seen when assessing the maximumM(·)L(·)(i)with increasing Nb for each metric (Figure 5.9).
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Increasing the bin size can cause large changes in the Lp distances. The LEMD provided the
best robustness with very low maximum percentage changes. This was expected in the
LEMD as the work needed to transform distributions H and K is unlikely to vary when an
appropriate number of bins is used.
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Figure 5.7: PRMemph : ∆
(
MeL(·)
)
versus Nb.
5.3. Experiments and results 117
5 35 65 95 125 155 185 215 245
-20
-15
-10
-5
0
5
10
15
20
Bin Number (i)
∆
( M
f L
1
(i
))
 
 
L1
(a) L1-distance
5 35 65 95 125 155 185 215 245
-20
-15
-10
-5
0
5
10
15
20
Bin Number (i)
∆
( M
f L
2
(i
))
 
 
L2
(b) L2-distance
5 35 65 95 125 155 185 215 245
-20
-15
-10
-5
0
5
10
15
20
Bin Number (i)
∆
( M
f L
Q
C
(i
))
 
 
LQC
(c) LQC-distance
5 35 65 95 125 155 185 215 245
-20
-15
-10
-5
0
5
10
15
20
Bin Number (i)
∆
( M
f L
E
M
D
(i
))
 
 
LEMD
(d) LEMD-distance
Figure 5.8: PRM f SAD : ∆
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M fL(·)
)
versus Nb.
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Figure 5.9: Maximum % ∆
(
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)
versus Nb. The curves were fitted with Nadaraya-Watson ker-
nel regression using a Gaussian kernel with a bandwidth of 25.
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5.3.1.2 Perceptual differences in distributions
The previous experiment examined the effect of Nb on various histogram distances. The
cross-bin measures exhibited more robustness to histogram quantisation. The LEMD pro-
vided the best stability, as shown by the maximum change in ∆
(
M(·)L(·)
)
with Nb increase
(Figure 5.9). The Lp-distances displayed significantly higher instability with respect to Nb.
This experiment builds on the previous by analysing specific cases where cross-bin dis-
tance metrics significantly differ from bin-to-bin metrics. This is to examine if the distances
given by L(·) match the perceptual similarity of the classified volumes Z . I chose the LEMD
as the reference for cross-bin distances and compared it to Lp-distances. The distances were
normalised to the maximum distance in the population. Analysis was performed at Nb = 95,
which was chosen by judging convergence of all plots in Figures 5.7 and 5.8.
I first assessed relationships betweenLEMD-L1 andLEMD-L2 (Figure 5.10). I observed
large non-linear relationships between the cross-bin and bin-to-bin distances. There were
cases in both relationships where the Lp distances produced large distances (L > 0.6) in
comparison to a low LEMD (L< 0.3). There were also cases where LEMD produces a large
distance (L> 0.8) yet the L2-distance was small (L< 0.3).
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Figure 5.10: Relationship between the LEMD and Lp distances. The density of the scatter plot is
overlaid.
These cases were assessed to understand instabilities in the metrics and their utility
in distinguishing differences in the distributions. In Figure 5.13, various pairs of patients
with similar patterns of emphysema progression can be observed. The patterns can be
differentiated by the type of distribution and can be either classified as exponential or skew-
normal distributions. An exponential distribution characterises very early disease patterns
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with minimal areas of local disease. A skew-normal distribution represents lung pathology
at a later stages with various regions of diffuse disease and certain isolated areas with a
more dense pattern. It is observable that there exists an instability in the bin-to-bin distance
when comparing exponential and positive skew-normal distributions.
Due to the high density of regions with values close to 0 in the exponential family, an
Lp-type distance will yield large bin-to-bin distances when computing the difference with
a skew-normal distribution. This will artificially inflate the pairwise distance. In contrast,
the amount of work needed to transform an exponential into a skew-normal is low and
translates to a small LEMD. This matches the perceptual differences between both classified
volumes. Considering the robustness of the LEMD towards the bin number and its stability
with respect to these special cases, the LEMD was employed in the proposed framework.
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Figure 5.11: L1 = 0.88 and LEMD = 0.18
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Figure 5.12: L1 = 0.69 and LEMD = 0.09
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Figure 5.13: L1 = 0.91 and LEMD = 0.28
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5.3.2 Manifold learning and fusion of disease and deformation distributions
5.3.2.1 Data
Patients with COPD (GOLD ≥ 1) from the COPDGene database [167] were analysed. A
total of 1,154 scans were downloaded from the COPDGene database. Scans from vari-
ous scanners (GE Medical Systems, Siemens and Philips) were used. The STANDARD
(GE), AS+ B31f and B31f (Siemens), and 64 B (Philips) reconstruction algorithms were
employed.
5.3.2.2 Data processing
The Pulmonary Toolkit [52] was used with the algorithm of Hu et al. [100] to segment the
lungs. Breath-hold scans were registered using NiftyReg [139]. A modified version of the
Niftyreg EMPIRE10 pipeline [137] was used. The transformation was a stationary velocity
field parameterised by a cubic B-spline and the similarity measure was MIND [91]. The
constraint term was the bending energy of the velocity field and was weighted at 1% of
the objective function for all stages of the pipeline. The transformation obtained from the
registration was used to resample the expiration scan into the space of the inspiratory scan.
Lung tissue was then classified using the PRM [71] by exploiting the coregistered scans.
To quantify the local deformation and disease distributions, I used a sampling size of
r = 20mm for the ROI. This is consistent with the size of the secondary pulmonary lobule.
Sampling was performed by creating a Cartesian grid of center voxels spaced every 5mm.
I chose a value of Nb = 60 as its effect on LEMD pairwise distances was minimal with
increasing Nb when Nb was greater than 50 (Section 5.3.1.1). The Earth Movers distance
(LEMD) was used as the distance function to calculate the pairwise distances and create
M(·) for each feature.
5.3.2.3 Quality control of the registration results
The local disease and deformation distributions are both dependent on the quality of the
registration. Quality control was therefore performed to reject registrations that may affect
the quality of the modelling. A 5-point qualitative scoring system was first used to assess
the quality of the registrations (Table 5.1). A registration was rejected if the score was ≤ 2
and accepted otherwise. Qualitative scores for 300 subjects were recorded and a frequency
distribution of the scores is displayed in Figure 5.14. The remaining patients from the
COPDGene cohort were assessed using the scoring criteria and were marked as accept or
reject. After manual inspection of the registration results and use of the scoring criteria,
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Table 5.1: Qualitative scoring system for registration quality control
Score Criteria
5 No noticeable errors.
4 Small isolated errors not likely to affect subsequent analysis.
3 Larger errors not likely to affect subsequent analysis.
2 Systematic larger errors that will affect subsequent analysis.
1 Large failures in the registration.
P = 743 patients were selected for the analysis. Examples of registration results for the
defined quality control scores can be viewed in Figure 5.15.
Figure 5.14: Frequency distribution of registration qualitative scores
5.3.2.4 Manifold learning with Isomap
Manifold learning of each similarity matrix was performed with the Isomap algorithm [209]
using the Dimensionality Reduction Toolbox [216]. The output of each Isomap step is a
set of embedding coordinates y of dimensionality d. The dimensionality d and the local
neighbourhood parameter K were determined for each embedding by estimating the recon-
struction quality of the lower-dimensional coordinates. The residual variance defined as
ρres = 1−ρ2D,y (5.10)
was calculated between the estimated geodesic distances in D and the Euclidean pair-
wise distances of the learned coordinates y(·). Pearson’s correlation coefficient (ρ2D,y) was
computed between D and the distances of y(·). The aim is to find the set of parameters d
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(a) Score 1
(b) Score 2
(c) Score 3
(d) Score 4
(e) Score 5
Figure 5.15: Illustrative registration results for the qualitative scoring system
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and K, which best satisfy the relationship in Equation 5.7. This was performed by finding
the pair of parameters K∗ and d∗ that minimises Equation 5.10 such that:
argmin
K,d
ρres (5.11)
For each embedding step (ye, y f and yJ), the combination of K and d that yielded the
minimal residual variance for each embedding was determined with Equation 5.11. Grid-
search parameters were set d∗ ∈ [1,5] and K∗ ∈ [5,100]. This led to the parameters K =
[50,30,45] and d = [5,5,4] for ye, y f and yJ respectively.
Two separate models were considered: 1) a model of the disease distributions (ye,
y f → yc1) and 2) a model of the disease and deformation distributions (ye, y f , yJ→ yc2). The
first model (yc1) aimed to solely study the variation of emphysema and fSAD distributions in
the COPD cohort. The second model (yc2) was constructed to investigate a more complete
representation of the disease process by combining both emphysema and fSAD distributions
with the local deformation distribution. Parameters for both models after application of
Equation 5.11 were Kc1 = 55 and Kc2 = 60 with dc1 = 4 and dc2 = 4.
5.3.2.5 Single manifolds of emphysema, fSAD and deformation
Correlations between the individual embeddings and moments of the distributions were
tested. This was performed by calculating Pearson’s correlation coefficient between the
first 3 dimensions of ye, y f and yJ with the following distribution parameters: median (ϕ),
median absolute deviation (ρ), skewness (γ1) and kurtosis (γ2). The median and median
absolute deviation were chosen over the mean and standard deviation due to the shape of
the various disease and deformation distributions. After inspection, I concluded that there
were 4 potential disease distribution shapes (normal, skew-normal, exponential, a mixture of
normal distributions) and 3 potential deformation distributions (normal, skew-normal and
a mixture of normal distributions). The median and median absolute deviation therefore
better quantified the range of distributions.
The first and second components of the individual embeddings had strong to mod-
erate correlations with the distribution parameters (Table 5.2). The first component had
the strongest correlations whilst the second and third components of the embeddings were
weaker but still mainly significant. For example, the first component of ye correlates very
strongly with all distribution parameters with weak, yet significant relationships with the
second. For y f , the first component strongly correlates with the median yet there is an equal
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Table 5.2: Pearson correlation coefficient between embedding coordinates and the distributions
using the median (ϕ), median absolute deviation (ρ), skewness (γ1), kurtosis (γ2).
[∗ = p < 0.05, † = p < 10−3]. © 2017 Springer Nature. Reprinted, with permission
from F. Bragman et al., Manifold learning of COPD, Medical Image Computing and
Computer Assisted Interventions, 2017.
PRMemph PRM f SAD J
ye1 y
e
2 y
e
3 y
f
1 y
f
2 y
f
3 y
J
1 y
J
2 y
J
3
ϕ 0.96† -0.19† 0.01 0.97† 0.07 -0.01 -0.48† -0.06 0.04
ρ 0.89† 0.22† -0.00 0.35† -0.36† -0.41† -0.46† 0.14∗ -0.09
γ1 -0.71† -0.28† 0.00 -0.86† 0.21† 0.16† -0.68† -0.24† 0.00
γ2 -0.41† -0.26† -0.01 -0.37† 0.33† 0.26† -0.36† -0.18† -0.01
correlation across the three components when considering the median absolute deviation
and the kurtosis. These relationships demonstrate that manifold learning of the distribu-
tions modelled the inter-patient variations in the studied population.
Two-dimensional projections of the underlying manifolds for emphysema, fSAD and
the Jacobian distribution are visualised in Figure 5.16. They display the progression of the
local-disease and deformation distributions correlated with FEV1%predicted. A point of in-
flection is present in all manifolds, which correspond to significant shift in FEV1%predicted.
The lower correlation with the second component of the embeddings (y(·)2 ) can be attributed
to the variation of the distributions in this region. At lower levels of disease severity
(FEV1%predicted ≥ 60), the distributions mainly represent diffuse levels of disease with
high homogeneity. As tissue destruction progresses and variations in lung deformation are
more present, several modes in the distributions become apparent. As severity increases
(FEV1 %predicted < 60), most distributions are seen to converge to similar states with
small clusters of patients representing distinct patterns e.g. upper lobe dense emphysema.
Detecting this point of inflection in the clinical management of COPD may be beneficial as
the progression of disease may accelerate greatly past this point.
5.3.2.6 Association of models with disease severity
Two models were constructed to predict COPD severity using FEV1%predicted and
FEV 1/FVC (Table 5.3 and 5.4). The first model (yc1) is a fusion of the emphysema (ye) and
fSAD (y f ) manifolds whilst the second (yc2) also combines the deformation embedding (yJ).
We considered three simple models (mean PRMemph, mean PRM f SAD and mean Jacobian
µ(J)) and compared them to univariate (Table 5.3) and multivariate (Table 5.4) models of
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(a) Learned embedding of emphysema distributions - ye
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(b) Learned embedding of fSAD distributions - y f
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(c) Learned embedding of Jacobian distributions - yJ
Figure 5.16: Embeddings of emphysema, fSAD and Jacobian distributions with FEV1%predicted
overlaid
5.3. Experiments and results 126
embedding coordinates (y). The univariate models only consider the first component of y(·)
such that Y = β0+β1 ·y(·)1 . The multivariate models make use of all dimensions of y(·) where
Y = β0 +∑iβi · y(·)i . Model performance was tested with the adjusted-r2 and the Bayesian
Information Criterion (BIC). It is defined as BIC = ln(n)k−2ln(L̂), where n is the number
of observed data points, k is the number of parameters in the model and L̂ is the maximised
value of the likelihood function. The BIC is a criterion for model selection amongst a finite
set of models ran on the same data. The model with the lowest BIC is preferred.
The univariate models (y(e, f )1 ) showed moderate improvement over the simple mean
models. However, the combined models (yc11 and y
c2
1 ) improved model prediction (Table
5.3). The multivariate model demonstrated best performance, with model 2 (yc2 = ye +
y f + yJ) performing best, even after adjusting for an increase in variables. It had a BIC of
620 compared to 625 (yc1) whilst the simple models had a BIC of 633, 650 and 648 for
PRMemph, PRM f SAD and µ(J) respectively.
The increase in explanatory power was also seen when correlating the first component
of the combined models (yc1,21 ) with FEV1%predicted. The first components of the combined
models had Pearson coefficients of r= 0.67, p< 0.001 and r= 0.70, p< 0.001 respectively.
Coefficients for the mean models were r = −0.63, p < 0.001, r = −0.50, p < 0.001 and
r = 0.52, p < 0.001.
To test whether manifold fusion based on mean differences of PRMemph, PRM f SAD
and µ(J) performed better than manifold learning and fusion of the proposed distributions,
I created a joint model between PRMemph and mean PRM f SAD in addition to a model with
mean values of PRMemph, PRM f SAD with µ(J). In this case, the pairwise distances were
mean differences between patients rather than the EMD between distributions. The same
process described in Section 5.3.2.4 was applied to learn parameters K and d for the mod-
els. This lead to embeddings ymean1 and ymean2 . The correlation of the first component
of each embedding was r = 0.60, p < 0.001 and r = −0.65, p < 0.001 in comparison to
r = 0.67, p < 0.001 and r = 0.70, p < 0.001 for yc11 and y
c2
1 . This further corroborated the
utility of manifold fusion of separate embeddings based on local disease and deformation
distributions.
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(b) Disease and deformation distribution embedding - yc2
Figure 5.17: Combined models of emphysema, fSAD and Jacobian distributions with
FEV1%predicted overlaid. © 2017 Springer Nature. Reprinted, with permis-
sion from F. Bragman et al., Manifold learning of COPD, Medical Image Computing
and Computer Assisted Interventions, 2017.
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Table 5.3: Regression of models versus various clinical measures of COPD severity. Model per-
formance quoted as adjusted-r2. [† = p < 10−3]. © 2017 Springer Nature. Reprinted,
with permission from F. Bragman et al., Manifold learning of COPD, Medical Image
Computing and Computer Assisted Interventions, 2017.
Mean features y(·)1
Y PRMemph PRM f SAD µ(J) yc11 y
c2
1 y
e
1 y
f
1 y
J
1
FEV1%predicted 0.40† 0.25† 0.26† 0.45† 0.49† 0.42† 0.29† 0.13†
FEV1/FVC 0.51† 0.30† 0.22† 0.54† 0.53† 0.54† 0.32† 0.09†
Table 5.4: Regression of models versus various clinical measures of COPD severity. Model per-
formance quoted as adjusted-r2. [† = p < 10−3]. © 2017 Springer Nature. Reprinted,
with permission from F. Bragman et al., Manifold learning of COPD, Medical Image
Computing and Computer Assisted Interventions, 2017.
y(·)
Y yc1 yc2 ye y f yJ
FEV1%predicted 0.48† 0.51† 0.43† 0.34† 0.14†
FEV1/FVC 0.59† 0.60† 0.55† 0.38† 0.10†
5.3.2.7 Trajectories of emphysema and fSAD progression
It is likely that trajectories of disease progression in COPD vary depending on the dominant
disease phenotype. I assessed whether these can be modelled in the tissue disease model
(yc1). I fitted trajectories of emphysema and fSAD progression in the manifold space of
yc1 to find distinct sets of patients where emphysema or fSAD is the dominant phenotype.
To parameterise the space yc1 , I used Nadayara-Watson kernel regression [145]. Kernel
regression is a standard tool for determining a smooth, estimated function by using its noisy
observations. A careful choice of the covariate (l) allows one to navigate the embedding
space in various ways to test associations with many clinical metrics. For instance, if we
were interested in studying the relationship between age of a patient and position in the
learned manifold, patient age would be used as a covariate l in the regression. This would
consequently provide a mechanism to study how the complex imaging features used in the
manifold learning correlate with age.
The kernel regression is found by the following equation:
yc1(l(·)) = 1
v∑p
KG
(
l(·)p− l(·)
h
)
· yc1p (5.12)
where h was set to 1 and is a smoothing parameter called the bandwidth whilst KG is a
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Gaussian kernel of the form
KG(x) =
1√
(2pi)
· exp
(
−x
2
2
)
. (5.13)
The parameter v is a normalisation constant and is determined by
v =
P
∑
p
KG. (5.14)
In the example of patient age regression, l is set to a vector l ∈ [agemin,agemin +
1, · · · ,agemax−1,agemax] where agemin and agemax are derived from the population. Equa-
tion 5.12 is then applied in the space of yc1 for each increment of l. The Gaussian kernel
in Equation 5.13 is used to calculate the average position within yc1 where the bandwidth h
controls the smoothness of the resulting curve.
In order to use the emphysema and fSAD disease distributions as covariates, I consid-
ered the Earth Movers Distance (LEMD) between the distributions of each patient and an
idealised healthy distribution (Figure 5.18). The mean level of emphysema or fSAD within
a patient may have seemed like a natural choice. However, this chapter has been arguing
for more precise methodologies for measuring disease spread within the lung. To extract
a scalar quantity from the proposed disease distributions, the EMD between a disease dis-
tribution and an idealised healthy distribution (Hideal , Figure 5.18) was proposed. This
computes how far away the distribution is from a purely healthy state and is analoguous to
the mean level of emphysema or fSAD but for the proposed distributions. Two trajectories
(yc1(l(emph)) and yc1(l( f SAD))) were quantified in the manifold space of yc1 by application
of Equation 5.12. These can be visualised Figure 5.19a.
I performed a naive classification of the patients in the space of yc1 by considering the
computed trajectories (yc1(l(emph)) and yc1(l( f SAD))). I hypothesised that a patient (p) is
seen to follow an emphysema progression trajectory if the Euclidean distance from yc1p to
yc(l(emph)) is smaller than the distance to to yc(l( f SAD)). At baseline, patients are classi-
fied as both emphysema and fSAD subtypes since progression of both distributions is in its
infancy. This is visible as the black scatter points in Figure 5.19b. When considering the two
sets of patients stratified by trajectory, the explanatory power of the embeddings improved
in comparison to yc1 (Table 5.4). The emphysema regression produced an adjusted-r2 of
0.52 and 0.63 when predicting FEV1%predicted and FEV1/FVC respectively whilst fSAD was
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Figure 5.18: Theoretical healthy distribution for emphysema and fSAD.
0.45 and 0.62. In comparison, the adjusted-r2 for yc1 without patient stratification was 0.48
amd 0.59 (Table 5.4). This suggests that it is necessary to stratify patients first based on
their expected trajectory of disease progression to better quantify response to therapy and
COPD management.
5.4 Discussion and conclusion
I have presented a method to model the spread of local features implicated in COPD pro-
gression. The disease distributions model local aspects of tissue destruction whilst parame-
terising global properties of heterogeneity and homogeneity. The deformation distribution
quantifies the local effect of disease on lung function. Patients exhibiting different mech-
anisms of tissue destruction can have identical global averages yet can display different
disease distributions. These variations are likely to cause differences in local biomechani-
cal properties, which are captured by the deformation distribution.
I have shown that models of disease and deformation distributions are better predictors
of COPD severity than conventional metrics. I have shown that embedding coordinates
based on distribution dissimilarities have stronger correlations with FEV1%predicted than
those learned from mean differences. Both these results suggest that the position of a patient
in the manifold space of yc1 or yc2 is critical to the assessment of COPD progression. This
is seen in the trajectory classification performed in yc1 . Determining whether a patient is
following a specific trajectory in the manifold space may help inform therapeutic decisions
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(b) Trajectory classification - yc1 ∈ d = 3
Figure 5.19: Trajectories of emphysema and fSAD progression in yc1 . © 2017 Springer Nature.
Reprinted, with permission from F. Bragman et al., Manifold learning of COPD, Med-
ical Image Computing and Computer Assisted Interventions, 2017.
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and improve our understanding of the various COPD phenotypes.
There are various limitations associated with the proposed framework, which can be
tackled to better model the complexities of COPD. The creation of the disease and deforma-
tion distributions was performed by sampling local ROIs across the lung. This disregarded
potentially important lobar information. As discussed in Section 5.1, various studies have
been performed to study whether upper-lobe and lower-lobe predominant disease have dis-
cordant pathophysiology. The framework applied in this Chapter could be extended with
the lobe segmentation algorithm I presented in Chapter 4. It may be important to include
lobar information in the processing. The deformation distribution for instance is likely to be
influenced by its position within the lung since the lower lobes experience a greater level of
deformation. The distributions can therefore be quantified on a lobar basis. Various models
can then be investigated by varying the strategy for manifold fusion. The proposed distribu-
tions can also be extended to joint distributions by including gravitational height based on
the dorsoventral axis. This circumvents the need for lobe segmentations. Adding regional
information in the modelling either trough lobar models or joint distributions is likely to
further increase the explanatory power of the models.
The nature of the ROI sampling can also be improved. Sampling the lung volume with
overlapping ROIs can introduce a bias in the local measurements. At the interface of a large
emphysematous cluster, the local measurement will not accurately reflect the underlying
macrostructure since the local emphysema average will be 50%. There are various strategies
that can help deal with this aspect. A random, sparse, selection of non-overlapping ROIs
may help alleviate the bias. A better option may be to perform a supervoxel segmentation
of the lung [1], as performed as a pre-processing step by Batmanghelich et al. [14]. This
would subdivide the lung into coherent, spatially contiguous regions that could be used to
constrain the sampling. Furthermore, classifying the image volume into emphysema and
fSAD classes may potentially ignore important textural measures that can be used to detect
specific emphysema subtypes [21, 245]. The local disease distributions provide a simple,
intuitive way of modelling lung texture. However, critical information embedded within
textural measures may add an important dimension to the analysis.
The method presented in this chapter has suggested that progression patterns of COPD
may be extracted from cross-sectional data by the kernel regression in the manifold space
of yc1 . I have shown that lower-dimensional embeddings based on modelled inter-patient
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distribution distances have stronger associations than traditional CT metrics with routinely
used spirometric measures. More testing is necessitated to understand whether the tra-
jectories represent distinct progression patterns. The longitudinal data, to be released by
the COPDGene study [167] may be important in this experiment. Further experiments
with various other clinical metrics such as the 6-minute walking distance, the BODE index
(Body-mass, airflow Obstruction, Dyspnoea and Exercise), SGRQ (St-Georges Respiratory
Questionnaire) and the DLCO (Diffusion capacity of the Lung for Carbon Monoxide) will
present further evidence in the need to quantify the proposed distributions and go beyond
traditional means of disease extent.
Chapter 6
Regional analysis of lung disease to study
exacerbation susceptible COPD
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Abstract
One of the principle aims of this thesis has been to develop tools that enable a
more precise quantification of COPD from CT. Disease can spread regionally
whilst the nature of local pathology may differ. This may affect biomechanical
properties of the lung that contribute to airflow limitation. In order to capture these
properties, a lobe segmentation algorithm was developed in Chapter 4 that enables
me to perform lobar analysis of COPD whilst I presented the concept of local
disease distributions in Chapter 5 to better model disease spread. These methods
were combined to develop a pipeline of analysis that enables the quantification of
different aspects of COPD at various anatomical scales.
The pipeline is presented within this chapter in addition to its application to the
study of exacerbation susceptible COPD. Airway wall thickness has been shown
to associate with exacerbation frequency yet there are conflicting reports on the re-
lationship with emphysema. Associations with small airways disease has not been
studied as of yet. It is not known whether regional differences differentiate sus-
ceptible and non-susceptible patients and whether measures of lung deformation
vary with exacerbation frequency. The developed pipeline was applied to study
these unknowns and determine whether regional analysis of lung CT improves the
prediction of exacerbation frequency. I show within this chapter that regional anal-
ysis of lung CT does not help predict exacerbation frequency. However, I suggest
new features that may improve associations between CT and spirometry for future
imaging studies.
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6.1 Introduction
Exacerbations of COPD are acute events that can dramatically alter the normal time-course
of COPD [186]. They are a major determinant in the mortality, morbidity and quality of life
of COPD patients [234] and cost the UK National Health Service over £253 million a year
[26]. Reducing the frequency of exacerbations and improving the efficacy of therapeutic
interventions related to exacerbations are key future targets in the management of COPD.
Susceptibility to exacerbations may be a distinct subtype of COPD. Although exac-
erbation frequency is seen to increase with COPD severity, there is an independent sus-
ceptibility phenotype [101] associated with higher severity of disease and a prior history
of exacerbations. Patients can either be susceptible or non-susceptible to exacerbations of
COPD. The current gold standard for diagnosis is based on a previous history of exacerba-
tions. Currently, a threshold of two or more exacerbations per year is used to stage patients
as exacerbation susceptible.
Computed Tomography (CT) has been increasingly used to develop quantitative tools
[189] and study COPD [121] for precise phenotypic characterisation. Current use of quan-
titative CT applied to exacerbations has shown that higher levels of segmental airway wall
thickness increase exacerbation frequency [87] whilst pulmonary arterial enlargement may
be a strong predictor of exacerbations that cause hospitalisation [237]. The association
between emphysema and exacerbations remains unclear. It has been reported that the oc-
currence of exacerbations accelerates emphysema progression in a two-year longitudinal
study [205]. In contrast, results from the three-year ECLIPSE study suggested there is no
relationship between exacerbations and emphysema progression [44]. This was observed in
an independent study finding no correlation between emphysema extent and exacerbation
frequency [69]. Independent of this, a recent study has shown that the use of convolu-
tional neural networks can predict acute exacerbations from CT [76]. Further conflicting
results were also present when assessing relationships between emphysema, airway wall
thickening and exacerbation frequency [87]. A negative relationship between emphysema
and exacerbation frequency was reported (p < 0.001) when the extent of emphysema was
between 10% and 35%. In contrast, there was a marginally significant (p = 0.047) positive
relationship between emphysema and exacerbations when the level of emphysema exceeded
35% [87].
It is now possible to quantify regional measurements and assess the extent of functional
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small airways disease (fSAD).Functional small airways disease can now be measured using
Parametric Response Mapping [70]. It is a distinct phenotype of COPD [96] and can predict
lung function decline in mild-to-moderate stages of COPD [19]. Introducing fSAD as a
component in CT-studies of COPD is likely to yield novel insights about mechanisms of
disease.
Segmentation of the lobes facilitates regional analysis of disease extent. This had led
to reports suggesting that the distribution of emphysema can vary in-terms of inter and
intra-lobar heterogeneity with varying effects on pulmonary function [104, 215]. It is not
known however if regional heterogeneity in emphysema and fSAD relate to exacerbations.
Regional variations in disease extent may affect lung deformation, which can be captured
using non-rigid registration of paired breath-hold scans. Regional analysis of lung defor-
mation may reveal potential asymmetries in the lung function of exacerbation susceptible
patients. Understanding potential regional differences may change the logic for lung vol-
ume reduction surgery (LVRS) using endobronchial valves [187]. It may also have potential
repercussions for clinical end-points in strategies to manage exacerbations [173].
Within this chapter, I present an analysis pipeline that is applied to study exacerba-
tion susceptibility but may also be applied to study other hypotheses related to COPD. The
goal is to study the extent of disease and lung deformation at various anatomical scales.
This is similar to the work of Murphy et al. [143] who analysed global and lobar fea-
tures to study associations with spirometry. Disease is measured using the Parametric Re-
sponse Mapping (PRM) technique, which allows classification of emphysema (PRMemph)
and fSAD (PRM f SAD). Lung deformation is analysed through the Jacobian determinant,
which measures fractional volume change on a voxel-wise basis. Moreover, the local dis-
ease distributions presented in Chapter 5 are quantified, which allows me to investigate the
extent of diffuse and dense disease. These are introduced and defined in Section 6.2.1.4.
By combining these measures from a global to a lobar level, this enables me to investigate
whether regional measurements of lung disease and deformation help to better phenotype
susceptible patients from CT.
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6.2 Methods
There are various processing steps in the analysis pipeline. The lungs first need to be seg-
mented (Section 6.2.1.1.1). The segmentations are then used to segment the lobes (Section
6.2.1.1.2). The segmentations are also used to help register scans acquired at inspiration to
those at expiration (Section 6.2.1.2). Using results from the registration, a variety of features
can be calculated. The Jacobian determinant can be obtained from the registration (Section
6.2.1.2) to analyse local volume change. The Parametric Response Mapping technique [71]
can also be used to classify tissue as PRMemph and PRM f SAD by analysing the joint his-
togram of voxel intensities after registration (Section 6.2.1.3). The PRM classification can
be exploited to create local disease distributions and obtain measures of diffuse and dense
disease (Section 6.2.1.4). These features can be analysed at a global level using the lung
segmentation or at a lobar level using the lobe segmentations.
6.2.1 Quantitative analysis
6.2.1.1 Lung and lobe segmentation
6.2.1.1.1 Lung segmentation
Lung masks were obtained using the Pulmonary Toolkit [52]. The Pulmonary Toolkit em-
ploys the algorithm of Hu et al. [100] to segment the lungs.
6.2.1.1.2 Lobe segmentation
The lobe segmentation algorithm described in Chapter 4 was employed. To deal with the
volume of patients in the COPDGene dataset, I created a groupwise fissure prior from a
subset of 300 patients using the same method as described in Chapter 4. To propagate the
groupwise fissure prior to unseen patients in the COPDGene cohort, I registered each new
patient to the groupwise space. I exploited the backwards transformation to resample the
groupwise fissure into the unseen patient space and perform the lobe segmentation (Figure
6.1).
The lobe segmentation output is five separate lobar regions for analysis. This allowed
me to compute upper-lobe, lower-lobe and inter-lobar metrics. Upper-lobe features were
quantified using the weighted mean of the upper right and upper left lobe with the lobar
volumes as weights. The same was applied for the lower lobes. Inter-lobar metrics were ob-
tained by calculating the standard deviation of a feature across all five lobes. Since the lobes
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are independent anatomical units, this will provide a measure of inter-lobar heterogeneity.
Groupwise Fissure New Patient
Segmentation
Resampling
Figure 6.1: Lobe segmentation of a patient not included in the groupwise fissure prior. A new patient
is registered to the groupwise space. The groupwise fissure prior is then resampled into
the patient space to help guide the lobe segmentation in regions of incomplete fissures.
6.2.1.2 Nonrigid registration and deformation features
I registered scans acquired at at forced residual capacity (FRC) to those at total lung ca-
pacity (TLC). I used the diffeomorphic extension of the NiftyReg open-source registration
platform [139]. The pipeline for registering paired breath-hold scans is the same as the one
applied in Chapter 5.
The output of the registration is a transformation that maps every voxel in the TLC
scan to the FRC scan. This transformation can be analysed to extract features that explain
lung deformation. I computed the Jacobian determinant (J) from the deformation on a
voxel-wise basis. It provides information on local volume change as the lung undergoes
deformation from inspiration to expiration. It has a value ranging from zero to infinity. A
Jacobian equal to one signifies no volume change. If the value is less than one, there is
compression. If it is greater than one, there is expansion. I calculated the inverse of J at
every voxel to analyse inspiration in the TLC reference frame. This was possible since the
registration is diffeomorphic and symmetric.
I computed the mean and the standard deviation of J. The mean Jacobian (µ(J))
quantifies the average level of volume change in the lung. The standard deviation of the
Jacobian (σ(J)) quantifies heterogeneity of volume change. When σ(J) = 0, there is a
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completely homogeneous pattern of volume change with no variation. The full range of
analysed features are summarised in Table 6.1.
Table 6.1: Global and regional deformation features.
Region Feature Quantification
Global
µ(J)
Average in lung maskσ(J)
Upper-lobe
µ(J)
Weighted mean of upper-lobe averagesσ(J)
Lower-lobe
µ(J)
Weighted mean of lower-lobe averagesσ(J)
Inter-lobe
µ(J)
Standard deviation of lobar averagesσ(J)
6.2.1.3 Tissue classification with Parametric Response Mapping
Voxel-wise classification of the lung was performed using Parametric Response Mapping
[71]. A voxel was classified as emphysematous (PRMemph) if it has an intensity below
−950 Hounsfield Units (HU) at TLC and below -856 HU at FRC. A voxel was classified as
functional small airways disease (PRM f SAD) if it has an intensity at FRC below −856HU
but greater than−950HU at TLC. The analysed PRM features are summarised in Table 6.2.
Table 6.2: Global and regional PRM features.
Region Feature Quantification
Global
PRMemph Average in lung mask
PRM f SAD
Upper-lobe
PRMemph Weighted mean of upper-lobe averages
PRM f SAD
Lower-lobe
PRMemph Weighted mean of lower-lobe averages
PRM f SAD
Inter-lobe
PRMemph Standard deviation of lobar averages
PRM f SAD
6.2.1.4 Quantifying the extent of diffuse and dense disease
The spread of emphysema in the lung and the appearance of small airways disease may
vary from patient to patient. The progression of emphysema may display large regions
of emphysematous bullae, emphysema progression that is diffuse or a mixture of both. I
used the local disease distributions (Figure 6.2), presented in Chapter 5 to capture these
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effects. These distributions go beyond global extents of disease (Figure 6.3). Extracting
features from the disease distributions consequently allowed me to model more precisely
the emphysema and fSAD spread in relation to exacerbation frequency.
Figure 6.2: Quantification of local disease distributions. The aim is to extract more sensitive mea-
sures of emphysema and fSAD progression in the lung. The average amount of emphy-
sema/fSAD provides context on the gross extent of disease. However, this measure does
not describe whether the lung is composed mainly of regions of diffuse or dense disease.
The local disease distribution aims to extract this information. 1) The lung classification
volume output (Z) from Parametric Response Mapping is sampled in local neighbour-
hoods to quantify the extent of emphysema/fSAD in small patches. 2) By sampling the
lung volume in enough regions, a distribution of the measurements can be built. This
distribution provides information on the extent of diffuse and dense disease.
I defined three states of tissue disease that enabled me to quantify more precisely the
spread of PRMemph and PRM f SAD in the lung. Lung disease, measured locally in the lung
(vk(·)) can be classified into three states (Figure 6.4):
vk(·) =

diffuse if vk < 0.30
intermediate if 0.30≤ vk ≤ 0.60
dense otherwise
(6.1)
These thresholds were determined after qualitative analysis of local ROIs. The fraction
of ROIs classified as diffuse, intermediate and dense within the lung provides complimen-
tary information to the average extent of disease (Figure 6.5). The extent of diffuse disease
is the percentage of diffuse classified regions and is defined as P1. The same process is
applied to intermediate disease to yield P2 and dense disease for P3 (Figure 6.5). The distri-
bution features used are summarised in Table 6.3.
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PRMemph PRMfSAD PRMnormal
Figure 6.3: Illustration of two patients with an equal levels of emphysema in the lung
(PRMemph=25%) but with a different anatomical presentation. The lung in the top row
has upper-lobe predominant emphysema, which is composed mainly of regions of dense
disease (vk(emph)> 0.60). In contrast, the bottom row displays a patient with a homo-
geneous presentation of emphysema. It mostly has regions of diffuse emphysema in the
lung (vk(emph)≈ 0.20) with limited regions of dense emphysema (vk(emph)> 0.60).
Table 6.3: Global disease distribution parameters.
Region Feature Quantification
Global
P1(emph) Extent of diffuse disease in lung mask
P1( f SAD)
P2(emph) Extent of intermediate disease in lung mask
P2( f SAD)
P3(emph) Extent of dense disease in lung mask
P3( f SAD)
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Figure 6.4: Illustration of PRMemph or PRM f SAD measured locally and its position in the local dis-
ease distribution. As the local measurement (x-axis) shifts from 0 to 1, the density of
the measured feature in that location increases. Given a local measurement less than
0.3 (e.g. 30% of PRMemph in the local neighbourhood), I define the disease as diffuse.
From 0.30 to 0.60, the disease is a mixture of both diffuse and dense and is termed in-
termediate. At any regions with > 0.60, the disease is dense. The y-axis represents the
probability i.e. frequency of region within the lung.
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(b) Local emphysema distribution of Figure 6.5a:
P1 = 0.51, P2 = 0.44 and P3 = 0.05
Figure 6.5: Illustration of diffuse (P1), intermediate (P2) and dense (P3) disease features. To quan-
tify the extent of diffuse, intermediate and dense disease in the lung, the percentage of
regions classified as diffuse, intermediate and dense are calculated. 1) Percentage of
diffuse disease (P1): % v <0.30. 2) Percentage of intermediate disease (P2): % regions
0.30≤ v≤ 0.60. 3) Percentage of dense disease (P3): % regions v > 0.30)
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6.2.2 Statistical analysis
Statistical analysis was performed using MATLAB 2013b1 and Python StatsModels statis-
tical library2. Group statistics between continuous variables were quantified by computing
the group mean and standard deviations. Significance between groups of continuous vari-
ables was assessed with a two-sample t-test with the assumption that the samples stem from
normal distributions with unequal variances. For categorical variables, a chi-squared (χ2)
test of independence was computed.
A negative binomial regression with a log-link was used to model associations be-
tween the CT-features and exacerbation frequency. I accounted for scanner variability with
dummy variables for each scanner type. I used post-bronchodilator FEV1%predicted as
a confounder. Since FEV1%predicted is obtained by normalising the raw FEV1 with re-
spect to age, height, gender and ethnicity, no further confounding variables were used. The
regression was also performed without FEV1%predicted as a confounding variable. The
regression coefficient for a feature when FEV1%predicted was used was denoted as βFEV1
and was β without in the table heading. The standard error for the coefficient was reported.
Associations between the CT-features and FEV1%predicted was performed by calculating
Pearson’s linear correlation coefficient (r).
The independent variables (Xi) in the regression were all standardised such that they
had zero mean and unit standard deviations. This allowed for a direct comparison of the
regression coefficients (βi). A unit standard deviation increase in Xi leads to a fold-change of
exp(βi) in exacerbation frequency (Y ). Since the variables all have unit standard deviations
after transformation, the magnitude of βi reflected the relative importance of the feature in
the prediction of Y within a multivariate model.
6.3 Results
6.3.1 Study population
Subjects participating in COPDGene (Genetic Epidemiology of COPD), a large multi-
centre observational cohort study were used in the analysis. Current and former smokers
with greater than or equal to 10 pack-year smoking history, with and without airflow ob-
struction were enrolled.
I downloaded 1,154 COPD patient scans from the COPDGene database that had paired
1www.mathworks.com
2www.statsmodels.org
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breath-hold scans and were acquired using the STANDARD reconstruction kernel. I man-
ually inspected all the registration results and the lobe segmentation results. The manual
quality control of the registrations was performed according to the qualitative scoring sys-
tem presented in Chapter 5, Section 5.3.2.3.3 Registrations were rejected when there were
major errors close at the fissures or close to the lung diaphragm.
Quality control of the lobe segmentations was also qualitative. However, no scor-
ing system was devised the measure errors. This is because segmentation failures occured
when there were errors in the airway labelling that could not be corrected or when the al-
gorithm failed at extrapolating the fissure boundaries in cases with significantly large areas
of incomplete fissures. As a result, patients with errors were easily rejected. I rejected 94
subjects resulting in 675 patients used for the subsequent analysis. As a sanity check, the
mean level of emphysema in the upper lobes and in the lower lobes in the reamining pa-
tients was calculated. Pearson’s linear correlation coefficient between these measures and
the data supplied by COPDGene (obtained through VIDA diagnostics) was calculated. A
coefficient of 0.99, p < 10−5 was obtained demonstrating correct lobar segmentations in the
final dataset.
6.3.2 Subject demographics
The baseline characteristics of the exacerbation susceptible and non-susceptible patients are
reported in Table 6.4. This showed as expected, that the susceptible group have much more
severe lung function impairment, demonstrated by significantly smaller spirometric scores
and a higher proportion of GOLD 3 and 4 patients. I also found that women are more
likely to be exacerbation susceptible (58.1% versus 42.8%, p = 0.001). Within this cohort,
the patients who were exacerbation susceptible were younger (mean age, 62.4 versus 64.3
years, p=0.017). I found no differences in smoking history (number of packs per year)
between both groups (mean, 54.5 versus 54.8, p=0.89).
3The results from the registration quality control in Section 5.3.2.3 were obtained on the same dataset anal-
ysed within this chapter. Consequently, statistics from Section 5.3.2.3 are applicable to this study.
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Table 6.4: Subject demographics
Parameter Non-Susceptible Susceptible p value
Subjects, n 538 136
Age, yr 64.3 (8.5) 62.4 (8.2) 0.017
Sex, (%)
Male 57.2 41.9
0.001
Female 42.8 58.1
GOLD classification, n (%)
Stage 1 69 (12.8) 3 (2.2)
< 10−5
Stage 2 220 (40.9) 41 (30.1)
Stage 3 162 (30.1) 49 (36.0)
Stage 4 87 (16.1) 43 (31.6)
Smoking history, pack-years 54.5 (27.8) 54.8 (24.1) 0.89
Exacerbations, n/yr 0.27 (0.44) 2.97 (1.25) -
FEV1, L 1.54 (0.73) 1.15 (0.58) < 10−5
FEV1% predicted 53.5 (21.9) 41.8 (18.5) < 10−5
FVC, L 3.02 (1.01) 2.62 (0.96) < 10−5
FVC % predicted 79.8 (20.2) 72.1 (19.9) < 10−5
FEV1 / FVC 0.50 (0.13) 0.43 (0.13) < 10−5
6.3.3 From global to regional analysis of lung CT
In this section, I investigated associations between the proposed CT-features and exacerba-
tion frequency. For each feature and at each scale of analysis, I performed a two-sample
t-test between the non-susceptible and susceptible group. This result was reported as p-
value in the results table. I then performed a regression between the proposed feature
and exacerbation frequency with the resulting coefficient β . This was then repeated with
FEV1%predicted as a confounding variable to account for FEV1 but also patient age, sex
and height. This lead to the regression coefficient for the feature as βFEV1 . The correlation
between the feature and FEV1%predicted was calculated with Pearson’s linear correlation
coefficient coefficient and reported as r.
6.3.3.1 Global measures of lung disease and deformation
The susceptible group of patients represents a cohort with more severe COPD. This was
exemplified in the global extent of emphysema (16.4% versus 12.3% p=0.004, Table 6.5),
the mean volume change (1.32 versus 1.37 p =< 10−3, Table 6.6) and also heterogeneity
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of volume change (0.26 versus 0.30 p=0.01,σ(J), Table 6.6). These all showed significant
associations with exacerbation frequency without accounting for FEV1%predicted. This
suggested that within this cohort, an exacerbation susceptible lung could be visualised as a
lung with more emphysema with less volume change that is more homogeneous. However,
with the addition of FEV1%predicted, these relationships were lost since FEV1%predicted
strongly predicted frequency in this cohort but also because PRMemph, PRM f SAD, µ(J)
and σ(J) were moderately to strongly correlated with FEV1%predicted suggesting multi-
colinearity effects.
Table 6.5: Global results for PRMemph and PRM f SAD. βFEV1 is the regression with FEV1%predicted
as a confounder and is β without. The correlation between the parameter and
FEV1%predicted is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
PRMemph 12.3 (12.7) 16.4 (15.2) 0.004 0.20 (0.06)† -0.11 (0.07) −0.64†
PRMf f SAD 29.1 (13.1) 30.8 (11.5) 0.120 0.12 (0.06) -0.14 (0.08) −0.51†
Table 6.6: Global results for µ(J) and σ(J). βFEV1 is the regression with FEV1%predicted as a con-
founder and is β without. The correlation between the parameter and FEV1%predicted
is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
µ(J) 1.37 (0.17) 1.32 (0.13) < 10−3 -0.22 (0.07)† 0.08 (0.08) 0.54†
σ(J) 0.30 (0.13) 0.26 (0.14) 0.01 -0.19 (0.07)∗ -0.01 (0.07) 0.38†
6.3.3.2 Global measure of local disease distribution
The creation of the local disease distributions (Section 6.2.1.4) and the resulting param-
eterisation allowed me to go beyond global measures of PRMemph and PRM f SAD. The
proposed P1, P2 and P3 parameters measured the extent of diffuse, intermediate and dense
PRMemph/ f SAD.
The results in Table 6.7 and 6.8 demonstrated their assocations with exacerbation sus-
ceptibility, showling largely negative results when attempting to predict exacerbation sus-
ceptibility.
There were significant differences between the mean levels of the features across both
populations such as in diffuse (P1(emph)), intermediate (P2(emph)) and dense emphysema
(P3(emph)) (Table 6.7). However, these differences were caused by the higher proportion
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of severe COPD patients in the susceptible group.
Importantly, all features correlated significantly with FEV1%predicted (r, Table 6.7
and 6.8), suggesting their potential to be used in future imaging studies. Additionally,
P2( f SAD) and P3( f SAD) were associated with exacerbation frequency independent of
FEV1%predicted (Table 6.8) although the polarity of the regression coefficient βFEV1 was
reversed from β .
Table 6.7: Global results for f (v(emph)). βFEV1 is the regression with FEV1%predicted as a con-
founder and is β without. The correlation between the parameter and FEV1%predicted
is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
P1(emph) 0.85 (0.20) 0.79 (0.25) 0.009 -0.17 (0.06)∗ 0.11 (0.07) 0.60†
P2(emph) 0.11 (0.14) 0.14 (0.16) 0.044 0.14 (0.06)∗ -0.17 (0.07) −0.60†
P3(emph) 0.04 (0.07) 0.07 (0.11) 0.003 0.19 (0.06)† -0.01 (0.06) −0.47†
Table 6.8: Global results for f (v( f SAD)). βFEV1 is the regression with FEV1%predicted as a con-
founder and is β without. The correlation between the parameter and FEV1%predicted
is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
P1( f SAD) 0.54 (0.28) 0.51 (0.26) 0.10 -0.11 (0.06) 0.16 (0.07)∗ 0.53†
P2( f SAD) 0.40 (0.23) 0.44 (0.21) 0.02 0.15 (0.06)∗ -0.16 (0.08)∗ −0.58†
P3( f SAD) 0.06 (0.11) 0.06 (0.11) 0.50 -0.04 (0.06) -0.09 (0.07) −0.14†
6.3.3.3 Lobar measures of lung disease and deformation
This section presents analysis of the lobar features and their associations with exacerba-
tion susceptibility and FEV1%predicted. Analysis of the regional features showed various
differences across groups, demonstrating the potential utility of lobar-based measurements
of disease. Regression results showed that these features do not help predict exacerbation
susceptibility when taking into account the degree of lung function impairment.
I found significant regional differences between the susceptible and non-susceptible
group. Lower lobe PRM f SAD was elevated in the susceptible group (0.28 versus 0.24
p = 0.004, Table 6.9) and was more strongly correlated with FEV1%predicted than upper-
lobe PRM f SAD (r =-0.60, p < 10−3 versus r =-0.40, p < 10−3, Table 6.9). The inter-lobar
metrics of PRMemph and PRM f SAD suggested a more heterogeneous presentation of emphy-
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sema (0.07 versus 0.05 p< 10−3, Table 6.11) yet more homogeneous fSAD across the lobes
(0.07 versus 0.08 p = 0.022, Table 6.11).
As observed in the previous sections (Section 6.3.3.1 and 6.3.3.2), these differences
were primarily due to differences in COPD severity across groups. The regression (β )
demonstrated that most regional features do not associate with exacerbation frequency when
adjusting for FEV1%predicted. Conflicting results were observed when associations were
tested without adjusting for lung function impairment. Upper-lobe features of lung deforma-
tion did not associate with frequency but lower-lobe features did (Table 6.10). Furthermore,
there was an association with inter-lobar µ(J) (Table 6.12). This also supported the idea the
susceptible lungs experience less expansion that is more homogeneous in the lower lobes.
When adding FEV1%predicted to control for spirometric severity, only lower lobe
PRMemph (Table 6.9), upper lobe PRM f SAD (Table 6.9) and upper-lobe µ(J) (Table 6.10)
associated with exacerbation frequency. A switch in the polarity of regression coefficient
from β to βFEV1 was also observed.
Table 6.9: Upper and lower lobe results for PRMemph and PRM f SAD. βFEV1 is the regression with
FEV1%predicted as a confounder and is β without. The correlation between the param-
eter and FEV1%predicted is r. [∗ : p < 0.05, † : p < 10−3]
Parameter Region n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
PRMemph
Upper Lobe 0.14 (0.14) 0.19 (0.18) < 10−3 0.20 (0.06)∗ -0.06 (0.07) −0.53†
Lower Lobe 0.10 (0.12) 0.14 (0.14) 0.005 0.17 (0.06)∗ -0.15 (0.07)∗ −0.62†
PRM f SAD
Upper Lobe 0.32 (0.13) 0.32 (0.12) 0.81 0.01 (0.06) -0.20 (0.07)† −0.40†
Lower Lobe 0.24 (0.14) 0.28 (0.13) 0.004 0.21 (0.06)† -0.07 (0.08) −0.60†
Table 6.10: Upper and lower lobe results for µ(J) and σ(J). βFEV1 is the regression with
FEV1%predicted as a confounder and is β without. The correlation between the pa-
rameter and FEV1%predicted is r. [∗ : p < 0.05, † : p < 10−3]
Parameter Region n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
µ(J)
Upper Lobe 1.31 (0.16) 1.28 (0.14) 0.11 -0.08 (0.06) 0.16 (0.07)∗ 0.43†
Lower Lobe 1.46 (0.23) 1.38 (0.18) < 10−3 -0.28 (0.07)† -0.02 (0.08) 0.55†
σ(J)
Upper Lobe 0.22 (0.11) 0.20 (0.11) 0.05 -0.10 (0.06) 0.08 (0.07) 0.35†
Lower Lobe 0.31 (0.14) 0.27 (0.15) 0.002 -0.26 (0.07)† -0.08 (0.07) 0.37†
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Table 6.11: Inter-lobar results for PRMemph and PRM f SAD. βFEV1 is the regression with
FEV1%predicted as a confounder and is β without. The correlation between the pa-
rameter and FEV1%predicted is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
PRMemph 0.05 (0.05) 0.07 (0.06) < 10−3 0.17 (0.06)∗ -0.04 (0.07) −0.51†
PRMf f SAD 0.08 (0.04) 0.07 (0.03) 0.022 -0.20 (0.07)∗ -0.08 (0.07) 0.25†
Table 6.12: Inter-lobar results for µ(J) and σ(J). βFEV1 is the regression with FEV1%predicted
as a confounder and is β without. The correlation between the parameter and
FEV1%predicted is r. [∗ : p < 0.05, † : p < 10−3]
Parameter n/yr < 2 n/yr ≥ 2 p-value β βFEV1 r
µ(J) 0.14 (0.07) 0.13 (0.08) 0.08 -0.14 (0.07)∗ 0.01 (0.07) 0.32†
σ(J) 0.08 (0.05) 0.08 (0.08) 0.63 -0.08 (0.07) -0.01 (0.06) 0.14†
6.3.4 Models of exacerbation frequency
6.3.4.1 Experiment design
In this section, I investigated whether the regional analysis of lung CT in addition to the
proposed measures of disease distribution measures helped improve the prediction of ex-
acerbation frequency. This was performed by iteratively increasing the complexity of the
model by including measures of lung deformation, lobar features and the extent of diffuse
and dense disease (Table 6.13).
Table 6.13: Nested models to evaluate associations with exacerbation frequency. Global measures
are features that were calculated within the lung mask. Inter-lobar represents the stan-
dard deviation of lobar features and lobar represents upper and lower lobe values. P1/2/3
represent the features of diffuse, intermediate and dense disease across the lung.
Model Features
Global PRM Global J Inter-lobar PRM Lobar PRM Lobar J P1/2/3
1 X
2 X X
3 X X X
4 X X X
5 X X X X
6 X X X X X
Model performance was assessed using Akaikes Information Criterion (AIC). The AIC
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penalises the log-likelihood of the regression with the number of independent variables in
the model. The AIC is defined as: AIC = 2k− 2ln(Lˆ) where k is the number of variables
and Lˆ is the maximised value of the likelihood function. A smaller AIC represents a better
model.
As a baseline model of performance (Model 0), I considered a model with only FEV1%
predicted. I used dummy variables to account for scanner variability in all models. Since
the AIC penalises the number of parameters, I also used dummy variables in Model 0.
6.3.4.2 Results
I observed that FEV1% predicted was the strongest predictor of exacerbation frequency in
all models (Table 6.14). I also observed that the addition of CT-based features did not sig-
nificantly improve the prediction. This includes traditional features such as mean levels
of emphysema but also the more complex metrics presented in this chapter. Despite itera-
tively adding more complex features, model performance did not increase although this may
have been biased by naively adding non-significant features in the iterative construction of
the nested models. The best model performance was seen in Model 4 (Table 6.13), which
considered global measures of PRMemph, PRM f SAD, µ(J), σ(J), and upper and lower lo-
bar measures of PRMemph and PRM f SAD although none of these variables were significant.
However, this is not significant since model 0 had an AIC equal to 1639.
Table 6.14: Performance of the nested models to evaluate associations with exacerbation frequency.
Only significant features at p < 0.05 are reported. [∗ : p < 0.05, † : p < 10−5]
Model AIC Features - β (SE)
0 1639 FEV1%predicted†: -0.63 (0.09)
1 1637 FEV1%predicted†: -0.62 (0.10)
2 1640 FEV1%predicted†: -0.60 (0.10)
3 1642 FEV1%predicted†: -0.57 (0.10)
4 1636 FEV1%predicted†: -0.57 (0.10)
5 1641
FEV1%predicted†: -0.62 (0.10)
Global σ(J)∗: -0.58 (0.28)
6 1643
FEV1%predicted†: -0.60 (0.10)
Global σ(J)∗: -0.64 (0.30)
Inter-lobar PRM f SAD∗: -0.18 (0.09)
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6.4 Discussion
Within this chapter, I presented a pipeline of analysis that aimed to extract features to model
various aspect of lung disease and lung deformation. The framework can be used to analyse
various anatomical scales to capture global and regional aspects of lung pathophysiology.
The pipeline can be used to study various clinical hypotheses related to COPD and other
progressive lung diseases. This includes finding better associations between FEV1 and CT
or studying the effect of lower lobe diffuse and dense emphysema on markers of COPD
severity and mortality.
The analysis performed within this chapter was applied to exacerbation susceptible
COPD. Understanding potential structural and functional differences between susceptible
and non-susceptible patients is important. Whilst the current gold standard for future exac-
erbations is a past history of exacerbations, identifying features that are sensitive to struc-
tural changes in lung tissue and associate with exacerbation frequency may help identify
patients for targeted research and therapeutic development.
Previous efforts in studying potential radiological phenotypes of COPD exacerbations
have focused on the global extent of emphysema [87, 205, 44, 69] and airway-related mea-
surements [87]. I have extended these studies by including Parametric Response Mapping
(PRM), which includes emphysema and an indirect measure of functional small airways
disease (fSAD) in addition to two measures of lung deformation. These features were anal-
ysed at the whole lung level and also at a lobar level (Tables 6.1, 6.2 and 6.3). This enabled
me to investigate potential regional associations with exacerbation frequency that may not
be present a global level. This is to my knowledge the first study that has analysed these
features at various anatomical scales in relation to exacerbation susceptibility.
Throughout the analysis, I found significant differences in various features across the
susceptible and non-susceptible groups. It was found that levels of diffuse emphysema
were reduced across the susceptible group yet dense emphysema was increased (Table 6.7).
Another example relates to the significant differences observed across groups when consid-
ering the biomechanics of the lung on a regional basis (Table 6.12). However, these results
can be attributed to a class imbalance in the non-susceptible and susceptible cohorts. There
was a higher proportion of GOLD 3 and 4 patients in the susceptible group (p < 10−5)
(Table 6.4). Since the majority of the studied imaging features correlated strongly with
FEV1%predicted, this biased the analysis. When accounting for FEV1%predicted in the
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regression of exacerbation susceptibility, no significant associations were found.
The experiment in Section 6.3.4 was performed to test whether the addition of regional
features added significantly to the prediction of exacerbation frequency when controlling
for global levels. This was performed by constructing nested models and iteratively includ-
ing more complex features. This experiment also yielded negative results, corroborating
the results seen when assessing the features individually. The main observation is that
FEV1%predicted most strongly predicts exacerbation frequency and that imaging features
may not be useful. However, recent work by Gonzalez et al. [76] has shown that deep learn-
ing of chest CT may be predictive of exacerbations. Further work is needed to interpret their
trained network to understand the limitations of the designed features proposed within this
chapter.
Despite the lack of positive findings, use of the pipeline has demonstrated the need
to go beyond global averages. Various features that quantified the nature of disease spread
(diffuse versus dense emphysema) and the extent of lobar disease correlated strongly with
spirometry and demonstrated significant differences across cohorts. At a global level, mean
emphysema was elevated whilst volume change and deformation heterogeneity were re-
duced in the susceptible group. However, it was then seen that only lower-lobe measures
of lung deformation in addition to lower-lobe fSAD varied across groups. The need to go
beyond the global averages was also seen in the inter-lobar measures and the distribution
features that described the extent of diffuse, intermediate and dense disease in the lung.
Moderate to strong correlations were observed in most cases.
There were various limitations in the study. I did not have access to airway wall thick-
ness data, which may be a significant feature in the prediction of exacerbation frequency
from CT scans as seen by Han et al. [87]. Their work was performed on the COPDGene
cohort. Inclusion of this feature in my analysis would have been important. In effect, they
observed an interesting non-linear relationship between airway wall thickness, total emphy-
sema and exacerbation frequency. Future work should include this feature to study how it
varies with the presented global and regional measures of disease spread.
A further issue in the work presented relates to the definition of exacerbation suscep-
tibility. Controversies remain over the exact definition of exacerbations [37]. Patients may
only inform their healthcare practitioners only in the most severe cases [240]. As a result, it
is possible that the exacerbation frequency data studied is not accurate. Moreover, the data
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relates to past exacerbation episodes. It may be a theoretically flawed process to attempt to
predict a clinical variable that defines past behaviour and not a current clinical state.
Lastly, there was possibly an interaction effect that was ignored in the experiments that
would need to be included in future models (Section 6.3.3). Furthermore, the experiment
design in Section 6.3.4 was also possibly flawed. The hypothesis was to test whether the
addition of various new features aided in the prediction of exacerbation frequency. How-
ever, model performance was biased by the addition of many non-significant features and
selection of the best model was not possible. A better strategy would be to employ Ran-
dom Forests, which implicitly ranks features when building the decision trees. The most
important features could then be used for further analysis.
6.5 Conclusion
In summary, I have presented a pipeline that facilitates the extraction of various CT-features
that aim to capture global and regional properties of lung pathophysiology. I presented new
features such as metrics that define diffuse and dense disease to those that capture inter-
lobar variations of disease. I observed moderate to strong correlations between all features
and FEV1%predicted, suggesting that these should be employed in future studies when
assessing links between CT, spirometry and other markers of COPD severity.
The presented pipeline was applied to the study of exacerbation susceptible COPD.
This is the first study to my knowledge that has analysed global and regional CT imaging
features in relation to exacerbation susceptible and non-susceptible COPD patients. This
was also the first study that has investigated a potential link between various measures of
lung deformation and the exacerbation susceptible phenotype. I did not find any significant
relationships between the proposed features and exacerbation susceptibility. However, I ob-
served that FEV1%predicted is the strongest predictors of past exacerbations. Further work
is necessary to evaluate whether the proposed measures are clinical useful in the analysis
and prediction of COPD exacerbations.
Chapter 7
Event-based modelling and clustering of
COPD
The work presented in this chapter is a joint project between F. Bragman and A. Young∗.
∗ Contributions
I initiated the collaboration with Alexandra Young. We both designed the initial experi-
ments, which involved selecting the features and choosing the number of clusters to model.
Alexandra Young developed the SuStaIn model [249]. Her implementation was employed
within this chapter and applied to the COPDGene data, which I supplied. I performed all
the resulting analysis and drafting of this chapter.
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Abstract
This thesis has been based on the development of tools to better study and
diagnose Chronic Obstructive Pulmonary Disease (COPD) from Computed
Tomography (CT). I have presented various techniques that aim to quantify
and exploit the distribution and regional extent of CT features to study various
clinical questions. In Chapter 3, I exploited the distribution of density-based and
biomechanical features to classify exacerbation susceptible COPD. In Chapter
4, I presented a lobe segmentation algorithm that was applied to study regional
disease extent in relation to COPD exacerbation susceptibility in Chapter 6. The
issue with the analysis however is that it ignored potential patient-differences in
the progression of COPD. The quantified CT features provide a snap-shot of the
disease process and do not differentiate between different progression trajectories.
The work I presented in 5 attempted to address this issue by building progression
trajectories of emphysema and airway disease.
In this chapter, I present to my knowledge, the first application of disease pro-
gression modelling to the study of COPD. I used a model called SuStaIn (Subtype
and Stage Inference), that was developed by A. Young to study neurodegenerative
diseases. I applied it to COPDGene, which is a large multi-centre study aimed at
precisely phenotyping COPD using clinical, imaging and genetic data. The stud-
ied cohort was cross-sectional with subjects at various degrees of lung function
impairment in addition to smoking controls. As a pilot study, I determined if clus-
ters of patients with similar disease progression trajectories could be uncovered.
I found two main data-driven subgroups of COPD with various associated clus-
ters. Importantly, each cluster represented sets of patients with distinct disease
progression patterns in contrast to traditional COPD clusters where patients have
common clinical and CT measures. The disease progression models has also fur-
ther strengthened the notion that early diagnosis of COPD is crucial to inhibit the
acceleration of lung function impairment.
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7.1 Introduction
Chronic Obstructive Pulmonary Disease (COPD) is heterogeneous in the population with
a large variability of potential clinical manifestations. The rate of FEV1 decline amongst
smokers is highly variable as seen in the ECLIPSE cohort over a 3-year longitudinal study
[226]. Since alterations to lung tissue and the airway tree are the primary drivers of airflow
limitation, this heterogeneity in lung function decline may be partly explained by varying
contributions of emphysema and airway disease. It is also possible that FEV1 may in fact be
a poor clinical marker when compared to new multi-dimensional metrics such as the BODE
(Body mass index, airway Obstruction, Dyspnoea and Exercise capacity) index [30].
There is a need for better clustering of COPD patients for precise, personalised
medicine. Effective management of COPD requires clinicians to understand the natural
progression of disease whilst appropriately managing therapeutic interventions with unique
clinical phenotypes. Unsupervised machine learning algorithms techniques known as clus-
tering can help with this task. Clustering of COPD has been performed by identifying
emphysema subgroups [131, 21, 245] and through determining distinct groups of patients,
with common clinical features and similar responses to therapy [133]. Applied to COPD,
various subsets previously unknown have been identified [31, 27, 73]. However, a funda-
mental limitation of these techniques is that patients in identified clusters may potentially
not have a similar temporal progression of disease. In fact, it is possible that patients within
the same cluster are at different stages of distinct progression routes. The quantification of
different progression routes in COPD may yield novel insights about specific phenotypes of
COPD.
Data-driven disease progression modelling concerns a family of statistical models
aimed at estimating the sequence of events (discrete) or the biomarker trajectory (continu-
ous) that best characterise the progression of a disease from an early, asymptomatic stage to
the most severe stage. Modelling patterns of disease progression may be critical for prog-
nosis since it permits both an estimation of a patient’s progress in the course of disease and
a prediction of future progression based on a number of observed biomarker values. The
development of disease progression modelling techniques have originated in the study of
neurodegenerative diseases. A variety of fully data-driven techniques have been developed
[250, 68, 55, 183, 102]. They facilitate the quantification of the full temporal resolution of
disease and have helped provide novel insights into the neurodegenerative disease progres-
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sion patterns, particularly in Alzheimer’s Disease.
The key similarity, which makes applying these models to the study of COPD partic-
ularly attractive lies in the assumption that neurodegenerative diseases are not reversible.
Akin to the progressive and irreversible nature of COPD, neurodegenerative diseases are
chronic progressive disorders characterised by the loss of structure and function of neurons.
Disease progression modelling of neurodegenerative diseases has shown that independent
anatomical units of the brain are pathologically altered in a sequential fashion [68]. More
recent developments are now able to cluster patients based on their sequence of events [250].
Despite the obvious links, application of these techniques to the study of COPD and other
progressive respiratory diseases has been limited. Vogl et al. [229] developed a spatio-
temporal disease pattern distribution model to monitor idiopathic pulmonary fibrosis (IPF)
and classify patients into IPF with Usual Interstitial Pneumonia and IPF without Usual In-
terstitial Pneumonia. Applied to COPD, Boes et al. [25] derived a three-compartment model
that simulates progression of tissue from normal, to functional small airways disease and
emphysema. The ensuing set of differential equations governing the model can be used to
estimate the progression of COPD.
The work presented in this thesis has focused on the development of methods to bet-
ter quantify COPD phenotypes and severity from CT scans. However, as a multi-factorial
disease, there are various potential mechanisms that act during the progression of disease.
Despite two patients experiencing equal levels of severity for a specific biomarker e.g. em-
physema extent in the lung, they may be at different stages in their own progression whilst
being part of different phenotypes of disease. These two patients may in fact belong to dis-
tinct groups, or disease subgroups, with different progressions of disease caused by different
underlying biological mechanisms. Application of the SuStaIn model [250] can tackle this
problem by uncovering distinct subgroups of COPD with differing progression of disease.
In this chapter, I present the application a novel unsupervised machine learning tech-
nique developed by Young et al. [250] called SuStaIn (Subtype and Stage Inference) to
quantify the progression of COPD. It is based on the work of Fonteijn et al. [68] and allows
for the simultaneous clustering of disease subgroups and characterisation of disease stage.
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7.2 SuStaIn: Subtype and Stage Inference
7.2.1 Event-based model of disease progression
The SuStaIn model was built on the event-based disease progression model of Fonteijn et
al. [68], which is described in this section. It is built on two main assumptions. The first
is that the disease processes are irreversible and cannot revert back to initial states. This
is mirrored in COPD, as it is clinically defined as a progressive, irreversible disease. The
second assumption is that there is a common sequence of events within the studied cohort.
This assumption was later removed by Young et al. [249] to allow for clustering of different
event sequences.
The model consists of a series of events E = {Ei | i = 1, · · · ,N} with an ordering S =(
s(1), · · · ,s(N)). The ordering S consists of a permutation of the numbers i = 1, · · · ,N,
which determines the event ordering of E such that Es(1), · · · ,Es(N). The events are indexed
by i = 1, · · · ,N for all patients j = 1, · · · ,J. They are contained in the full data matrix
X ∈ RJ xN where X j = {x1 j,x2 j, · · · ,xN j} corresponds to the measurements of patient j.
Given a control population and a COPD population, both data matrices are defined as Xcontrol
and XCOPD.
The events are specified before the modelling and correspond to specific biomarkers or
variables that are hypothesised to be formative in the progression of disease. In the model,
they are specified as either normal (healthy) or abnormal (pathological). In the context
of COPD, these events could correspond to airway wall thickening, gas trapping, mucus
hypersecretion and emphysema. The ordering S would therefore specify the sequence upon
which these events occur in the progression of COPD.
In order to fit the disease progression model, evaluating the probability density func-
tion P(S |X) is required. This measures the likelihood of a particular sequence S given the
measurements of the cohort in X . The sequence S that maximises P(S |X) is consequently
the most likely ordering of events given the studied data.
To determine the most likely sequence, the likelihood that a particular measurement is
still normal or has become abnormal must be quantified and is defined for both respectively
as P(xi j |¬Ei) and P(xi j |Ei). Both distributions are independent of j and can be quantified
a priori with XCOPD and Xcontrol . In the work of Fonteijn et al. [68], a mixture model with a
Gaussian component (P(xi j |¬Ei)) and uniform distribution (P(xi j |Ei)) is fit to XCOPD and
Xcontrol . Given a patient measurement xi j, P(xi j |¬Ei) and P(xi j |Ei) are easily quantified.
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If a patient j is at position k in the sequence S, events Es(1), · · · ,Es(k) have occurred
whilst Es(k+1), · · · ,Es(N) have not. The joint probability of observing the patient’s data (X j)
given the sequence S whilst the patient is at event k can be formulated as
p(X j |S,k) =
k
∏
i=1
p(xi j |Es(i))
N
∏
i=k+1
p(xi j |¬Es(i)). (7.1)
By assuming independence of the measurements across all patients and marginalising
the hidden variable k, the total likelihood can be formulated as
p(X |S) =
J
∏
j=1
 N∑
k=0
p(k)
(
k
∏
i=1
p(xi j |Es(i))
N
∏
i=k+1
p(xi j |¬Es(i))
) (7.2)
where P(k) is a uniform prior such that P(k) = 1/N. The probability density function
P(S |X) can be obtained by application of Bayes’ theorem
P(S |X) = p(S) p(X |S)
p(X)
(7.3)
The above equation can be solved using a Markov Chain Monte Carlo algorithm
(MCMC), which yields a set of T candidate orderings. The characteristic ordering S¯, rep-
resents the most likely event sequence, which occurs most frequently in the set of candi-
dates. This ordering thus represents the modelled biomarker trajectory of the studied cohort
XCOPD.
7.2.2 The SuStaIn model
The model of Fonteijn et al. [68] assumes an instantaneous switch from normal to abnormal
for a biomarker in the progression of disease. However, a biomarker is much more likely
to follow a specific progression pattern as it evolves from normal to abnormal. This is the
theory underlying the SuStaIn model [249]. In SuStaIn, a subtype is referred to as a group
of subjects with a particular biomarker progression pattern. This biomarker progression is
described as a series of events, where each event corresponds to a biomarker reaching a
particular z-score compared to a control group. The process is modelled as a linear z-score
event-based model, which represents the disease progression as the continuous, monotonic,
linear accumulation of biomarkers from one z-score to another. The final progression model
of a subgroup is defined as a mixture of linear z-score event-based models (Figure 7.1).
The second extension of SuStaIn with respect to the original event-based model is the
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number of clusters. The SuStaIn model assumes a fixed number of subgroups c = 1, · · · ,C
in a studied cohort. This number can either be be pre-set or determined through cross-
validation. The specific ordering Sc of each cluster and the position of the patient in Sc are
quantified through SuStaIn.
The linear z-score model consists of a set of N z-score events E(i,z), which correspond
to the linear increase of a biomarker i = 1, · · · , I to a z-score z(i,r) = z(i,1), · · · ,z(i,Ri) (Figure
7.1). The trajectory of a specific biomarker i is modelled as a piecewise linear function g(t)
on an arbitrary time axis t. A z-score event E(i,z) occurs at each disease stage k starting
at time tstart = (k)/(N+1) and ending at tend = (k+1)/(N+1). The sequence of events Sc for a
specific subtype is therefore modelled by the ordering of all z-score events E(i,z) for the
biomarkers i = 1, · · · , I.
The linear z-score model quantifies sequential events in the timeline of the disease
progression and is not temporal. The time axis (t) of the progression is arbitrary. It initiates
from t = 0 to t = 1 where t = 1 signifies conclusion of the disease progression. In Figure
7.1, a hypothetical model is illustrated. Whilst one can infer that biomarker 1 (gi=1(t))
reaches z2 before biomarker 2 (gi=2(t)), it is not possible to extrapolate whether this occurs
at a faster or slower temporal pace i.e. months versus years. However, I can differentiate
biomarker trajectories that reach z-scores in succession as fast-acting versus those that occur
more sporadically across t as long-acting.
Inclusion of the linear z-score model in the overall model likelihood (Equation 7.2)
and removal of the normal and abnormal likelihoods leads to the following
p(X |S) =
J
∏
j=1
 N∑
k=0
∫ t= k+1N+1
t= kN+1
(
P(t)
I
∏
i=1
P(xi j | t)
)
∂ t

 (7.4)
where the integral term represents the joint probability of a particular linear z-score
model given the biomarker measurements of patient j. The prior P(t) = 1 and is assumed
to be uniform.
The overall model (M) likelihood for all clusters C is defined as
p(X |M) =
C
∑
c=1
fc P(X |Sc) (7.5)
where fc is the fraction of patients in cluster c and C is the number of subgroups.
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Figure 7.1: Linear z-score event-based model for a hypothetical model with I = 2 biomarkers and
N = 7 events. The first event in this model is Ez(1,1) and corresponds to biomarker i = 1
reaching a z-score equal to 1. The second event is Ez(1,2), corresponding to i = 1 and
z = 2. The second biomarker (i = 2) then becomes abnormal in the third event Ez(2,3).
The disease progression of this hypothetical model is thus defined by the series of events
Ez(i,r) govern by the biomarker progression gi(t).
A hierarchical method is employed to fit the SuStaIn model. Given the desired number
of clusters (Cmax), the clustering is performed sequentially from C = 1 to C =Cmax. At each
iteration, C−1 candidate sets of C clusters are generated by sequentially iterating through
the C− 1 clusters and finding optimal splits for each cluster. Each new candidate set is
composed of the two new clusters (after optimal split) and the remaining C− 1 clusters.
These are used to initialise the model and generate the set of C clusters for each candidate
set. Of the C−1 candidate sets, the model with highest likelihood is retained as the solution
at iteration C. For example, at C = 4, there are 3 clusters (c1,c2,c3) at the C−1 stage. Three
candidate sets of clusters are produced by computing the optimal split of each c1,c2,c3 e.g.
candidate set 1 is equal to C1 = {c1a,c1b,c2,c3}, candidate set 2 is C2 = {c1,c2a,c2b,c3}
and candidate set 3 is C3 = {c1,c2,c3a,c3b}. SuStaIn is then run C−1 = 3 times using C1,
C2 and C3 as initial conditions to the fitting. If C1 has the highest likelihood, the new set of
clusters for C = 4 is C1 = {c1a→ c1,c1b→ c2,c2→ c3,c3→ c4}.
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7.3 Experiments and results
I applied the SuStaIn model using data from the COPDGene study [167]. The aim was
to perform unsupervised clustering using only routine measurements that can be acquired
from Computed Tomography (CT) scans. Since each cluster represents a distinct group
with a shared common biomarker trajectory, application of SuStaIn allowed for the first
time the quantification of various progression patterns of COPD. Furthermore, the linear
z-score model underlying the SuStaIn methodology facilitated the detection of subgroups
with faster acting events versus longer-term periods of pathological damage in the timeline
of the disease progression.
7.3.1 Data
7.3.1.1 COPDGene cohort
The COPDGene study [167] is one of the largest studies to date aiming to investigate the
underlying genetic factors of COPD. To identify genetic risk factors and determine suscep-
tibility to COPD and other related phenotypes, a total of 10,000 subjects were recruited.
This included healthy smoking controls and patients across the spectrum of COPD sever-
ity (GOLD 1, 2, 3 and 4). There are two major components to the COPDGene study: 1)
cross-sectional analysis and 2) long-term longitudinal follow-up of all patients. For the
duration of the work presented in this thesis, only the cross-sectional component of the
COPDGene study had been completed. No longitudinal follow-up data was available. The
data supplied by COPDGene presented the unique opportunity to apply disease progression
modelling and potentially uncover various subgroups from cross-sectional data that differ
based on their disease progression. However, no validation of the progression models could
be performed.
7.3.1.2 Patient selection
I downloaded the entire database of patient measurements from the COPDGene cohort
[167]. This consisted of 10,092 patients with 344 associated variables. There were 4,437
COPD patients (GOLD ≥ 1) and 4,245 smoking controls (GOLD= 0). The remainder
(1,347) were unclassified such that they had a FEV1/FVC > 0.7 but an FEV1%predicted < 80
or they were non-smoking controls. From the 4,437 patients with COPD and the 4,245 con-
trols, I only selected patients who had data available for all CT features of interest (Section
7.3.1.3). This led to a total number JCOPD = 1,360 and Jcontrol = 1,163 used in the SuStaIn
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model.
7.3.1.3 COPD features
A mixture of CT features from the COPDGene variable set were considered. This allowed
me to account for different aspects of COPD pathology (Table 7.1). The first family of fea-
tures (tissue) concerned those that can be detected by analysis of the voxel attenuation. The
two most common densitometric features are emphysema and gas trapping. Emphysema is
quantified by computing the percentage of voxels in the lung with an intensity below the
threshold of −950HU on a scan at total lung capacity. A metric for gas trapping, which in-
directly measures effects of small airways disease, is obtained by analysis of scans acquired
at forced residual capacity. It is defined as the percentage of voxels with an attenuation
below −856HU. The COPDGene database provided results for upper-lobe and lower-lobe
emphysema. Given the plethora of work studying effects of apical and basal predominant
emphysema, lobar quantities of emphysema were considered over whole lung values of
emphysema.
The second family of features used was based on measurements of airway morphology.
Airway abnormalities such as airway wall thickening and luminal narrowing are hallmarks
of chronic bronchitis and bronchiolitis, which are both distinct phenotypes of COPD. Air-
way measurements from CT such as the Wall Area % (WA%) and the Pi10/15 square-root
of wall area (SRWA) aim to capture these effects and were used in this study.
The WA% is the ratio between the wall area and total bronchial area. It measures the
degree of airway thickening with respect to luminal area. The COPDGene database pro-
vided the WA% for segmental and sub-segmental airways. The segmental bronchi occur
after division of the lobar bronchi and supply air to regions of the lung known as the bron-
chopulmonary segments. They are the fourth generation of the airway tree, averaging an
airway diameter of 5mm to 8mm in a healthy lung [146]. The sub-segmental airways are in
in the sixth and eighth-generation and have approximately a mean diameter of 3mm [146].
They lead to the respiratory bronchioles where gas exchange is initiated.
To measure pathology associated to the lower parts of the respiratory tree, the Pi10 and
Pi15 square-root of wall area (SRWA) measures have emerged [148]. Measurements are
taken in the large and intermediate-sized airways, which can be accurately assessed using
CT in order to predict the wall thickness of the smaller airways. The SRWA is measured in
the upper-zones of the airway tree. By measuring the perimeter of these airways (Pi), the
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typical SRWA of airways with a 10mm (3.18mm diameter) and 15mm (4.78mm diameter)
lumen perimeter can be predicted by a linear regression. It has been seen that dimensions
of the large and intermediate-sized airways reflect the dimensions of smaller airways [148].
7.3.1.4 Quantitative CT analysis
The data used in the study (Table 7.1) was processed by COPDGene and downloaded from
the database. The analysed CT-features were obtained by analysis of paired breath-hold CT
scans by COPDGene collaborators using the VIDA Pulmonary Workstation 1.
Airway dimensions for segmental and subsegmental airways were collected for six
bronchial paths: 1) right upper lobe apical bronchus (RB1), 2) right middle lobe poste-
rior basal bronchus (RB4), 3) right lower lobe posterior basal bronchus (RB10), 4) left
upper lobe apicoposterior bronchus (LB1), 5) superior lingular bronchus (LB4) and 6) left
lower lobe posterior basal bronchus (LB10). These were chosen based on the consensus
of COPDGene investigators [166]. Airway indices were measured from the centreline of
the airways to the airway edge in each slice of the image volume. Measures for wall area
percentage (WA%) were quantified for each branch. For each patient, measurements are
averaged for the segmental and subsegmental data. Moreover, measures for Pi10 SRWA
and Pi15 SRWA were determined through the measurements of all these branches.
Table 7.1: Variables used to model COPD progression with the SuStaIn model. SRWA - square root
of wall area, WA - wall area, Ao - total area and Ai - luminal area.
Type Feature Quantification
Tissue
Upper-lobe emphysema % <−950HU in the upper lobes at inspiration
Lower-lobe emphysema % <−950HU in the lower lobes at inspiration
Whole lung gas trapping % <−856HU in the expiration scan
Airway
Pi10 SRWA
Prediction of
√
(WA)Pi15 SRWA
Wall Area % segmental
100× (Ao−Ai)/(Ao)Wall Area % sub-segmental
7.3.2 COPD progression models
The SuStaIn model was applied by seeking out two (Model 1) and five clusters (Model
2) of COPD. The optimal number of clusters given the studied cohort XCOPD should be
determined by cross-validation prior to analysis. However, the aim of this experiment was
to firstly, dichotomise the COPDGene cohort into its two main disease progression patterns
1vidadiagnostics.com
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(Model 1) then further analyse what clusters could be quantified with SuStaIn by increasing
the number of clusters (Model 2). The number of clusters for Model 2 was then increased
to five to allow SuStaIn to uncover more progression trajectories.
7.3.2.1 Model 1: two-cluster model
The biomarker trajectories for both clusters can be visualised in Figure 7.3. The proportion
of GOLD classified patients in both clusters is shown in Figure 7.2. A χ2 test of indepen-
dence was performed by comparing the frequency of GOLD stages between both clusters.
I found significant differences between clusters (χ2(DF = 3) = 7.82, p < 10−5). Cluster 1
had significantly more GOLD 1 and 4 patients whilst GOLD 2 and 3 were more expressed
in cluster 2.
There are important differences between both clusters, which highlight two potential
main phenotypes of COPD (Figure 7.3). These can be categorised by the sequence of events
and the linear accumulation of the z-scores. Cluster 1 can be classified as a Tissue-Airway
progression pattern since features related to the voxel intensity become abnormal first. Con-
versely, cluster 2 is an Airway-Tissue progression pattern since pathological variations in
the airway-related metrics are the first to become apparent.
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Figure 7.2: GOLD stage proportion in Model 1
In cluster 1 (Figure 7.3a), there are early signs of gas trapping then lower-lobe emphy-
sema. This is followed by a rapid progression of upper-lobe emphysema, which is illus-
trated by the progression of z-score events. Gas trapping and lower-lobe emphysema then
progress with lower-lobe emphysema approaching maximum severity first. Importantly, gas
trapping and measures of emphysema progress to their most severe stage before initiation
of the airway-related pathology. These are manifested first by airway wall remodelling in
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(a) Cluster 1 - 51% of COPDGene cohort
(b) Cluster 2 - 49% of COPDGene cohort
z1 z2 z3 z4
Figure 7.3: Model 1 - two cluster disease progression model. Opacity of the z-score events quanti-
fies uncertainty in the event ordering.
the subsegmental then segmental airways.
The progression of cluster 2 (Figure 7.3b) is initiated by a cascade of events in the
airways. Abnormalities are first present in airway walls of subsegmental then segmental
airways. This is closely followed by changes in the Pi15 SRWA and Pi10SRWA features.
However, the progression of these features appears to be long-lasting over the spectrum of
events. Pathological alterations in the airways directly lead to gas trapping, which is fast-
acting and aggressive within this cluster. This is then followed by a slow progression of
emphysema in the lower lobes and fast acting emphysema in the upper lobes.
7.3.2.2 Model 2: five-cluster model
An increase in the amount of clusters yielded a new set of biomarker trajectories with dis-
tinct progression patterns (Figure 7.5 and 7.6). I observed a dichotomy in the population
based on the sequences of events. There were three Tissue-Airway clusters (Figure 7.5)
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and two Airway-Tissue clusters (Figure 7.6). A χ2 test of independence within the Tissue-
Airway and the Airway-Tissue subgroups was performed respectively to test for differ-
ences in the GOLD proportion of subjects (Figure 7.4). There was no significant difference
(χ2(DF = 6) = 12.12, p = 0.06) between the clusters within the Tissue-Airway subgroup
(Figure 7.4a). There was also no significant difference (χ2(DF = 3) = 6.41, p = 0.09)
within the Airway-Tissue subgroup (Figure 7.4b).
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Figure 7.4: GOLD stage proportion in Model 2
The biomarker trajectories of the Tissue-Airway clusters (Table 7.2, Figure 7.5a, 7.5b
and 7.5c) can be characterised by the z-score accumulation and whether events occur syn-
chronously. In the first cluster (Figure 7.5a), progression of gas trapping in addition to
emphysema in the upper and lower lobes occurs synchronously. Once these biomarkers
reach maximum severity, airway-related pathologies are initiated. Airway wall thickening
of the sub-segmental airways first occurs, which is followed by thickening of the segmental
region, and followed by a synchronous progression of all biomarkers until conclusion of the
disease progression. The progression of airway-related pathology was similar in clusters 2
(Figure 7.5b) and 3 (Figure 7.5c). The most distinct differences were in the progression of
upper and lower lobe emphysema. Cluster 2 can be defined as a rapid upper-lobe emphy-
sema sequence (Figure 7.5b). It reaches the highest severity of upper-lobe emphysema at
event 7 in contrast to event 10 and 14 in clusters 1 and 3 respectively. The opposite was
observed in cluster 3 (Figure 7.5c), which can be described as an aggressive lower-lobe em-
physema subgroup. The presence of gas trapping is first apparent then followed by a rapid
increase in lower lobe emphysema.
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(a) Cluster 1 - 33% of COPDGene cohort
(b) Cluster 2 - 19% of COPDGene cohort
(c) Cluster 3 - 13% of COPDGene cohort
z1 z2 z3 z4
Figure 7.5: Model 2 - tissue-airways clusters. Opacity of the z-score events quantifies uncertainty
in the event ordering.
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Table 7.2: Characteristics of the Tissue-Airway clusters
Model Biomarker Property
Cluster 1 - Figure 7.5a
Gas trapping
Synchronous progressionUpper-lobe emphysema
Lower-lobe emphysema
Cluster 2 - Figure 7.5b
Gas trapping
Fast-acting upper-lobe emphysemaUpper-lobe emphysema
Lower-lobe emphysema
Cluster 3 - Figure 7.5c
Gas trapping
Fast-acting lower-lobe emphysemaUpper-lobe emphysema
Lower-lobe emphysema
The SuStaIn model quantified two clusters that were determined to be part of the
Airway-Tissue family (Table 7.3, Figure 7.6a and 7.6b). In the first cluster (Figure 7.6a), the
progression of COPD is initiated by abnormalities in wall area percentage in the segmental
and sub-segmental airways (WA%). This is then followed by a rapid progression of the
Pi10 and Pi15 SRWA metrics, which suggested that remodelling of the airways occurs at
an aggressive pace in this COPD subgroup. A sequence of rapid events in the tissue related
features occurs after the initial progression of airway-related metrics. Gas trapping abnor-
malities reach a severe z-score rapidly followed by a synchronous worsening of emphysema
in the upper and lower lobes.
A more uncertain initiation in the progression of the second Airway-Tissue cluster was
observed (Figure 7.6b). Gas trapping and abnormalities in wall area percentage initiates the
progression pattern. A domino effect in the sequence of tissue-related events is then seen.
Gas trapping first progresses to a moderate severity stage, followed by the rapid progression
of upper-lobe emphysema and longer-acting lower-lobe emphysema.
7.3.3 COPD disease severity and disease progression
Application of the SuStaIn model to a large population of COPD patients allowed me to
divide the COPDGene cohort into two major subgroups of disease; Tissue-Airway and
Airway-Tissue models of COPD progression. Both these models contained distinct clusters,
which are characterised by the event sequences and the aggressiveness of specific biomarker
progressions (Table 7.2 and 7.3). An important property of SuStaIn is that each patient was
indexed within the clusters by their respective progression stage E. This allowed me to test
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Table 7.3: Characteristics of the Airway-Tissue clusters
Model Biomarker Property
Cluster 4
Pi10 SRWA
Fast-acting airway and tissue pathologyFigure 7.6a
Pi15 SRWA
Segmental WA%
Sub-segmental Segmental WA%
Cluster 5
Pi10 SRWA
Slow-acting airway pathologyFigure 7.6b
Pi15 SRWA
Segmental WA%
Sub-segmental Segmental WA%
(a) Cluster 4 - 24% of COPDGene cohort
(b) Cluster 5 - 12% of COPDGene cohort
z1 z2 z3 z4
Figure 7.6: Model 2 - airway-tissue clusters. Opacity of the z-score events quantifies uncertainty in
the event ordering.
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whether COPD severity, as defined by the disease progression event E was consistent with
the staging of severity through spirometry (Section 7.3.3.1) but also exacerbation frequency
(Section 7.3.3.3). This analysis was performed on model 2 (5 clusters).
7.3.3.1 Disease progression event stage and GOLD classification
Associations were first investigated between the progression event stage and GOLD clas-
sification (Table 7.4) in the 5-cluster model (Section 7.3.2.2). Significant differences were
found across the Tissue-Airway progression clusters for each GOLD stage yet none in the
Airway-Tissue subgroup (Table 7.4).
A post hoc Tukey-Kramer test was performed for all three clusters of the Tissue-
Airway subgroup at each GOLD stage. A consistent significant increase was found in the
mean event of patients in cluster 1 with respect to cluster 3 except at GOLD 4 (GOLD 1:
p = 0.03, GOLD 2: p < 10−3, GOLD 3: p < 10−5, GOLD 4: p = 0.21). There was only a
significant increase between clusters 2 and 3 at GOLD 3 (p < 10−5). There were no other
significant differences across clusters for the event stage. It can be seen that clusters 1 and 2
of the Tissue-Airway subgroup have on average, consistently higher mean event stages per
GOLD classification. This suggests a more rapid deterioration of the lung anatomy before
lung function becomes abnormal in clusters 1 and 2.
Table 7.4: Mean (St.D.) of progression stages for of all patients per GOLD stage stratified by cluster
Subgroup Cluster GOLD 1 GOLD 2 GOLD 3 GOLD 4
Tissue-Airway
1 5.91 (3.41) 7.88 (3.45) 11.54 (3.03) 14.62 (2.99)
2 4.35 (2.58) 6.84 (3.50) 12.45 (3.56) 14.69 (3.50)
3 3.96 (3.13) 5.73 (3.81) 8.95 (4.43) 13.46 (5.12)
One-way ANOVA p = 0.01 p < 10−3 p < 10−5 p = 0.19
Airway-Tissue
4 2.88 (1.67) 5.82 (4.07) 10.30 (5.19) 16.27 (4.56)
5 3.74 (2.14) 5.61 (3.78) 11.16 (4.71) 14.22 (4.78)
One-way ANOVA p = 0.13 p = 0.70 p = 0.32 p = 0.09
7.3.3.2 Disease progression event stage and spirometry
Relationships between event stage and spirometric indices (FEV1%predicted and
FEV1/FVC) were examined in each cluster. For each cluster, the event stage of the pa-
tient was plotted versus their respective spirometric values (Figure 7.7 and 7.8). Pearson’s
Linear Correlation was calculated between the event stage and spirometry. Strong signifi-
cant correlations were observed across clusters (Table 7.5).
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I also determined the event stage upon which biomarkers first became moderately ab-
normal (z2) and very severe (z4) (Table 7.5). For instance, within cluster 1 of the Tissue-
Airway subgroup (Figure 7.5a), lower-lobe emphysema first reached z2 at event 3 and upper-
lobe emphysema was the first biomarker to reach z4 at event 10. These were overlaid in Fig-
ures 7.7 and 7.8 as vertical lines. This illustrated cases within each cluster where patients
had advanced severity as defined by the event stage yet mild to moderate COPD as seen by
spirometry. Various sets of patients in each subgroup were observed with discordant rela-
tionships between their disease progression stage and their respective lung function score.
For example, cluster 2 (Figure 7.5b) and cluster 5 (Figure 7.6b) had various patients with at
least one biomarker at the most severe (z4) yet with mild lung function impairment.
Table 7.5: Event stage for feature abnormality and Pearson’s Linear Correlation (ρ) of event stage
with spirometry. [∗ : p < 10−5]
Subgroup Cluster z-score Feature ρ(FEV1%p) ρ(FEV1/FVC)
Tissue-Airway
1
z2 = 3 Lower-lobe emphysema −0.72∗ −0.76∗
z4 = 10 Upper-lobe emphysema
2
z2 = 3 Upper-lobe emphysema −0.77∗ −0.81∗
z4 = 6 Upper-lobe emphysema
3
z2 = 2 Gas trapping −0.65∗ −0.73∗
z4 = 8 Lower-lobe emphysema
Airway-Tissue
4
z2 = 4 Pi15 SRWA −0.66∗ −0.72∗
z4 = 18 Gas trapping
5
z2 = 3 Gas trapping −0.70∗ −0.73∗
z4 = 8 Upper-lobe emphysema
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(e) Cluster 3 - FEV1%predicted
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(f) Cluster 3 - FEV1/FVC
Figure 7.7: Relationship between disease progression and spirometry in the Tissue-Airway sub-
group. The horizontal lines in the FEV1% predicted plot correspond to the thresholds
used in GOLD classification for GOLD 1, 2, 3 and 4. Those used in the FEV1/FVC
plots were arbitrarily chosen.
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(c) Cluster 5 - FEV1%predicted
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Figure 7.8: Relationship between disease progression and spirometry in the Airway-Tissue sub-
group. The horizontal lines in the FEV1% predicted plot correspond to the thresholds
used in GOLD classification for GOLD 1, 2, 3 and 4. Those used in the FEV1/FVC
plots were arbitrarily chosen.
7.3.3.3 Exacerbation susceptibility and COPD disease progression
Various studies have focused on testing associations between CT features and exacerbation
frequency [44, 87, 203]. However, none of these studies have been able to test effectively
whether there is a relationship between disease progression of COPD and susceptibility
to exacerbations of COPD. Therefore, I investigated whether there were any relationships
between the clusters and exacerbation susceptibility. I also analysed correlations between
disease event stage within the clusters and exacerbation frequency.
The frequency of susceptible ( f ≥ 2) and non-susceptible ( f < 2) COPD patients in
each subgroup and cluster (Figure 7.9 and Table 7.6) was first analysed. I first tested whether
the subgroups had different distributions of susceptible and non-susceptible patients. They
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both had the same frequency of patients (Table 7.6) and this was corroborated in a χ2 test
of independence (χ2(DF = 1) = 0.02, p = 0.88). There was no significant difference in
the ratio of susceptible to non-susceptible patients between both subgroups; suggesting that
there is no leading progression of disease for the susceptible subgroup of COPD.
I also tested the hypothesis that there were differences between the distribution of
exacerbation frequencies between subgroup clusters (Figure 7.9a and 7.9b). I found no
significant difference between the three clusters in the tissue-airway subgroup (χ2(DF =
12) = 6.17, p = 0.91) and also within the airway-tissue subgroup (χ2(DF = 6) = 5.93, p =
0.43). In line with our results assessing differences between the tissue-airway and airway-
tissue subgroups, these results confirmed no specific within subgroup differences in the
disease progression of susceptible and non-susceptible patients.
Furthermore, I calculated Spearman’s rank order correlation between exacerbation fre-
quency and disease progression event stage. I observed weak relationships in all tissue-
airway clusters and also within cluster 5 of the airway-tissue subgroup (Table 7.7).
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Figure 7.9: Frequency of exacerbations for each COPD progression cluster
7.4 Discussion
A novel unsupervised machine learning algorithm has been applied for the first time to
COPD imaging data. The SuStaIn model has identified two dominant subgroups of COPD;
the Tissue-Airway and Airway-Tissue subgroups. Within the Tissue-Airway subgroup, the
presence of gas trapping and emphysema first became apparent, which was followed by
airway-related abnormalities. In the Airway-Tissue subgroup, disease progression was ini-
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Table 7.6: Frequency of exacerbation susceptible and non-susceptible patients per COPD clusters
Subgroup Cluster Susceptible Non-Susceptible χ2-within χ2-between
Tissue-Airway
1 0.17 0.83
 p = 0.91
p = 0.88
2 0.18 0.82
3 0.19 0.81
All 0.18 0.82
Airway-Tissue
4 0.18 0.82
}
p = 0.43
5 0.19 0.81
All 0.18 0.82
Table 7.7: Spearman’s rank-order correlation between exacerbation frequency and disease progres-
sion event stage per COPD cluster
Subgroup Cluster ρ p-value
Tissue-Airway
1 0.21 < 10−5
2 0.27 < 10−5
3 0.22 0.002
Airway-Tissue
4 0.09 0.14
5 0.31 < 10−5
tiated by airway-related pathologies.
The clustering and staging of SuStaIn has facilitated the quantification of distinct clus-
ters within the Tissue-Airway and Airway-Tissue COPD subgroups (Figure 7.5 and 7.6,
Table 7.2 and 7.3). By analysing the event stage of patients and their respective spirometric
readings, I have been able to show that significant structural alterations in lung tissue can
occur prior to these changes becoming apparent through spirometry (Figure 7.7 and 7.8).
The speed of progression of the biomarker trajectories also differed across clusters and sub-
groups, which may suggest different underlying mechanisms responsible for the disease
process. This discordance between disease event position and clinical measures of lung
function are also indicative of the need to detect early the progression of COPD before the
bulk effect of pathology initiates a rapid progression in lung function decline.
I also investigated potential relationships between exacerbation susceptibility and the
quantified clusters. Patients that are susceptible to COPD exacerbations are an important
high-risk group. It is not known if the disease progression of susceptible patients differs
from the non-susceptible group. I have observed that there is no correlation between dis-
ease progression and susceptibility to exacerbations. This may suggest that the mechanism
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responsible for the progression of COPD is distinct from the underlying cause of exacer-
bation susceptibility. Whilst I have found no significant differences in the susceptibility
to exacerbations between clusters, isolating COPD patients from large cohorts for focused
within-cluster analysis may yield key differences in contrast to a cohort-wide study. This
could be applied to analysis performed in Chapter 6. Moreover, future work should aim
to include exacerbation frequency in the SuStaIn modelling to determine whether there are
distinct clusters where exacerbations occur prior to CT structural alterations and vice-versa.
The results confirm in part findings from previous unsupervised clustering efforts [32]
on COPDGene. Castaldi et al. [32] identified four separate COPD clusters by using CT
features and spirometric measures such as functional residual capacity (FRC) % predicted,
FEV1% predicted and bronchodilator responsiveness as a percentage of FEV1. The identi-
fied clusters that are similar to those observed in this chapter are the: 1) mild-upper zone
predominant emphysema with airflow obstruction cluster and 2) airway predominant dis-
ease cluster. A key difference is that the identified clusters in my work represent patients
with similar progression routes of disease and patients can be at various different stages of
their progression. In contrast, clustered patients in the work of Castaldi et al. [32] may pos-
sibly be following distinct progression routes yet may have similar features. Future work,
aimed at bridging the clustering of Castaldi et al. [32] with the SuStaIn subgroups will be
able to effectively determine this.
There is a strong case for the early detection of COPD. The work of Fletcher and
Peto [67] initially outlined the rate of lung function decline in COPD; suggesting slow
decline at onset followed by a more rapid phase at advanced stages of disease. Recent
studies have suggested that faster progression of lung functional impairment occurs earlier
[207] and particularly at mild-to-moderate stages of COPD [207, 58]. These results are
mirrored in studies showing that smokers may develop emphysema, measured in CT before
exhibiting abnormal lung function [181, 195]. These undetected structural alterations may
be critical in the early, accelerated decline of lung function and the remaining course of
COPD progression. The results from Section 7.3.3.2, which showed relationships between
disease progression event stage and spirometry provide evidence of the need to early detect
COPD progression. Patients may already be at stages of advanced disease yet at mild-to-
moderate stages of COPD. This is illustrated by the thresholds z2 and z4 in Figures 7.7 and
7.8 and summarised in Table 7.5.
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Despite the novel findings and potential exciting future avenues of research stemming
from this chapter, there is a crucial need to validate the disease progression patterns. I
found strong correlations between event stage and spirometry (Section 7.3.3.2), which sig-
nifies that the progression trajectories model the continuum of lung function impairment
from moderate to very severe. Morever, the two uncovered subgroups (Tissue-Airway and
Airway-Tissue) reflect the current knowledge in COPD phenotypes (emphysema versus air-
way predominant) [200], which weakly validates the results. However, longitudinal data is
necessary to perform robust validation of the results. The data supplied and made available
from COPDGene at the time of this project was cross-sectional. This was not sufficient to
validate the modelled longitudinal trajectories. Existing frameworks that exist for simulat-
ing cross-sectional or longitudinal biomarker datasets from disease cohorts [251] could be
used to evaluate the performance of the modelling presented in this chapter. However, the
follow-up longitudinal data that will be released as part of the COPDGene study will help
reflect the accuracy of the predictions made in the modelled subgroups. Whilst the time-
scale of COPD progression is over decades, it is expected that employing the follow-up data
and validating on separate data sources such as the ECLIPSE study [225] will help elucidate
whether the uncovered clusters are true subtypes of COPD and help determine the clinical
utility of this modelling.
7.5 Conclusion
In conclusion, disease progression modelling of COPD has allowed me to quantify two
main subgroups of COPD; Tissue-Airway and Airway-Tissue. It also allowed me to un-
cover clusters within each subgroup, which differed by the aggressiveness of the biomarker
changes and the sequence upon which they became abnormal. These results may have great
clinical repercussions as they suggest that patients can be stratified by their most likely
progression of disease. Whilst the analysis must be repeated by determining the optimal
number of clusters and the clusters must be validated using independent and longitudinal
data, they may be important starting-points for assessing potential genetic associations and
differences in therapeutic response. This has the potential to revolutionise the management
of COPD and improve future treatment of patients.
Chapter 8
Summary and discussion
This aim of this thesis has been to develop automated tools to analyse Computed Tomog-
raphy (CT) scans to improve the analysis and diagnosis of Chronic Obstructive Pulmonary
Disease (COPD). There are various components of COPD that cause pathological alter-
ations in a number of pulmonary structures, which in combination lead to airflow limitation
and other comorbidities. The method upon which COPD affects the lung may also vary
widely across patients such as in upper-lobe and lower-lobe predominant disease. There
are consequently various subtypes of COPD with potentially important clinical differences.
This necessitates precise phenotypic characterisation of COPD subjects from CT.
In this chapter, I summarise the work presented within this thesis. I present an overview
of the main original contributions of each chapter. I then suggest the future directions of
this project and initial results when present.
8.1 Summary
8.1.1 Classification of exacerbation susceptible COPD
Chapter 3 presented a framework for classifying exacerbation susceptible and non-
susceptible patients although it could be applied to staging COPD severity. This could
be performed in a multi-class setting by predicting patient GOLD stage. The spread of
disease and its effect throughout the lung can vary from homogeneity to heterogeneity.
Such complex changes cannot be accurately represented by classification tools that exploit
average measures [143, 23]. Moreover, patients can be susceptible or non-susceptible to
exacerbations at equal levels of functional impairment with similar levels of emphysema.
This inhibits the application of algorithms that classify patients based on local probabilities
of COPD [194, 193] or on dissimilarity measures of lung texture [192].
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These limitations were addressed by attempting to quantify a signature unique to the
patient that is based on the distribution of density-based and biomechanical features across
the lung. This was performed by analysing features locally and then modelling their global
distribution. This distribution could be exploited after dimensionality reduction using Prin-
cipal Component Analysis as features in a classifier. I demonstrated the performance of
the algorithm by classifying exacerbation susceptible and non-susceptible patients at equal
levels of COPD severity (GOLD 3). This was to my knowledge the first time this had been
performed. Despite the complexity of the problem, I showed that it is possible to classify
exacerbation susceptible patients at equal levels of severity although the performance of
the algorithm was variable when tested on various hold-out sets in a repeated k-fold cross-
validation. Recent work however has attempted to classify exacerbation frequency using
convolutional neural networks with promising results [248].
The future application of the algorithm lies in the analysis of the distributions with
respect to COPD severity. Before attempting challenging problems such as the classification
of susceptible patients, it is necessary to gain a better understanding of how the distributions
vary in a population of control and COPD patients.
A potentially important aspect of the framework is sampling the local distributions
and their ensuing global distribution. This may implicitly capture information about em-
physema subtypes. Previous work has classified emphysema subtypes based on local ROI
intensity distributions [131] whilst fibrotic disease patterns can be disentangled from em-
physema using a PCA on integral geometry features [39]. More recent work has exploited
texton-based, difference of Gaussian (DOG) and local binary patterns (LBP) features for
unsupervised labelling of ROIs [245]. Parameterisation of local intensity distributions with
the addition of textural features and their ensuing distribution across the lung may model
the spread of varying emphysema subtypes.
8.1.2 Segmentation of the pulmonary lobes
In Chapter 4, I presented a lobe segmentation algorithm. The regional quantification of
disease may be critical in monitoring disease progression but also in patient stratification for
surgery. It has been seen that a more homogeneous presentation of emphysema accelerates
decline of FEV1 [206]. The presence of apical or basal emphysema may have discordant
effects on lung physiology [81, 75]. Identifying patients that have upper-lobe predominant
emphysema is also important for staging lung volume reduction surgery [36].
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The lobe segmentation algorithm combined the segmentation of the fissures with a
groupwise fissure prior to find segmentation labels for the lobes. The main aim of the algo-
rithm was for it to be unsupervised at all stages of the pipeline. The state of the art in fissure
segmentation is based on supervised classification [223], hard-coded empirical parameters
[109, 238], shape models [174] and line-enhancing filters [242]. I presented a method to
segment the fissures by assuming a generative model between a multi-scale fissure enhance-
ment filter and the underlying segmentation of the lung. It can be argued that the method
is not fully unsupervised since it requires setting parameters for the filter. I showed that
the method was generally insensitive to the parameter choice. The method could be made
fully unsupervised by merging the segmentation of fissures obtained from a range of filter
parameters through majority voting. I also demonstrated the utility of constructing a group-
wise fissure prior from a set of complete and incomplete fissure segmentations without prior
need for manual segmentations. Constructing a deformable model of the fissures without
manually labelled fissures is difficult. However, I showed that its application had the ability
to guide the segmentation in regions of incomplete fissures. The algorithm achieved state
of the art performance when tested on multiple datasets. However, there were still outliers
in the performance of the algorithm notably due to errors in the airway seed labelling. In
the future, the dependence on the airway tree for seed labelling should be reduced.
8.1.3 Manifold learning of COPD
I presented a new method to quantify the spread of emphysema and functional small airways
disease (fSAD) in Chapter 5. Current methods for quantifying disease extent in the lung rely
on global averages and lobar averages. They may not be able to capture local aspects of lung
disease and quantify their spread. This makes it difficult to accurately quantify inter-patient
differences. Sørensen et al. [192] developed a new distance metric that relies on bipartite-
graph matching of local ROIs. Harmouche et al. [88] presented a new severity measure
based on the extent of various emphysema subtypes within the lung. A fractal exponent can
also also be derived, which represents the size distribution of emphysematous clusters [134].
Despite these advances, techniques that can accurately quantify inter-patient differences in
disease spread within pulmonary image analysis are limited and sparse.
I introduced the concept of local disease and deformation distributions as methods to
better phenotype COPD from CT. This extended the framework introduced in Chapter 3.
By sampling tissue classification results locally throughout the lung, a disease distributions
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can be built, which captures the local properties of disease spread and how it varies glob-
ally across the lung. I also built a deformation distribution, which quantified local volume
change across the lung. Inter-patient differences could be quantified by considering his-
togram distances. I applied a framework previously employed to study neonatal brain devel-
opment [4] to investigate the progression of the proposed distributions. Manifold learning
enabled me to capture variations in the distributions in a large cohort of patients. Fusion
of the embeddings facilitated the construction of a single embedding, which encapsulated
various aspects of COPD. Analysis of the embedding coordinates showed that the presented
distributions associated more strongly with common markers of COPD severity than con-
ventional metrics. The position of a patient in the manifold space of COPD may be an
instrumental factor in the severity of disease. Importantly, kernel regression in the manifold
space allowed me to build potential trajectories of disease progression. These however need
to be validated. Longitudinal data that will be released as part of the COPDGene study
[167] may be instrumental in this validation. This data was not available at the duration
of this project. However, a more interesting future application lies in merging the results
with the disease progression modelling in Chapter 7. This will demonstrate if the distance
travelled along the modelled trajectories represents a viable metric of disease progression.
8.1.4 From global to regional analysis of lung CT: application to exacerbation
susceptible COPD
In Chapter 6, I exploited the lobe segmentation algorithm (Chapter 4) and the disease distri-
butions (Chapter 5) to develop a pipeline that analyses lung CT from a global to a regional
level. The aim was to extract features that measure different aspects of lung disease, which
can be used to investigate various hypotheses related to COPD. The pipeline was applied
to the study of exacerbation susceptible COPD to investigate whether regional informa-
tion associates with exacerbation frequency. Studies have currently shown that airway wall
thickness associates with exacerbation frequency yet the relationship with emphysema is
highly non-linear [87] with contrasting findings in the literature [203, 44, 69]. It is not
known if fSAD associates with exacerbation frequency, whether regional differences differ-
entiate susceptible and non-susceptible patients and whether lung deformation varies with
exacerbation frequency.
I showed with the pipeline that many new features associate with FEV1%predicted.
Inter-lobar measures of emphysema, lung deformation in addition to measures of diffuse,
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intermediate and dense emphysema and fSAD were all strongly correlated with spirometry.
Novel CT-metrics such as Jacobian heterogeneity are being developed to investigate new
links between parenchymal destruction and lung function impairment [18]. Furthermore,
they may improve the prediction of respiratory morbidity and mortality [22]. Further studies
are needed to assess whether the features employed in the analysis significantly improve the
link between CT and COPD severity.
The analysis pipeline was able to find group-differences between the exacerbation sus-
ceptible and non-susceptible groups. Regional analysis was able to disentangle potential
differences where global measures could not such as global fSAD, lower-lobe fSAD and
inter-lobar fSAD. This suggested regional analysis of lung disease may be important for
future studies. Univariate tests demonstrated that many of the features do associate with
exacerbation frequency yet do not when FEV1%predicted was included in the regression
models. However, when accounting for all features in the most complex model, it was seen
that volume change homogeneity and inter-lobar fSAD may be predictive of exacerbation
frequency. These features may be worthy of future studies to evaluate their potential link
with exacerbations.
8.1.5 Disease progression modelling of COPD
Chapter 7 presented the application of disease progression modelling to evaluate COPD
disease progression. I applied SuStaIn (Subtype and Stage Inference) developed by Young
et al. [249], which is a novel unsupervised algorithm that bridges clustering with event-
based modelling. Event-based modelling concerns a set of statistical models that aim to
estimate the sequence of events that best characterise the progression of disease from an
early, asymptomatic stage to the most severe stage. The SuStaIn model is able to cluster
patients based on the trajectory of disease progression whilst also finding their respective
stage in their potential course of disease.
I applied SuStaIn to 1360 COPD patients from COPDGene [167]. I was able to
uncover two potentially important subtypes of COPD; Tissue-Airway and Airway-Tissue
subtypes. Within the Tissue-Airway subtype, disease progression was initiated by various
abnormalities in lung tissue then followed by alterations to the airway tree. Airway abnor-
malities first became apparent in the Airway-Tissue subtype, which led to the progression
of tissue related pathology. There were various clusters within each subtype with differing
progressions of disease. By analysing disease stage with respective spirometric readings,
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I was able to reinforce the notion that early detection in COPD is critical as significant
pathology may be present before spirometry becomes abnormal. This clustering approach
when applied to COPD is truly novel since previous clustering efforts have grouped patients
based on cross-sectional data [232, 33, 27, 73]. Clustering COPD patients based on likely
disease progression has the potential for better patient stratification for focused analysis in
large clinical studies such as COPDGene [167] but importantly, to help better understand
our understand of the general history of COPD.
8.2 Future directions
The work presented within this thesis has focused on the development of quantitative tools
for the study and diagnosis of COPD. The underlying motivation has been to develop a suite
of techniques, which facilitates the precise phenotypic characterisation of COPD from CT.
There are two main future directions arising from my work, which should be pursued. The
first is centered on extending the work of Chapter 3, 5 and 4 towards a statistical framework
to create models of health and disease. The second relies on extending Chapter 7 by includ-
ing exacerbation susceptibility and frequency in the mathematical framework of SuStaIn
whilst including the features presented in Chapter 6.
8.2.1 Statistical models of lung structure and deformation
The lung anatomy is incredibly complex and varies widely across the population. Coupled
with the discussed complexities of COPD, it is obvious that there is a great need to define a
normative range of pulmonary variation to clarify subject-invariant structure-function rela-
tionships and better identify deviations from health to disease. Statistical modelling in the
context of pulmonary image analysis is however not a new concept. Computational mod-
els of respiratory motion have been studied extensively in the field of radiotherapy [128].
Statistical models of lung motion have been built to predict lung tumour motion [60, 116].
Groupwise analysis based on the construction of an atlas has been employed for voxel-wise
regression analysis to evaluate response to treatment in Hyperpolarised-MRI [213]. These
techniques can be exploited to better study COPD.
There are two main challenges that need to be addressed to create statistical models of
lung structure and function. Accurate inter-patient groupwise registration is necessary and
methods for analysing textural and deformation-based information in the groupwise space
need to be developed.
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Inter-patient lung registration was performed in Chapter 4 to create the groupwise fis-
sure prior and represents a good starting point for future work. In order to improve the
accuracy of the fit, anatomical landmarks can be employed. This was previously performed
by Li et al. [112, 113] who developed a hybrid landmark and intensity-driven registration
algorithm and manually identified corresponding points on the airway tree. Identifying cor-
responding landmarks is laborious and smarter techniques for introducing landmarks are
possible. The fissure segmentation presented in Chapter 4 could be used to help drive the
registration. This was performed by Schmidt-Richberg et al. [182]. Other options include
applying the Frangi vesselness filter [172] or the vessel density [54] simultaneously with
the original intensity image in a multi-channel registration.
There are many interesting applications that can be pursued if I consider that an ac-
curate groupwise space has been achieved. A Principal Component Analysis (PCA) could
first be applied on the resampled intensity images. The principal components may corre-
late with various clinical markers of lung function impairment whilst the principal modes
of variations could be used to visualise regions of the lung that correlate most strongly by
extending the analysis to voxel-based morphometry [9]. This sees a direct application in
studies that are attempting to ascertain how regional variations in emphysema affect lung
function. More advanced dimensionality reduction can also be used such as manifold learn-
ing, which was applied in Chapter 5. This would negate the need for constructing local
disease distributions for inter-patient quantification.
The framework developed by Ehrhardt et al. [60] can also be applied to analyse lung
deformation in the groupwise space. The deformation field obtained from the paired breath-
hold registration of each patient can be mapped into the common groupwise space. This
may help determine normative values of lung deformation that are normalised by the patient
anatomy in a control population to understand the deformation of lung that has been affected
by COPD.
Statistical modelling of lung structure and function may be instrumental in phenotyp-
ing COPD from CT. A major question within this thesis has been centered on exacerbation
susceptible COPD; does an exacerbation susceptible lung differ significantly from a non-
susceptible lung at equal levels of severity? By constructing separate statistical models
of exacerbation susceptible and non-susceptible lungs, our understanding of the potential
differences may be improved, which may significantly impact future COPD treatment.
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8.2.2 Disease progression modelling and susceptibility to exacerbations
The work presented in Chapter 7 applied event-based modelling to uncover various distinct
progression trajectories of COPD. As a post-hoc analysis, I investigated potential relation-
ships between the progression trajectories and susceptibility to exacerbations. I observed
no specific cluster with significantly more susceptible patients. However, it is important to
include exacerbation frequency as a biomarker in the modelling. A fundamental question
in COPD regards the origin of exacerbations and progression of COPD. Is the presence of
exacerbations a function of the progression of COPD and its inherent severity or do exacer-
bations act as a precursor to the pathological changes observed in the lung? Mechanisms by
which exacerbations contribute to the decline of health status in COPD also remains largely
unknown [170]. The preliminary analysis performed in Chapter 7 could not determine this.
Inclusion of exacerbation variables as part of the modelling may potentially elucidate the
relationship between exacerbation and COPD progression.
SuStaIn is based on the linear z-score accumulation of various biomarkers. It models
the trajectory of each biomarker as it progresses from a normal to severe state through a z-
score based on the deviation from the control population. Several changes need to be made
to SuStaIn to allow it to effectively model continuous data with count data (exacerbation
frequency, n/yr) and binary data (exacerbation susceptibility and exacerbation severity).
Lastly, the features developed in Chapter 6 provided regional information relating to
emphysema, fSAD, lung deformation in addition to metrics defining diffuse and dense dis-
ease. These features can all be included in the modelling to produce a more fine-grained
picture of the disease process. This inclusion however is not trivial. A hypothesis in the
literature is that fSAD precedes emphysema in the progression of disease [71, 25, 98].
A fundamental question in the modelling must be answered. A strong assumption in the
event-based model is that there is a monotonic increase in the biomarker measurements. If
the hypothesis that fSAD precedes emphysema is correct, then it is expected that the extent
of fSAD will decrease with disease progression as emphysema dominates. This violates
the assumption of the model. Correct modelling of fSAD and emphysema progression in
addition to the inclusion of exacerbations in the SuStaIn modelling are likely to have a
significant impact in improving our understand of COPD.
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8.3 Conclusion
This thesis has presented new automated tools to analyse Computed Tomography (CT)
scans to improve the analysis and diagnosis of Chronic Obstructive Pulmonary Disease
(COPD). The work presented has been motivated by the complexities of COPD and the
need to better phenotype COPD from CT. My work has led towards a new method that clas-
sifies CT scans based on the distribution of local features. I have presented a new method
to quantify disease extent in the lung and have shown a potential way to identify trajecto-
ries of disease progression from CT analysis. I have developed a novel lobe segmentation
algorithm and have applied it to study whether regional analysis of lung disease associates
with exacerbation susceptibility. Lastly, I demonstrated the possibility of identifying novel
subtypes of COPD using event-based modelling.
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